var title_f23_11_23728="Parasympathetic ganglia neurons";
var content_f23_11_23728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Human airway parasympathetic ganglia neurons have complex morphology and electrophysiology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 373px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF1AhsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACignAyelICGAKkEHkEd6AFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisHx34lg8H+EdU1+7heeGxi8wxIQC5JAABPTkigDkPijqJ1fVoPB63gsNKNsdQ1++83yzDZBsCINngysCpPZQ3XNdn4T1bQNU0mJfC1/YXmn2irbqLKZZEiCgBU+UnGBjivFvhD4Wv/AIj/ANq+M/HWW0nWrpZ7bRj/AKqRI/liaXu6LztX7pOWIORXvGnabY6ZD5Wm2VtZxcfJbxLGvHTgAUAW6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOM+MWqS6V8N9be0DG+uofsNqqkhmmnIiTGOc5cH8K579n6LVdF0XWfCGvXSXd34evfs8cwJy8MiLKh55x8zAewx2r0i+021v57OW7jEptJPOiVuVWTGA2O5GTg9s5615R8ak1jwhr+lfEDw9KBbQNFY61aYAW4t2kwrnjqpcjPUZHbNAHsdFFFABRRRQBzXxA1nWdA8O3Op6FpEGqvao00sD3Bicooy2wBG3HAPHH41q+HtWtte0LT9WsG3Wt7AlxGT12sAcH35q+QGBDAEHgg9687+G6/8Ix4l13wQ3Frb/wDE10oA8LaTO2Yv+AShwP8AZZaAPRa8j+JLL8RfFkXw5spyum26Jf6/PH1WMMDHbA9nc/MfQL35FXfE3xIk1HWrrwl8Oo11LxRG5iuZ5EYWunAcNJI2MMQeAozkjHsem+Hvg2z8GaM9vBI91qF0/wBov7+XmS7nPLOx+pOB2H40AdHZ2sFlaQWtpEkNtAgjjjQYVFAwAB6AVNRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUN6Lg2cwsjEt0UIiMoJQNjgsByRntU1FAHll98MNcm36jF8Q/En/CQr88UxdVtFbk7TbqNuw+mTW78NPGNx4hiv9K162Wx8UaO4g1C2B+V8j5Zo/WNxyPy9z21eR/EPXLDwd8afBeqXirFFrFrc6RPKq8/fiaIt6gMSM9txoA9crG8ZaDD4n8Karoly22O+t3h3/wBxiPlb8Dg/hWzRQBxnwj8RzeJPBNpJqPy6zYs1hqUR+8lxEdr5HbOA30auzrzOwifSP2gb+3sfksta0QX93F2NxFKIg4HqUYA+uAa9MoAKKKKAKllqdjf2RvLC8t7q0G4edBIJEyvUZXI4xXj2veKLS++I3hrxBocwmtb3w5qf2WVUKtIYyj9+cZTjNO+JNhd/CzT9a8U+E1hPh+6X/iaaM3yIsj4jFxAR91sldy9COeorjdd05PBHhn4Y3eoXKQQJomoWE854VJJrUyIN3Yl+BQB6r+z94eg0P4Y6TcBhNf6tGNSvLkj55pJfn+Y98AgfgfWvR65P4S2r2fwu8JwSMWdNLtsk+8anH4ZxXWUAFFFMmljhieWZ1jiQFmdzgKB3J7UAPorNs9f0e9kCWerafcOTtCxXKOSfTANXrm4htbeSe6ljhgjUs8kjBVUepJ4AoAoa/r2k+HrMXeu6jaafbMwRZLmUICx7DPU1etbiK7tYbm2kWSCZBJG6nIZSMgj6g18/eMvid4Zvvi74Yme0n1TQ9Jt7iRtQihZoIZZGRDNkjDIgHLjIBbjpX0EZ4hb+eZU8jbv8zcNu3Gc56Yx3oAkoriLX4meHnsLjVb69t9O0MSGOzvruURi9K/faJDyyA8Bh97sMYJ6zSdRs9X0y21DTLhLmyuYxLDMh+V1PQigC3RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXjWr6Rp/wARPjvAtxG0+meDrVXkIPytfSOGVD6hVTJ98A16X411v/hGvCOs62IDcHT7SS5EQON5VScZ7D3rD+EOjnTfB8V/csH1PXHOsXzgYHnTgMVHfao2qP8AdoA7aiiigDyr4i3v/CLfFjwb4lvBt0i6hm0S5m7QPIyvGW9iykfhXqtZXinw/p3inQbzRtatxcWN0myROhHowPYg4IPqK534f6lqVpf3vhHxJOtzqmmRRy296Bt+3WjZVZSOzqVKvjjOD/FQB29YPi/xXpnhWySbUpJHnmby7azt08y4uXPRI4xyx/QdTisfxf4/ttKvTo2gWc2v+JmHy6dZkHyfRp36RL7nn0FUvAXgK4stak8WeMLv+0/F1yhXcCfIsI2/5YwKegGcFup/E5APK/ihd+NfGureF9D1+xttA0HWdXjiTSmbzbueKP53llK/KFAx8oOckZzjNehftJ6DBr/wvbTl4vGvrVLCNerzNIECgd/kdzj0Ge1VPjPZ3kvxM+FFzYyeU0eqSxu5OBtKKzL9SiOMd6teFjL4/wDiTfeI7hnXQvDVxLp2lwZ+Wa5AKzXB9cA7F/E0AemaVYw6Xpdnp9oCLe1hSCME5IVVCj9BVqiigArxn9oBom1zwNb+JFnPgi5vng1NYpSitKyjyBKQR+7Dbiee3sK9mrnvH/hWx8a+EtR0LU1HlXMZCSY5ikHKOPcHB/TvQB4f8d/Bfwn8J6Vp1xe2N3pWoTTD7KuiECeTbgk7WO3A4+brkjFdF4e8LFNEi8R/F/W7qbS4D5tjpWqzKY7VDyn2jAAmmx2IOD2z0808KeL/AArrPiLQJviXfRXF34b0yW0EDo0olukuMKyhR87FFXA5z1r2jRNFv/G+tw+LPHNgdP0qy/eaRo10RuhI5NzcDp5nA2r0Ue9AE/hPTp/F+v3/AIk1nSfsOhTacdJ07T7hfnntmfc8sqfwBtqBUPIAOetZ8Hwu1n7JF4YuvEnneAIZNy2XlsLySLJItnmB5iBPpkqAvStOb43/AA6hubuCTxPa77YkPtjkZWI/ukLhvwzXZ6F4g0zXPD0GuabdLJpc0ZlSdwUGwZyTuwRjB60AeYfEDwpoWp+PtM02ysPtuuXFh9nAmIe20exX5WmWIjAds7U/2ueADXq2h6VZ6Ho9npemQrBZWkSwxRjsoGPz964P4IrJqmn634svC8tzrmoSvDM4wTZxsUgAHZdoJHruzXpVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEF/Z2+oWU9newxz2s6GKWKQZV1IwQR3BFeReOfDi/DKyh8W+DJb23s7CaMahpb3UkttJaMwVysbE7GXIYFcdDxXslUdd0u21vRb7S79A9peQvBKp7qwIP8AOgC3BLHPDHNC6vFIodGU5DA8gin15h8BNSuY/Dd54T1m4STWvDNy2nyr/E0I5hfnqCvQ+1en0AFeSfHw6ho39g+KNJuYbI2skmmXd7KhYWtvdFFM+AQSUZVI7ZP1r1uuD+PCxP8AB3xaJsbfsDkZ/vDBX9cUAb/gzwzpPhXQ4LDQ4VWHAd5s7nuHPWR26sx659/St2uJ8A3KeGfhBoFx4kvIoI7LS4WuJ3Y7VUIMZJ5PGB9a4qPXPi14v36z4Pt9B0nw9MM2MeqhzPPH/DKQoO3dwQD2x9SAdJ8ftGl1H4dXeo2M7W2q6E41eynUgFJIgSevqpYY+lVf2aNQj1P4P6RciUS3TS3Bu37mZpnZi3udwP4ivHtb8W+OPFDj4VeNLVrfxBqOowBri1QKhsuWkY7Thhhc8Y4Bz0r160srf4f/ABZtrexVbXw74phMa26DbFBfQqu3A6DzIwRjuUoA9UorJ8Wa/Z+F/Deoa3qZcWdlEZZAgyx9APcnA/GvM9K8Q/Efx/pglsNLtvBOkTgSLqN3ILi5MXXKREAKSO7fh2NAHoPjDxnoHhC1SbX9RitmkOIoRl5pjnGEjXLN+Arzu4t/GHxS1Yh31Twj4FRSpQgQ3+o5HORyY0+vOOxz8rNA8XfC3wtrs1rZX76t4iPFxqKWst9cTv3UzIjZP+ypwOnFX9bh8W/EuYWdibzwp4PYbbiadNl/fqeqqnWFOoycMfTHFAHinh258OfC/wCM13YeCrFfF0t6iWlnI8ozZ3RYgp5m3afcjkDj1r2cfC/WvFl+bv4oeInv7UEFNF0tnt7IDrh/4n+pwfenfFvSrDwb8MNPPhjTbaK70nULKTS4FUAvN5yrtHcs6s4J6nJzXrMRZokaRNjlQWXOdp9M96AOG8Y/DDw5r/gefw5BpttYQbM27WsSxtE46EHH4H1BNeb+GLvxvH8LF8AHwTqMeqi1k0z+0Z5I1s1jbcvmbs5OFPQA5xX0HRQBn+HtNXRtB03TIyrLZ20duGVdoO1QucdulaFFFABRRXJ/EnxhF4O8P/aI4GvNWun+zadYx8vczt91QPQdSew/CgA+IXjzSfA+nJNqBkub+c7LTTrYb7i6c8AIvp6noPrgVS+HUHi+7nutd8Z3K2hvIwtvocIBSyQHILP1aQjr2GcewofDTwFH4ftz4k8XvHfeMrpDLfahO4cQDr5cZPCIo44x09MV6LDLHNCksLrJFIoZHQ5DA8gg9xQA+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorP8Q6rHoehahqtxDPPBZQPcSR26hpGVASdoJAJwDxmvKtP/aS+HV1jzr++syf+e9m5/8AQN1AHstFYnhDxXovjDS21Lw3ei9shIYjKI3QbhjIwwB7itugAooooAKKKKACiiigAooooAjubiG1haa5ljhhXG55GCqMnHJPvTopEljSSJ1eNwGVlOQwPQg9xXm/7R//ACRjxD/27/8ApTFXS/DL/km3hP8A7BNp/wCiUoA6WiiigAooooAKKKKACiiigAooooAKKKKAPLdWt10T9oXw/e20WxfEOl3NnckdHeDbIrH328fQV6lXm/xdm/sPU/CXi+4iMmmaHeyfbinLRRTxmHzcdwrMpOOcc9q6Lxv4rj8LeHYteNs17paTRfapYWyYbdzgzAAHcFJUkDtk9qAOmryz43h9cm8NeC0kEdtrV2Z9RfdjbZ2+JJMnPAJ2DNcz4f8Ait4St/inqstnrd0nhzUbcGW6uw/2QXqEY8p2+4GQnI4GVFV/2grux8XR6Pb+BtRfVfFUPnAW+kXCyFrKRQJxIVOApAUDJ5JwAc0AX/D66n8YNdjudZ0sWfw109/M0+1fg6lIhwkjjvEBkhfunj71e4gBQAoAA4AHasfwfrGla74csb7w/JG+nNGEjVOPK2jHlkfwlcYIPTFbJOBk9KAPHrjwlpfxG+InirUNTjuoTo6Q6RYXltO0MsMwUyySIVPUGVQD7HivLvFnxAfRp9J8L+MNYTUNc8P+I7O6t9ViUMsloPvNIRn5wrMGHX69aseDZfFPxLsvECx6lJ4c8Hx6vd6hf6tFKUe4Q9IVIx8qoMls45HpVPwN8OfCvxG8Z3F/4X0PyfBWk28lk011cSb9QuypKyYzkAblPUduOcAA7+XVrHxPpd14++I4EXgu0lJ0PSXU5ucEhZ5I/wDlo74+RDwBk471s2fhTxH8Rpk1Hx9O2m+GZAJLXw5aSFWdSOPtTjBJx1QcfTGDwvwzmuPGs8HiT4gP9m0LwLbraKskmYZ72LPmXB4AJVQnHqRj0r6D8Mawde0WDUhY3VjFcZeKO6ULIY/4WKgnbkc4PI70AWtL02y0mxis9LtLeztIhtSGCMIqj2Ap2pX9ppdjPe6jcxWtpAheWaVgqoo6kk151e/GvwfH4nl8Pw6hJ9qWQ2zXxhzZwTdAryZA+9xkce4rz/4Y+FdS8Y/EnxJJ8U71ddutDa3NrbxyBrH94GdWCD5TwAdpHfnNAHYeHdZ/4Wn8QLTVLO0uR4N8PbpbW4njKLfXrfKJFB5KIhbB9WBr16mxxpFGkcSKkaAKqqMBQOgAp1ABRRRQAUUV5l8QfiaNO1D/AIRnwVa/294xnUhLaE7orT/ppO3RQP7uc+uMigDpPHvjfTPBthG95vutSuT5djptuN093J0Coo7Z6noP0rB8B+Cr99c/4TLxzKLnxPMhFvbK2YNLib/llGO7YOGfvz7k2/ht4Dfw60+seIrz+2PF18P9L1GQfdXtFEP4EHoMZ/IDvKAPO/iubw+VHanUzbyWN2t2uxP7O8gp85uWPzKQPu7Pm68EZpvwla62lJzqhtV06z+x/Ig07yPL+Q27D5i2Pvb+enAGK9DnijnhkhnjSSKRSjo6gqykYIIPUGiCGK3gjht40ihjUIkaKFVVAwAAOgAoAfRRRQAUUUUAFFFFABRRRQAUUUUAFFFYul+JtN1PxNreg2rynUdHEBulaMhR5qF0w3Q8CgDaooooAKKKKACiiigAooooAR1V0ZHUMjDBBGQRX59X3wq1K4+Nt74F0xGXbdsVmZSRFan5xI30Qj6njqa+2vin4rXwX4G1PWVMP2qKMraxyglZZj9xOOeTXmNx4T+IKS33jTUPGOg6NqAsYVMtvZYieNHLkTFwWAwxHy8ngdhQB7J4V0Cw8LeHrDRdIi8qys4hHGO57lj6kkkk+pNa1eL/AAA+MP8Awnsup6PrU1n/AGzaSM8EkCNEl5Bk/OqNyCOMj0I4617RQAUUUUAFFFFABRRRQAUUUUAea/tH/wDJGPEP/bv/AOlMVdL8Mv8Akm3hP/sE2n/olK5r9o//AJIx4h/7d/8A0pirpfhl/wAk28J/9gm0/wDRKUAdLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGP4w8P2nirwxqWh6iZFtb6ExO0Zwy9wR9CAa4b4IXkqaPrPgnWp4ry98NXB08sw5ntSoMTMp7bSV/wCA16jXgXxOvB8LPjFZePntLqfQdYtTYap9nXPlSLt2OexyAvBI+63egD2q10DSLXRV0e30yyTSlUoLQQr5WDzjbjFQeH/Cnh/w48z6Bomnaa8wxI1rbpGXHoSB09q43w98c/h7raExeIYLNwcGO+UwH8C3B/A1Zk+J9rqdxc2vgTSbzxXcWx2zSWjpFbRN2VppCFJ9l3UARX3wqtrTUNQ1LwXrep+GNRvZfOmFqwltpH7loHBU5PpivMvi9448a+CfBms6B4yeG5n1O3MWl65psflBzuUSJKn8DbCcFf16jtPEPxa8SeF7eO48RfDXWIbU/fmtLuO5VD77Bx364ry343eM9N+MHwmm1PwyJ4X8P3qT3lldIom8pwUWQbSfly3P456DIBF418Y6Fof7MmleF/Duu6fNq1xDBHeQW0odwHzJKDjp83ynP0r1nwfr/hTwB8DIrnSNV06aOzsTMxjmVzLcsuSpAOclzjHYfSvBfiB4Y8M3vhD4QTeHrG3Fxq+y0vJLNcPM48pXDerhy455zWR+0F4Y0m2+Mtv4c8H2cFqskNrbNBDjaJ24HA6HBTOec5PegC34W8a6hrvgvR/BWg6Lf67fXGpSaprUIUKs480MEDDOEOFLM2OeOlfQ1r4d+JPjRLhfGWsw+GNHnTZ/Zmi7WnZe4acg7c99p59u/b/D7wPovgbQbXTdGtIUeOMJNc7B5s7dSzt1OTzjoOgrqKAOf0PwboGieFl8O2WmW/8AZPlmOSCRA4mz1L5+8T1JNXPDnh7SPDWnix0DTrXT7QHcY4IwoY+p7k+5rUooAKKKjubiG1t5J7qWOGCNSzySMFVR6kngCgCQnAyelQWN5bX9qlzY3ENzbPnbLC4dGwcHBHB5BFePeM/GLfEq4bwV8N795BK4Gr6zAD5NrbfxKj/xSNwABkYzz1Ifong3xt8NnvbHwD/ZWr+Gp5DLb2WpzvFNZuR821wCGQnnHB/UkAPiVr3iPxV44Hw88GPNYRRxxy65q6EBraGQZCIezFe/XnjGCa77wH4F0DwLpjWfh6zEPmHdNPI2+advV3PJ+nAHYCsj4XeDtS0G71/XfEtzaz+ItenSa6FnuEESou1I03cnAJyT/TnvqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr51+E+uXmp/tT/EZJG8qD7M0TQoTtc28kUUbn/a27v8Avo19FV8afB7XIdQ/aw1C+0m9ZtO1K5viHUlVnjKu6gg4OMqpwe4FAH2XRRRQAUUUUAFFFFABRRRQB4x8aZ4te8ceD/Cv2lBawTNrOpqtxtKwQYI3KATnnI9cGsmxtIfjH4sGreJJbq38EHEWh6dNcCD+0pEO6SVourr8p/Ae1eX/ABX+IFkfFfxLltrq3fULhIdBtoBBJlolJ82QP2ZWG3HQ571rQ6Z4LvvDVjrfjbxva2epXMCx6HHoXnmPSUjI5SJRu3bgdxYDknBzzQB6H8a/AcHh6aD4l+DrZLTW/D4Waa1gURxXUCnDhgMYIQtkjqoI9K9g8La9YeJ/D9jrWjymWwvI/MiZlKnrggg9CCCD9K8U+EXxntNR1+bwZ4q1m21a4ZitjrP2c20d6rDiKSN1XZJzgcYbpknBab4Ou/w7+J/iH4c3zlNOvXOp6Hu5BjOdyDqeAuPmYf6snHzUAe80UUUAFFFFABRRRQAUUUUAea/tH/8AJGPEP/bv/wClMVdL8Mv+SbeE/wDsE2n/AKJSua/aP/5Ix4h/7d//AEpirpfhl/yTbwn/ANgm0/8ARKUAdLRRRQAUUUUAFFFFABRRRQAUUUZ5x3oAZLLHCu6V0jXOMscClkcRxs7Z2qMnAJP5CvFP2g9B17xzqOmeF9J0e4utOhtp9QuJmkMEJmKtFAolIwWVmLlO4xnFeh/CzU9T1bwBo1zr9ld2WrrAIbuG7iaOTzE+UuQQOGxuHs1AGt4X1u18SeHdO1nT932W+gWeMN1AI6H3HSrOrWVlqOm3Fpqtvb3NjKhE0VwgaNl6/MDxivPvhZMvha+1DwFqLGGSzmkuNIMrf8fVk7lhtPcxklCOowD0NdV4s8aeGvCkKN4k1izsVkbYqSvlmJ/2Bk49TjA70AfOd38HNB+JOsSTeBdHbw74eildX1aaR3F2w4xBAW+5nncSAe1db8CtT1D4eeJrz4YeMp7ZCg+1aPdZ2rcox5RSep7gHkEMOcCveNNmtLiwt5tOeGSzkQNC0ONjKehGOMVyfxL+Gvh/4h2lvHrcU0d3a5NteWz7JoSfQ4IIyAcEH8KAO1r5b+Nw0TwB8SLXxdox0u5tLsPpuv6LFcqJJxIp3ExjpleSf7yrnqa2734V/FvT7a9tNB+JUs9iq/6Mty7iZv8AZL4Yp9QfyrxjW/hVC2tJ4astel8RfEO6m3zx23NpapgtIZpm5ZunPHuMkUAc/wCOo7XRtZ0OXwB4gu73RbhhqGm2zSnzrCcvtKMgPDgovzcZGOvU9/4f8ES+GPj98P4Ndv5r/W9QRdT1BZDuaG4PmMFJ5JwVBJPuemK8NmjvfD2vvFKvk6hp1yVYHnZJG39CK9YHjm78f/tF6Br2hW8em3EtxbQRLO28AABXLY65Bbp2x3oA+66KZLLHCm6aRI1zjLEAUyO5glJEU8TkckK4NAE1FGecd6yfFuv2Phbw5qGtapKsdrZwtK2WALkDhRnqxOAB6mgDJ8c/EPwv4Hiz4j1aC2mZPMS2HzzSDpkIOcZBGeleS+HbK5/aA1ltd8QpcWngGwlMdhpgk2m+kH3nlKnoMDp9AepMnws+F1v42MnxA+JcI1PU9Z/f29jLkQ20PRAV7/KBgHgDHU5r3yytLextY7ayt4ra2iG2OKFAiIPQAcCgCvo2kadoljHZaPY21jaIMLFbxhFHGOg7+9XqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+CvA1rb2Gn/DrX7i2jt4IvF8iXWoMgUKg+ysqs/oMSkfRvevtjx5eXGneBvEV7ZSmK6ttOuZoZBglHWJip59CBXyjr1lcXP7HPhO9hCMmn6q9zNubB2me4jGPX5pFoA+xZLmCOZYpJ4llbGEZwCc9OKmr438cTy/FTWLjxDomlaheRXGhQW6Nb6NJdKt6k25oBKB+5P8At5+63vX17pDXD6VZNewC3ujAhmhD7xG+0bl3d8HIz3oAt0UUUAFFFFABWT4s1WPQvC+rarO7Rx2drJOzqu4rtUnOO9a1eUftO+IV0H4P6yizxR3WoqtlCkgJ8wOwEgHvs3nJ9KAPlT4NaUnifx5e+JfE10o0/SS2r6hNIQnmvu3Bc5UAs2cY/KnRfEk6B4k1fxf4Naz0/VNXlmibTGsg62kJ2kOsmANxYE7QMeuelXo/A2qXNn4f8Mr4htxpc1n/AG7qduAP9AXaDvdgPmJRgVUnrkcdT6B8N/gTonji2l1yeC70vw3NC0elxicNdTc/6+U8r1zhQB7+4B5HqWu3+q+BNZh8Wac2o6nHfJ5esMVN5bSrgNFcMQXaJlLbckfMmBkDA9Ij1fWfGnw9k12C/F14p8A3Ed3a3jBXa4s3UMA/zkGRdhLcE5AXJOTXk3xH+HviP4cXcFtr8aRR38bGJ4Zg6SqrDKnHcHYcH1FWPg340m8D+Kv7Qkt5bnRpozbanCi53wPweexBII5GSMUAfdHwp8aWvjzwVYazbHEzoI7mMrt2TAYcAZPGc456U34k+E9V8WWNnBo3ii+8OyQSF3ltA+ZQRjadrpwOvevm34WeLrH4a/Fmaxs7oN4G8RlZrWUgBU3fcJJ5XYSyMO3GfWvsMHIyOlAHiH/Cm/GP/RW/EH5Tf/JFH/Cm/GP/AEVvxB+U3/yRXt9FAXPEP+FN+Mf+it+IPym/+SKP+FN+Mf8AorfiD8pv/kivb6KAueIf8Kb8Y/8ARW/EH5Tf/JFH/Cm/GP8A0VvxB+U3/wAkV7fRQFzwbUvgZ4k1Syks9T+KGsXlpJjfBcQyyI2CCMqZyDggH6ivZ/DGl/2H4b0nSfO8/wCwWkVr5u3bv2IF3YycZxnGTWlRQAUUUUAFFFFABRRRQAUUUUAFeWXmvvZ/tK2Wjhsw3/hzLLnHzpPIyn/vkOPx9q9Tr51+K+h/ELxE9zrJ8HaNDcaYryabeWmoMNQgC5KkMp2v/e2Y746mgD6Kori/g54vPjn4d6TrUwC3joYrpQMYmQ7WOO2cbsdgwrtKAMTxZ4V0Txbp4svEOnxXsCtuTdlWjb1V1IZT9CK523+D3w/gspbUeFtOkSUYeSZTLKfpIxLj8DXe0UAeRT/Bp9GiZvh74t13w9Kp3R2zTm5tM+hjft+J/Gtn4d+L9bn1u88K+O7O2s/EdrGJoZ7YnyNRh6GSLPOVOAw7Z7dB1nizxLpPhLRJ9W1+8jtLGHq7ZJYnoqqOWJ9BXz18X/iNquv2Oia54M8JeILVtFuxdjWb+zMMaRsu1lHJzG+RuJ4wo+oAPUvjZ4l1qwsNP8N+DYvN8T687QQN2togB5k7egGQMn1zzjB8W+Ivg+D4K/B+4istbc+K9duY457tPkkkjX5njjP3lQHaSc5OeeoFdZ4O0D4h+JfG/iLxKfGGlW97ZxJpVvPaWYubWQfLLJGu4ggKxALDJJz6Yrkf2k0+Il94KhHjDw9opsNOuFk/tbT5ySCfk+4zZAYsOMHnHpQB8ySSPLI8krs8jkszMcliepJqbTbybT9Qtry2do57eVZY3U4KspyCPyqtVvStOvNW1G3sNMtpbq8uHEcUMS7mdj0AoA+jbCTU/wBpjx3PFd3U2j+E9IiVxbxHc7FjgE/wl2IJyR8oGADyT6VB+zH4GgwY7rXVcDBZbtQT+SV13wJ+H/8AwrzwJb6fciJtWuG+0Xskfdz0TPcKOPrk969EoA8Fk/Zm8PiXfa+JPElue224Q4/HbW3o37P3hG0aF9XuNZ10xOHVNRvGaMEdPkXAP0Oa9fooAbGixoqRqFRQAqqMAAdhTqKKAGyyJFG8krqkaAszMcBQOpJ7Cuc/4T7wd/0Nnh//AMGUP/xVdDdQR3VtLbzruhlQxuuSMqRgjI9q85/4Ub8Ov+he/wDJ25/+OUAdMnjzwg7BU8VaAzE4AGowkk/99V0lebxfBD4exSpJH4fw6EMp+23HBH/bSvSKACiiigAooooAKKKKACiiigAooooAKKKa7qm3cyruO0ZOMn0oAdRRRQBxPxt1QaP8JfFV2YjMDYSQbQ23/Wjy859t+fwrj9H8H2vib9l7TdCgt442uNFjnhVW8tftO3zFZiAesnJ9cmtb9pi7t7X4K+IluZ4omuEjihDsAZH8xTtX1OFY4HYH0ru/CmjQeHvDOl6PZySyW1jbR28by43sqqACcADPFAHx9+yH44k0Txs/hu6kH9nauDsB/huFHy447jI7dQe1fa1fCvx9+Feu+DvF+pa9plrcy6BcXIuIbyJgWhkclirBcFcNnBxjG3nNelfB/wDaVs2s4NK+IbNbywRbV1VVaQTYH/LRFUkMf7wyD3x3APqCiqGn6xpuo2EN9Y31tPaTIrxypICrBhkHPuKv0AFFFFABXyT+1v4xl1fxhovg7Q4xcz2EqXMyhNxNy3CR4I7KcnqDvHpXr37S3jZ/Bvw1uRp989nrWouttZtE4Ei8gyOMnOAuRuHILr04NfGPhjxW2l3es6pOs174jvoXgtryaYr9naUFZJy+7JfaSBngbt2eMEA6/wAMXupazc+KJtVnklF15l3r81jP8y2cJ+aFcKUAZioUhiNq4xjFe+2GneLvHdzZ6ZrWoHwLojWLvY6Vpd2rXlxGCqs0jDjaAy9APvDjrXCabpXhi80/wX4B8JzQ3Zlki1PxRdW0kUibEXcyyTH5SFYsAqkjA9+eC8V/F+4uPjla+LtKLrpmmSrbWkA4DWi5Vlx0G8Fz7bh6UAe8z21/8H78xanZXnif4eSeZOtzLELm60mQgllOesR2g54xyTz975l8Saho3hPxNrlt4I1BtT0HUEMW1mbZJbsDmOQMqtvVsFW7YB61+hOn3lrqumW17ZyJcWV3EssTjlZEYZB+hBrn/G3w/wDDXjTTUstf0yOaKJi8TRs0TRuVI3AqRnr0OR7UAfnbc399HZWejauk4tLSXzkhddskSuAWCFh8oYYbpjODX2d+zN8SW8VeH/7C1i4aXXdPjEgeSZHae3J+RiQc7lyFYEZHBPXFeLeNf2a/EGg6Nrmsx6pZ3dtYhpoLeMSPNJCCfvfKAGC4PGR16V4/4dvtY8K6lpPiSxingEc++3mIZY5ihG5MjGR2IB6GgD9N6K8d+DXx10j4i382l3Nn/Y+rqN0MEk4kW4XvsbA+Yd1x05Gecel6t4l0PR4YpdW1jT7KOVxEjT3CIGY8hQSevBoA16KQEMAVIIPII70tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5t4KjXQfiz4y0GJfKsr+G31u1hUAIrNuinI+rohPufevSa8h+PXh3xFJdeHvF3gtJ5dV0OVvtFrbybZLq2YqzIB/Fyn3e+TgE4ru/AXjLSfHGgR6rokxKE7JoJBtlt5B1R17Efr1HFAHR1n+ItXttA0HUdXvyRa2MD3EmOpVVJwPc4wK0KwPH+lNrvgbxBpaKrSXlhPDGGOBvKEL+uKAOI+HGm33jmW28deNbeEiVN+iaYRvjsoW5EpBHMrDHzdhjGM4HqN1bw3dtLb3USTW8yGOSORQyupGCCD1BHauJ+Bd39s+EHhSQuGZLFIW5zgp8hB9xtxXd0AVNJ0yx0ewisdKs7eysosiOC3jEaJk5OFHA5JNQeI9E0/xJod5pGsW63FhdxmOWMnGR6gjkEHBBHQitKigD5V0b9lBv7cnfWfEKDSFmJhjtYyZpI88BmbAU464DV9CeEPAfhjwegHh3RbOzk2hDMqbpWHu5yx/OumooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPnjxx+0W2geKvEHhmLQ4xf2swtbO7lugIS5IG+UEDaozngnp26185Hx7e3l9BfeKdY1/W3Erzi2j1J7YWtyGyk0TAMoGCwAVVI56DGffPi3+zhqHijxdqWv6FrNujXpaeS3u1IPmf3VKj7uMdaz/hD+z9/a0Fxe/EnSBp5hhFlbWNu2wyYXm4dlY5b5sD3UkjpQByXhL9pTXvDcs9reJL4l0xQBbSXxW2uVAAHzMgYN0PXJOc57Vp6z+1drlw9odJ8P2VkqSbpxLOZ/NT+6PlXb355rN8bfs3eJtI1V38PW0Gs6fczSpDGk3lvaqT+7MhbG7AIzjuK63Rv2UIn0BW1jxBLHrLIx2W6BoEbHyjJGSPXp7UAcX8S/jJP8YdCsPCkOgDT7+fU7drdxdiRHYh02tlV28uvPPevtmMFUVT1AAr5R+Fv7Puqx+MLW+8RW66RBok0ckckE3nHUJkkDBwD9xCB7H2619YUAI6q6MjqGRhggjIIr5d+L/7NAurhdQ+HQjieR2M+nzy7UGTkGNj0A/un2x6V9R0UAfnj8Q/hT4v+Huh2l3rcaiwvH/ei2lLpFKpYIJMcZIJKnnqR1yKpaP8AFH4gaQWu7PxRrTIw8ndczNcR9jgCTcoPA6c4r9Frm3huoWhuYo5oW+8kihlP1BrH1vwj4f1zRX0jU9Is5tNeQSm3CbF3jo3y4wfegD4Tufjl8RbrTbuyn8S3BS4UKZI40ikTBz8joAVJ6fSul0j9pjx1Y2Atrj+z71kgEUc00J37hj53IPzHAPpknNfVGl/CDwDpeoQ3tj4YsY7mFtyMS7gHp0YkH8RW7q3g3w3q2nzWOoaHp8trMAHQQKucEHquCOQOhoA+APiX8TPEXxGmsX8RyWxSyVlhjt4tiqWI3HqSSdqjrjge9dl8C/hVefEu5tJ9Qt4rHwvpr4nnSMrJeuTkoH6k4ABOcKMYGSc/Tuo/Ab4c3tnJbjw7FbF8fvbeaRXXBzwST6Y6V6BoGk2mg6JYaTpsfl2VlAlvCpOTtUADJ7njk9zQBz2ofD7RW8G6j4c0GCPw/a30Igml06FEkZAMEEkHcSuVJOTgnnPNeS/8MoeFv+g9rf8A5C/+Ir6KooA5r4d+FI/BPhW10G31C7v7a1LeTJdbS6qTnbkAcAk4/LoBXS0UUAMmijmheKZFkikUq6OMhgeCCO4rxiX9mn4fSQ7PJ1NX8xpDIt1hiCB8uMYwMZHGeTzXtVFAHyB49/Zm1nRJbvV/A2p/a4bYfaYLVtyXasGyFjZeGYAAg/KSRwM4z82OrI7I6lXU4IIwQa/VKvNfEXwQ8Aa813LdaGsV1dSmaW5gmdJC5bcxzkjk57d6APjaD4yePYNAs9Hg8RXcVraOjQumFlATG1C4GSox0Oc9DkcV3XhL9pTxX4fvbmPWpIfE9mc+WzqLZw3GCGVOnB4K9+tavxt/Z6/sJ9OvfAyzTWU8sdrNbzyF3SR2wrggfc55z0xn6ZniT9nfxf4aCS6LZWPiOO5tRDKhOHt5WX52UEr0IO1s9xkUAdfL+1qojbyvCJMnyYDX+B907+fL7NgD1HJx0rpfh7+05oWvakbPxNY/2AXIEM5n82E+zttXb9cY968YtP2aviFcW0UzW2nQGRQxiluwHTPY4BGfxrUf9lrxmNJS4W+0lr0n5rTzGGBnH39uOmDQB61rf7UXg3T9RltrKy1XUYk4+0Qoiox9tzAke+Kn039p7wLdPILuPVbJVRCrSW4feSMsBtJ+6eMnr2r5IttF8S+G/HsOkW1nLF4khuPIih8tZCznKjAYFWBzweneq2rQ+IINUujqdldQ32pu0ciyWuwzMXUkIu3Gd237v9aAPrTxD+1J4Ts90eiadqeqTGPMZ2CFN/OFJb5vTkKevektP2pPC3m2cGpaTq9rMyqLohFZbeToy9QzAHvjPtnivl3wb4J8Y62+oTeGdGvJ3sd0FyQqqYiysGXDY+bGeByPbiuUujMbmU3XmfaN58zzM7t2ec55zn1oA/QV/jh8Pl0EaqfEVsY9ob7MObjk4x5X3s/05rovh9450Tx9pNxqPhyaaW1gnNu5liMZ3hVbofZhXwHZ+Br9tOM+ow6laTPEJreJdOllEyEZU7l4GenNfVH7G1heaf8ADzV47+1uLWRtVdgk0ZQkeTFzgjpxQB75RRRQAUUUUAFFFFABXB+Kvh3Be6wfEPhe9k8P+JwPmu7dcxXQznbcRdJB78N78Cu8ooA8t0v4pS6NqMmkfFHT4/Dl6v8AqdQVmawvOMny5CPlOOdrHP48Vc1D4qaVfsdO8CH/AISXXJRtijtVY20RP8c02NqoOpwS3YDmu/vbO2vrdoL63huYG+9HMgdT9QeKLO0trGBYLK3ht4V6RxIEUfgOKAMbwD4f/wCEW8JadpLSJLPChe4lRdqyTOxeRgOwLsxA9MV0FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVj+L/EFn4V8MalrmptttLGFpWGcFz0VB7sxCj3IoA1ldXLBWVipw2DnB9D+dOr5D/Zm+LF3P8StX07xHdZi8SXDXMW5vkjuj0VfQMuFH+4gr68oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMw+H9IOvjWzplmdYEflC9MK+cExjG7rjFZnxF8H2Pjfwtd6TehY5WUta3W3L2sw5SRTwcg46EZGR3rpqKAOY+HHg+y8D+FLTR7HEkqjzLu5xhrqcgb5WySckjuTgADtVi98G+Gr7WE1W80HS59SQhlupLZDICDkHdjOea36KAADAwOlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVBe2dtf27W99bw3MDYJjmQOpxyMg8VPRQB5l8NfDumR+IvG8kmjWSGLXc2ztaKCii3gI2HHA3ZPHfNem0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSMwUZYgD3NAC0UisrfdYH6GloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisTxrPrlt4W1G48KQ2lxrUURktobpWKSEclflIOSMgc9cZ4oA268++OvglPHfw51LTkRTqEA+12THtMgOB/wIbl/4FntXLfs4eNvGHj6LXNV8UG3isLeVbW3hht/LHmgZkyTluAUHX+I17HqF3DYWFzeXbiO2t42mlc9FVQST+QoA81/Zy8DjwT8NbJLiMLqmpYvbs91LAbE/4CuBj1Leteo1wXwk1zVtVsdVg8QP5l7b3Kzo+3A8m4iSdE+qeYY/+ACu9oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPJfEniHVrb9o/wAK6FBfTJpFzprzTWoPyO4W5IJ9/kX8hXrVeIeLP+TsPBf/AGCZP/QLuvb6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPOLy+fw78Q7Kw0WGCDQ5ZDPqyqoy1zeOVhYeh3xNn/rp9K3Pi1K0Pwt8XyI21xpN1tPv5TAVzXineB491Fcs2nzWEoHcC3Edxge3zH8zWz8amB+FfiJM8TW4gB9N7KgP4bs0AR+C7IWHjvxJEkLxI+naZIAegAWaPaO/Hl13dcnD+7+K93kNmfRIcHPB8ueXOR2P70fmfSusoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPEPFn/J2Hgv/ALBMn/oF3Xt9eIeLP+TsPBf/AGCZP/QLuvb6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorlPirrtx4Z+HevaxYuEu7S2LwsVDfPkBeD7kV0tjcx3tlb3UB3QzxrKh9VYZH6GgCaiiigDitBsk1q08cW0/+pv9Rntieo2i3ihOD/wE/jkVg+I7t9X+CGmFz5lxcvptrMp6tJ9qhjlX65Dj1rrPh8rf2XqbsRmTWNQIA7AXUi/+y5/GuM1JGi0xtGeEyJB40t1j2HG1XnjvM/h5hGPagDs9XItviD4dn4AubW7sz7t+6lX9Inrp65fxuxguvDF0o5h1eNT64kjki/8AagrqKACiiigAooooAKKKKAMjxZ4j03wnoU+sa5M8GnQMiyyrGz7NzhQSFBOMsOgqPwv4r0LxVZ/avDuq2t/CCQfJf5lwccqeR+I5rE+KdjD4t8HeI/CdhdWkmtz2BkjtGmUOOcoxGchSygZ6VnfBb4V6Z8NND8uPZda3cqPtl9t5bvsT0QH8+p7AAHo9FFFABRWfrGt6VokUcms6nY6fHIdqNd3CRBj6AsRmsr/hPvB3/Q2eH/8AwZQ//FUAdLRXNf8ACfeDv+hs8P8A/gyh/wDiqP8AhPvB3/Q2eH//AAZQ/wDxVAHmviz/AJOw8F/9gmT/ANAu69vrwLVdX03Wv2pvB1xo+oWeoW66ZJG0trOsqhgl0SpKkjOCDj3Fe+0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFcJ4v8AiDaeHfEFlbuYZtMRJf7SmizJJbSYHkIFXOWdgyhcZzt9a7Swu4b+xt7y1cPb3EayxuP4lYZB/I0Act8WY1m8D3EEkAuI57uygeIjO5Xu4VIx34Jqf4bytH4dOkzFjPos8mmOSMErHjym/wCBRNE3/Aqb8SQ76PpkUcnl79Z04McZyBdxMR+O2mTTQaB49eW6lWCz12GNFd2IX7XEdoXPQM6OoHr5WOuKAOuooooA5L4VskngyKaOUzLNe3svmE53bruY/wBa5XVkZ/iT9kbcBJr9ldDyzywFhNww9Mw5/Kuk+DRRvhloEkSeWs0LTbc5wXdmPP1JrIvbS7l+OlqIrU/ZI7KG+luAvAKrdwhScYz++HHXA9qAOi+JLLF4Wa6c4WzvLS6Yn+FY7mNmP4AE11FVdWsINV0u80+7XdbXcLwSr6qykH9DXll3rHjXSrG2OsobK18P+QdQvIwrx6srTIm5CcsgEXmO44IYqMkZyAeu0UUUAFFFFABUdxMlvbyzTNtjjUux9ABk1JXN/EmZovAWvLHnzp7R7aLHXzJR5af+POKAOJ8PaTbWXw+0HxhewxHXi8Wr3d/t/elZyvnAt12iJ9u3oAi/3Rj1qsy90e3ufDU+igbLWS0azwB0Qps/lVTwLqMuqeEtNuLvIvVj+z3Snqs8ZMco/B1agDeooooA5/xj4N0HxlbW9v4ksPtkNu5kiXzpI9rEYJyjDP41yv8Awo34df8AQvf+Ttz/APHK9KooA81/4Ub8Ov8AoXv/ACduf/jlH/Cjfh1/0L3/AJO3P/xyvSqKAOI8N/CnwZ4a1q31bRdG+zahb7vKl+1TPt3KVPDOQeGI5FdvRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWb4i1RtG0qW8i0++1KRSFS1so98shJwMZIAHqSQAKvzSrDGXfdtHopb9BUZuogcfP9/Z/q26/l+tAHGfC/QrEaAdcn02OLU9cmbUrlpYgJTuleWEOD/EiyAD0xTYt/gPVLeO91Rz4Tud8MCSwqE058hkVpQM+WR5igtwuEGecnqzrViOskg+R5MeS+dqkhu3qDxTZNZ04xSF5GMYCbswuRhx8vbnI/wDr0AYXxA8q4bwomBKsut27JjkHarvn8ApOfaul1bTrTV9NudP1KBLizuEMcsT9GU/qD6Ecg8iuUsNA8NWetQT2r3yfZrqQ21ksky2tvMEZXKRDCD5Xb1Xk7cEnPRjXdPMYcTPtMRm/1L/cB25xj17daAMK08zwfq1pYS3E03h6+ZYLV7mdpXs58HEbO5LNG4HykkkN8vIZca0HiXS7/wANXmtaXfQ3WnwJMTcQkFcxbg2D0OCp56Hr0putS6Jq1hc6dq8SXVnIY45oJYWZW3fMmRjnoD7Y5xXnvirwc+p6frtloHiWXS7TUpZHgsorZo4VcQpHMshAJaMorEKABucn5iBgA7b4WW8lr8NPCsM6hZl0u28wYx8xjUn8ck11FU4LmzgtI1idUgSJSowRtToOKla7gVyhkAbeI8f7R6CgCeqWtadBrGj32m3i7ra8ge3kH+yylT/OpheQEKRKCG3Y/wCA9aab62CM/nLtVQxPoD0oA5nwH4hurq2i0fxHayad4htYIhLFO6H7V8pBmiKk5Usj8dRjkDIrr64z4k2tre+Hrq9to421rS/9KsZQn7xZovn2K3UBtpUjoQxB610C6/pZ0qHUnvoIrCWITLPK4RNhxgkngdR+dAGnRXjus+Ktd1LRNa8RaVrNqltpc7tY6XaR/PfLFNtxM7bifMEbqqoF++DkkUui+NNS8JeHZNP1Oy1DW9SinkeO43ZSRMCaZWk52vHudAhALbVA65AB7DXMeO9066BYKAftmr2+4f7MRNwf/RNVdS+JnhDT4g0mt20rtEJo4rcmV5ASAqqF6sdwIXqRzjAJqhYalc6/4m0/UtTgt9H0/TC/lWtxcK9zJNMoWN2CEoilGfA3End0GKAPQK5Pw/jS/Guv6ScLDeBNWthz/EPLmUfR0Vz7zVuJrWmuyqt9blmZ0UbxyyAFh9QCM1znitrLUltNT0jWra01jTkae2meTMTxMyq8cqjrG5VQT1BCsOQKAOzorhTrWv6nI1k9xpGgOsiQvNHOL13Z8kCIEKASBwXU/wC6cc17Tw/pETrJN408RXaSb8LJq7KDsGXxs2ngdcHigD0KmxSJLGskTq8bDKspyCPrXDXfhzwTIskly4w8ayzMdQmHnxtgDzTv/eKcjhsisjxxYeFvDmkSa7osVnp93pd3BK4sm8lWCSKZYyi4U7ow4IxQB6lRUdtPFc28c9vIssMihkdDkMD0INSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzvxB8U2vgvwbqmv32Gjs4iyR5x5sh4RPxYge3WuA/Zo+JM/j/wAJXUWsTrJrunzkTnAHmRuSyMB6Dlf+Aj1rtfiJ4C0j4gadbWHiB7w2kEnnCK3mMYZ8YBbjnAJx9TXnH7M/w60TSPC2jeLbFr1NWvrR0uMz5jdS54K4/wBkH8KAPc6KKKACiiigAooooACMjB6Vwi/DDRGsJbO6uNVurZ2P7ia9kMIQcRR+VnZtjG3bxnKgnJru6KAMXwXon/CN+FNK0hp2uZLSBY5J2zmV+rOc9yxJ/GtojIwelFFAHO+G/Bmh+HtMgsLCyR4ILpryEzgSNHKcgFSem1DsXuFAFdFRRQAUUUUAFFFFABVbVLKHU9Mu7C6G63uoXgkHqrKQf0NWaKAM3w1a3lj4d0y01OWOW+t7aOKeSMkq7qoBYZAPJGa0qKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKoaFpFjoOk22maRbrbWNspWKJSSFGSepJPUmr9FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB418QrzT1+J32fx3f39j4aGnK+n+TPNDDJcbzvLNEQTIB0BPTtzz6zoxibR7E20k0sBgjMck5JkddowWzzuI655zVyigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Camera lucida drawing of a human bronchial parasympathetic ganglion neuron. The complex morphology of airway ganglia neurons, with an extensive dendritic arbor and multiple synaptic contacts, facilitates integration of synaptic input. B) Digital overlay of consecutive intracellular recordings of human bronchial ganglion membrane potential and synaptic potentials. Stimulation (at arrow, with associated shock artifact) of an extrinsic vagal nerve branch initiates depolarizations known as fast excitatory post-synaptic potentials (fEPSPs). The fEPSPs, most of which are subthreshold for action potential formation, are mediated by acetylcholine acting on airway parasympathetic ganglia neuron nicotinic receptors. C) Temporal dissociation of multiple fEPSPs (following shock artifact [arrow]) in human bronchial ganglia neuron reveals that several preganglionic inputs regulate the excitability of each bronchial ganglia neuron.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kajekar R, Rohde HK, Myers AC. The integrative membrane properties of human bronchial parasympathetic Ganglia neurons. Am J Respir Crit Care Med 2001; 164:1927. Copyright &copy; 2001 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23728=[""].join("\n");
var outline_f23_11_23728=null;
var title_f23_11_23729="Klisic test";
var content_f23_11_23729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    The Klisic test for hip dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 465px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Klisic test is performed by placing the index finger on the anterior superior iliac spine and the middle finger on the greater trochanter. An imaginary line between these two points should point toward or above the umbilicus. The line will pass below the umbilicus if the hip is dislocated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23729=[""].join("\n");
var outline_f23_11_23729=null;
var title_f23_11_23730="Sulfur and salicylic acid: Pediatric drug information";
var content_f23_11_23730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfur and salicylic acid: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36418?source=see_link\">",
"    see \"Sulfur and salicylic acid: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41395?source=see_link\">",
"    see \"Sulfur and salicylic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12959541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ala seb [OTC];",
"     </li>",
"     <li>",
"      Pernox&reg; Lemon [OTC];",
"     </li>",
"     <li>",
"      Pernox&reg; Regular [OTC];",
"     </li>",
"     <li>",
"      Sebex [OTC];",
"     </li>",
"     <li>",
"      Sebulex&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiseborrheic Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36418?source=see_link\">",
"      see \"Sulfur and salicylic acid: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     General guidelines; consult specific product labeling. Children &ge;2 years and Adults: Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo: Initial: Massage onto wet scalp; leave lather on scalp for 5 minutes, rinse, repeat application, then rinse thoroughly; use daily or every other day; 1-2 treatments/week will usually maintain control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Soap: Use daily or every other day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F247574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cleanser, topical [scrub]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pernox&reg; Lemon: Sulfur 2% and salicylic acid 1.5% (56 g, 113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pernox&reg; Regular: Sulfur 2% and salicylic acid 1.5% (113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ala seb: Sulfur 2% and salicylic acid 2% (118 mL, 355 mL) [contains soya lecithin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sebex: Sulfur 2% and salicylic acid 2% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sebulex&reg;: Sulfur 2% and salicylic acid 2% (200 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13865223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Avoid contact with the eyes; for external use only",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Preparations containing sulfur may react with metals including silver and copper, resulting in discoloration of the metal",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic shampoo for dandruff and seborrheal dermatitis; acne skin cleanser",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F13865175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local: Topical preparations containing 2% to 5% sulfur generally are well tolerated, local irritation may occur, concentration &gt;15% is very irritating to the skin, higher concentration (eg, 10% or higher) may cause systemic toxicity (eg, headache, vomiting, muscle cramps, dizziness, collapse)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulfur, salicylic acid, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants are more sensitive to sulfur than adults; do not use in children &lt;2 years of age. Topical preparations containing 2% to 5% sulfur generally are well tolerated; concentration &gt;15% is very irritating to the skin; higher concentrations (eg, 10% or higher) may cause systemic toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid contact with eyes; discontinue use if skin irritation develops",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to salicylic acid monograph.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Salicylic acid works synergistically with sulfur in its keratolytic action to break down keratin and promote skin peeling",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: 1% of topically applied sulfur is absorbed; sulfur is reduced to hydrogen sulfide",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41395?source=see_link\">",
"      see \"Sulfur and salicylic acid: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contact physician if condition worsens or rash or irritation develops",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12819 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23730=[""].join("\n");
var outline_f23_11_23730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12959541\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050105\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050101\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247574\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13865223\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050108\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050103\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050107\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13865175\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050111\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050100\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050099\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287364\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050098\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050110\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050104\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12819\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12819|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36418?source=related_link\">",
"      Sulfur and salicylic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41395?source=related_link\">",
"      Sulfur and salicylic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_11_23731="Sertaconazole: Drug information";
var content_f23_11_23731=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sertaconazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/10/33955?source=see_link\">",
"    see \"Sertaconazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ertaczo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F220633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F220619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tinea pedis:",
"     </b>",
"     Topical: Apply between toes and to surrounding healthy skin twice daily for 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F220627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tinea pedis:",
"     </b>",
"     Topical: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F220620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as nitrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ertaczo&reg;: 2% (30 g, 60 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F220607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only. Apply to affected area between toes and to surrounding healthy skin. Make sure skin is dry before applying; wash hands after application. Avoid use of occlusive dressing. Avoid contact with eyes, nose, mouth, and other mucous membranes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F220606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of tinea pedis (athlete's foot)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F220631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Dermatologic: Burning, contact dermatitis, dry skin, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Desquamation, erythema, hyperpigmentation, pruritus, vesiculation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F220610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sertaconazole, other imidazoles, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F220597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue drug if sensitivity or irritation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; avoid contact with eyes, mouth, or vagina.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies following oral administration. No studies have been conducted using the topical formulation on pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F220622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16571138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if sertaconazole is excreted in breast milk. The manufacturer recommends that caution be exercised when administering sertaconazole to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F220611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Ertaczo External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (60 g): $319.39",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F220603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reassess diagnosis if no clinical improvement after 2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F220613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dermofix (BE, ES, ID, KP, PT);",
"     </li>",
"     <li>",
"      Fuganol (GR);",
"     </li>",
"     <li>",
"      Gyno-Zalain (PE);",
"     </li>",
"     <li>",
"      Monazol (FR);",
"     </li>",
"     <li>",
"      Sertacream (IT);",
"     </li>",
"     <li>",
"      Zalain (AR, BG, BO, BR, CL, CN, CO, CR, CZ, DE, DO, EC, GT, HK, HN, MX, NI, PA, PE, PH, PL, PR, PY, RU, SG, SV, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Zalain Cream (SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F220596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alters fungal cell wall membrane permeability; inhibits the CYP450-dependent synthesis of ergosterol",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F220609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Minimal",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10187 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23731=[""].join("\n");
var outline_f23_11_23731=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220618\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220633\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220619\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220627\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220620\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220605\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220595\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220607\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220606\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220631\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220610\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220597\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300037\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222903\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220601\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220612\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220622\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16571138\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220611\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220603\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220613\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220596\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220609\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10187\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10187|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/10/33955?source=related_link\">",
"      Sertaconazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_11_23732="Pemetrexed: Patient drug information";
var content_f23_11_23732=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pemetrexed: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     see \"Pemetrexed: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alimta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alimta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691944",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lung cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pemetrexed or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take folic acid 1 week before, during, and for 3 weeks after your care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697822",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give you a vitamin B",
"       <sub>",
"        12",
"       </sub>",
"       shot 1 week before and every 9 weeks during your care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697606",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be given a drug that will help stop you from getting a skin rash while getting this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11270 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23732=[""].join("\n");
var outline_f23_11_23732=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207166\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854885\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017394\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017393\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017398\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017399\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017401\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017396\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017403\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=related_link\">",
"      Pemetrexed: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_11_23733="Organ trafficking, transplant tourism, and transplant commercialism";
var content_f23_11_23733=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Organ trafficking, transplant tourism, and transplant commercialism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/11/23733/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/11/23733/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/11/23733/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/11/23733/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/11/23733/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/11/23733/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/11/23733/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most countries in the western world prohibit compensated organ donation. Within the United States, the National Organ Transplant Act of 1972 states, \"It shall be unlawful for any person to knowingly acquire, receive, or otherwise transfer any human organ for valuable consideration for use in human transplantation.\" Penalties include a fine of up to $50,000",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imprisonment for up to five years.",
"   </p>",
"   <p>",
"    Although condemned by the international community, organ trafficking, transplant tourism, and commercial transplantation are likely here to stay. Patient desperation, which is driven by the disparity between organ supply and demand, finds an outlet in unregulated countries. It is important to remember that, compared with dialysis, transplantation is the best treatment for end-stage renal disease.",
"   </p>",
"   <p>",
"    Evidence indicates that health care practitioners who support organ trafficking and transplant tourism often dispense substandard care. Another concern is the risk of morbidity and mortality experienced by the living donors who are preyed upon by unscrupulous centers.",
"   </p>",
"   <p>",
"    This topic review will address some of the current issues affecting the international transplant community that threaten to undermine altruistic organ donation and transplantation. The discussion will include the related issues of organ trafficking, transplant tourism, and transplant commercialism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The actual number of transplants resulting from organ trafficking, transplant tourism, and transplant commercialism is largely unknown. Some estimate that organ trafficking may account for 5 and 10 percent of all kidney transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within the United States, the extent of transplant tourism was evaluated by examining United States national transplant waiting list removals without a corresponding United States transplant recorded in the database [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/2\">",
"     2",
"    </a>",
"    ]. Three hundred and seventy-three foreign transplants were documented, 90 percent of which were kidneys.",
"   </p>",
"   <p>",
"    Internationally, it appears that most such organs have been kidneys. One report suggested that kidney trafficking is \"big business\" in some of Europe's less affluent communities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/3\">",
"     3",
"    </a>",
"    ]. Another described the \"mother of all scandals in human organ trafficking in India\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/4\">",
"     4",
"    </a>",
"    ]. It was estimated that up to 1500 transplants were performed and $31.4 million changed hands in a single center in northern India. The donors were paid about $523, with allegations of very poor post-operative care. It is thought that six such donors died, although the true number may be larger. In addition, it has been alleged that two-thirds of 2000 kidneys from transplants performed in Pakistan went to foreigners [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least one model of compensated living kidney donation has been established in a regulated fashion. An Iranian model has apparently led to the elimination of their national kidney transplant waiting list [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/6\">",
"     6",
"    </a>",
"    ]. Foreigners are neither permitted to undergo kidney transplantation from Iranian living donors nor are they permitted to volunteer as kidney donors for Iranian patients. In this report, 1881 renal transplant recipients were described, all of whom were Iranian with the exception of 19 (one percent) Afghani or Iraqi refugees, 11 (0.6 percent) other foreign nationals, and 18 (0.9 percent) Iranian immigrants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RECIPIENT OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stories of dreadful complications and poor outcomes have circulated about organ donors and recipients in unregulated countries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. A number of published, single-center reports also describe poor outcomes experienced by recipients of commercial living donor kidneys. For example [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/8,12-15\">",
"     8,12-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The outcomes of 115 patients who had been commercially transplanted in various countries and presented for follow-up care to a center in Turkey were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/12\">",
"       12",
"      </a>",
"      ]. Most had been transplanted in India with smaller numbers transplanted in Iraq and Iran. At a mean follow-up of 65 months, there were numerous infections, and allograft survival was significantly worse at various time points compared with living-related transplantations performed locally. However, no difference in patient survival rates was noted.",
"     </li>",
"     <li>",
"      In a study of 10 patients with \"surreptitious\" overseas kidney transplantation, four experienced life-threatening infections. At a mean follow-up period of two years, nine recipients were alive, and the mean serum creatinine concentration was 1.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (97.24",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third study of 33 kidney transplant patients who had received a kidney abroad, the one-year allograft survival was significantly lower compared with a matched UCLA cohort (89 versus 98 percent), while the acute rejection rate was markedly higher (30 versus 12 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/15\">",
"       15",
"      </a>",
"      ]. Over one-half (17 patients) of those who had obtained a kidney abroad also had an infection.",
"     </li>",
"     <li>",
"      A study that compared records of 215 Taiwanese who received commercial cadaveric renal transplants in China (tourism group) to those of 321 transplant recipients (domestic group) reported a higher 10-year cancer incidence in the tourism group (21.5 versus 6.8 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study also reported a trend toward decreased graft and patient survival that was not significant (55 and 82 versus 60 and 89 percent, respectively). Patients in the tourism group tended to be older (46 versus 40 years) and were more likely to have received depleting antibody induction than the domestic group which may have contributed to the difference in malignancy rate. However, omission of pre-transplant screening in the tourism cannot be excluded since donor records were completely unavailable.",
"   </p>",
"   <p>",
"    Taken together, these reports suggest that transplant tourists have a more complex post-transplantation course with a higher incidence of acute rejection, severe infectious complications, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/17\">",
"     17",
"    </a>",
"    ]. The effect of transplant tourism on graft loss is not clear since some [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/9,17\">",
"     9,17",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/12,16\">",
"     12,16",
"    </a>",
"    ], studies have shown acceptable graft function among transplant tourists.",
"   </p>",
"   <p>",
"    Health care providers in regulated countries are responsible for caring for patients who have undergone surreptitious transplantation. Transplant is a treatment, not a cure, and requires long-term immunosuppression, prophylaxis, and care. Patients who receive a kidney outside of the United States are not eligible for government (Medicare or Medicaid) or pharmaceutical assistance. This can lead to enormous problems providing immunosuppression and antiviral agents when the patient returns to the United States. The fact that many patients live who have been transplanted under such circumstances is likely a reflection of the excellent care of horrendous complications that are provided after the event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ISTANBUL CONFERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2004, the World Health Organization called on member states \"to take measures to protect the poorest and vulnerable groups from transplant tourism and the sale of tissues and organs, including attention to the wider problem of international trafficking in human tissues and organs.\" As a result, the Transplantation Society and the International Society of Nephrology held a consensus conference in Istanbul in April 2008. One hundred and fifty-two participants from 78 countries attended. The result of these deliberations was the \"Istanbul Declaration on Organ Trafficking and Transplant Tourism,\" subsequently published by a variety of high impact factor journals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/5,18-22\">",
"     5,18-22",
"    </a>",
"    ]. The document is divided into various sections that include a preamble, definitions, principles, and proposals, which are paraphrased in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the declaration, organ trafficking was defined as \"the recruitment, transport, transfer, harboring or receipt of living or deceased persons or their organs by means of the threat or use of force or other forms of coercion, of abduction, of fraud, of deception, of the abuse of power or of a position of vulnerability, or of the giving to, or the receiving by a third party of payments or benefits to achieve the transfer of control over the potential donor, for the purpose of exploitation by the removal of organs for transplantation.\" Transplant commercialism was defined as \"a policy or practice in which an organ is treated as a commodity, including by being bought or sold or used for material gain.\" Travel for transplantation was defined as \"the movement of organs, donors, and recipients or transplant professionals across jurisdictional borders for transplantation purposes.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The details of the published principles are available in the source document. Briefly, these principles include the implementation of programs for preventing and treating organ failure, legislation governing organ recovery, equitable allocation, optimization of medical care of both donors and recipients, and prohibition of organ trafficking and transplant tourism. The World Health Assembly specifically called on countries to prevent the purchase and sale of human organs for transplantation by prohibiting advertising, soliciting, brokering, organ trafficking, and transplant tourism, and to include penalties for such acts that encourage organ trafficking or transplant tourism.",
"   </p>",
"   <p>",
"    To increase deceased organ donation, proposals included collaboration between governments and health care institutions to remove obstacles and disincentives, legislation to initiate donation programs and promote infrastructure development, maximization of \"the therapeutic potential of deceased organ donation\" and sharing of information, expertise, and technology. To ensure the protection and safety of living donors, \"the act of donation should be regarded as heroic and honored as such by representatives of the government and civil society representatives,\" and determination of donor suitability should be guided by the Amsterdam and Vancouver Forums.",
"   </p>",
"   <p>",
"    The Istanbul group also recommended that organ donors be provided with the opportunity to participate in life and health insurance schemes. Unfortunately, being an organ donor may impact the likelihood of obtaining life, disability, and health insurance. A systematic review of the literature uncovered 23 studies between 1972 and 2006 that provided data on 2067 living organ donors, 385 potential donors, and 239 responses from insurance companies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23733/abstract/23\">",
"     23",
"    </a>",
"    ]. Almost all companies would provide life and health insurance to living organ donors, usually with no higher premiums. However, concern about insurability was still expressed by 2 to 14 percent of living organ donors in follow-up studies, and 3 to 11 percent of donors actually encountered difficulties with their insurance. In one study, donors whose insurance premiums increased were less likely to reaffirm their decision to donate. Based on this information, some living organ donors had difficulties with insurance despite companies reporting otherwise, a finding that has potential implications for public policy development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Proposals",
"    </span>",
"    &nbsp;&mdash;&nbsp;To increase transplantation, the Istanbul group made a number of proposals. Again, these are presented in full in the source documents. Briefly, the proposals include the following concepts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Governments should take appropriate action to increase living and deceased organ donation by establishing or maximizing donation practices.",
"     </li>",
"     <li>",
"      Donor suitability should adhere to the recommendations of the Amsterdam and Vancouver Forums. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30697?source=see_link\">",
"       \"Evaluation of the living kidney donor and risk of donor nephrectomy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The care of organ donors is the responsibility of jurisdictions that sanction organ trafficking, transplant commercialism, and transplant tourism.",
"     </li>",
"     <li>",
"      Provision of care includes medical and psychosocial care at the time of organ donor surgery and for the consequences related to donation.",
"     </li>",
"     <li>",
"      Cost reimbursement does not constitute payment for organ donation; it is due in part to the cost of treating the recipient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these recommendations may be at variance with United States living donation practices. As an example, living kidney donors are currently ineligible for the loss of earning reimbursement. However, such individuals are eligible for reimbursement for other expenses incurred as a consequence of organ donation (visit the National Living Donor Assistance Center website:",
"    <a class=\"external\" href=\"file://www.livingdonorassistance.org/\">",
"     www.livingdonorassistance.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most centers do not provide routine long-term medical follow-up of living donors, let alone psychosocial support in the event their donated organ fails. However, there is much interest in developing a national living donor registry based in longitudinal follow-up of such individuals long-term post-nephrectomy. Currently, there is no mechanism by which living donors can be provided with medical insurance beyond the resources of the individual concerned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most countries in the western world prohibit compensated organ donation. Despite this, organ trafficking, transplant tourism, and commercial transplantation, although condemned by the international community, are likely here to stay. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The actual number of transplants resulting from organ trafficking, transplant tourism, and transplant commercialism is largely unknown. Some estimate that organ trafficking may account for 5 and 10 percent of all kidney transplants. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence suggests that adult transplant tourists have a more complex post-transplantation course with a higher incidence of acute rejection and severe infectious complications; however, kidney function is acceptable. Similar outcomes have been reported in pediatric kidney transplant recipients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Recipient outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A consensus conference in Istanbul in April 2008 resulted in the \"Istanbul Declaration on Organ Trafficking and Transplant Tourism.\" Principles include institution of programs to prevent and treat organ failure, legislation governing organ recovery, equitable allocation, optimization of medical care of both donors and recipients, and prohibition of organ trafficking and transplant tourism. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Istanbul conference'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proposals from the Istanbul Conference include the following concepts:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Governments should promote both deceased and living organ donation by establishing or maximizing donation practices.",
"     </li>",
"     <li>",
"      Donor suitability should adhere to the recommendations of the Amsterdam and Vancouver Forums.",
"     </li>",
"     <li>",
"      The care of organ donors is the responsibility of jurisdictions that sanction organ trafficking. Provision of care includes medical and psychosocial care at the time of surgery and for the consequences related to donation.",
"     </li>",
"     <li>",
"      Cost reimbursement does not constitute payment for organ donation; it is due in part to the cost of treating the recipient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Proposals'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/1\">",
"      Budiani-Saberi DA, Delmonico FL. Organ trafficking and transplant tourism: a commentary on the global realities. Am J Transplant 2008; 8:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/2\">",
"      Merion RM, Barnes AD, Lin M, et al. Transplants in Foreign Countries Among Patients Removed from the US Transplant Waiting List. Am J Transplant 2008; 8:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/3\">",
"      Kovac C. Kidney trafficking is \"big business,\" says Council of Europe. BMJ 2003; 327:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/4\">",
"      Kumar S. Police uncover large scale organ trafficking in Punjab. BMJ 2003; 326:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/5\">",
"      International Summit on Transplant Tourism and Organ Trafficking. The Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Clin J Am Soc Nephrol 2008; 3:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/6\">",
"      Ghods AJ, Nasrollahzadeh D. Transplant tourism and the Iranian model of renal transplantation program: ethical considerations. Exp Clin Transplant 2005; 3:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/7\">",
"      Hussein MM, Mooij JM, Roujouleh H, el-Sayed H. Commercial living-nonrelated renal transplantation: observations on early complications. Transplant Proc 1996; 28:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/8\">",
"      Mansy H, Khalil A, Aly TF, et al. Outcome of commercial renal transplantation: two years follow-up. Nephron 1996; 74:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/9\">",
"      Frishberg Y, Feinstein S, Drukker A. Living unrelated (commercial) renal transplantation in children. J Am Soc Nephrol 1998; 9:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/10\">",
"      Mourani CC, Mallat SG, Karam PE. Mycotic aneurysm after commercial kidney transplantation. Pediatr Nephrol 1999; 13:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/11\">",
"      Ben Hamida F, Ben Abdallah T, Goucha R, et al. Outcome of living unrelated (commercial) renal transplantation: report of 20 cases. Transplant Proc 2001; 33:2660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/12\">",
"      Sever MS, Kazancio��lu R, Yildiz A, et al. Outcome of living unrelated (commercial) renal transplantation. Kidney Int 2001; 60:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/13\">",
"      Prasad GV, Shukla A, Huang M, et al. Outcomes of commercial renal transplantation: a Canadian experience. Transplantation 2006; 82:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/14\">",
"      Canales MT, Kasiske BL, Rosenberg ME. Transplant tourism: Outcomes of United States residents who undergo kidney transplantation overseas. Transplantation 2006; 82:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/15\">",
"      Gill J, Madhira BR, Gjertson D, et al. Transplant tourism in the United States: a single-center experience. Clin J Am Soc Nephrol 2008; 3:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/16\">",
"      Tsai MK, Yang CY, Lee CY, et al. De novo malignancy is associated with renal transplant tourism. Kidney Int 2011; 79:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/17\">",
"      Sun CY, Lee CC, Chang CT, et al. Commercial cadaveric renal transplant: an ethical rather than medical issue. Clin Transplant 2006; 20:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/18\">",
"      International Summit on Transplant Tourism and Organ Trafficking. The Declaration of Istanbul on organ trafficking and transplant tourism. Kidney Int 2008; 74:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/19\">",
"      Steering Committee of the Istanbul Summit. Organ trafficking and transplant tourism and commercialism: the Declaration of Istanbul. Lancet 2008; 372:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/20\">",
"      Participants in the International Summit on Transplant Tourism and Organ Trafficking Convened by the Transplantation Society and International Society of Nephrology in Istanbul, Turkey, April 30-May 2, 2008. The Declaration of Istanbul on organ trafficking and transplant tourism. Transplantation 2008; 86:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/21\">",
"      The Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Istanbul Summit April 30-May 2, 2008. Nephrol Dial Transplant 2008; 23:3375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/22\">",
"      Delmonico FL. The development of the Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Nephrol Dial Transplant 2008; 23:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23733/abstract/23\">",
"      Yang RC, Thiessen-Philbrook H, Klarenbach S, et al. Insurability of living organ donors: a systematic review. Am J Transplant 2007; 7:1542.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7340 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-190.81.197.98-68DAC4FE3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23733=[""].join("\n");
var outline_f23_11_23733=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RECIPIENT OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ISTANBUL CONFERENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Proposals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30697?source=related_link\">",
"      Evaluation of the living kidney donor and risk of donor nephrectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_11_23734="Waring blender syndrome";
var content_f23_11_23734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Red cell fragmentation (\"Waring blender syndrome\") due to defective heart valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a patient with the \"Waring blender\" syndrome due to defective prosthetic heart valve. The smear shows marked red cell fragmentation with multiple sharp edges and small fragmented cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23734=[""].join("\n");
var outline_f23_11_23734=null;
var title_f23_11_23735="Dietary energy requirements in adolescents";
var content_f23_11_23735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dietary energy requirements in adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/11/23735/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/11/23735/contributors\">",
"     Nancy F Butte, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/11/23735/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/11/23735/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/11/23735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/11/23735/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/11/23735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional needs during adolescence are influenced mainly by the onset of puberty with its associated increased growth rate and changes in body composition and organ systems. After age 11, girls accrue approximately 12 percent of their adult stature and 36 percent of adult weight, and boys approximately 20 percent of their adult stature and 50 percent of adult weight [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/1\">",
"     1",
"    </a>",
"    ]. Growth during adolescence is accompanied by an increased proportion of body fat for girls and an increased proportion of lean body mass and blood volume in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended dietary energy requirements in adolescents are defined to maintain health, promote optimal growth and maturation, and support a desirable level of physical activity. Dietary energy recommendations must be accompanied by strong encouragement for physical activity compatible with health, prevention of obesity, and adequate social and psychologic development.",
"   </p>",
"   <p>",
"    The recommended dietary energy requirements in adolescents are reviewed here. Dietary requirements for other nutrients in adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28631?source=see_link\">",
"     \"Dietary history and recommended dietary intake in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=see_link\">",
"     \"Calcium requirements in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"     \"Iron requirements and iron deficiency in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASAL METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basal metabolism is the energy expended for cellular and tissue processes that maintain life. It is measured under standard conditions of thermoneutrality, immobility, and fasting. The basal metabolic rate (BMR) relative to weight increases from birth to two years and then gradually declines through adolescence (",
"    <a class=\"graphic graphic_figure graphicRef76918 \" href=\"UTD.htm?21/60/22479\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of age on BMR is a function of changes in body composition through childhood and adolescence. BMR is strongly correlated with the fat free mass (FFM) that comprises the bulk of the active metabolic tissue. The marked sex differences in intensity and duration of the adolescent growth spurt and in the proportion of FFM dictate the energy and nutrient needs of boys and girls. The World Health Organization (WHO) has endorsed the Schofield equations for the estimation of BMR that take into account sex, age, and body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For males, 10 to 18 years of age:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp;BMR",
"    <span class=\"nowrap\">",
"     (MJ/day)",
"    </span>",
"    = (0.074 x body weight [kg]) + 2.754",
"    <br/>",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp;BMR",
"    <span class=\"nowrap\">",
"     (kcal/day)",
"    </span>",
"    = (17.69 x body weight [kg]) + 658",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For females, 10 to 18 years of age:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp;BMR",
"    <span class=\"nowrap\">",
"     (MJ/day)",
"    </span>",
"    = (0.056 x body weight [kg]) + 2.898",
"    <br/>",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp;BMR",
"    <span class=\"nowrap\">",
"     (kcal/day)",
"    </span>",
"    = (13.38 x body weight [kg]) + 693",
"   </p>",
"   <p>",
"    Several studies have evaluated the accuracy of these equations in adolescents, and whether they have universal application remains unclear. Measured BMR values coincided with predicted values in boys and girls 7 to 16 years of age in Holland, the United Kingdom, and the United States. The equations overestimated BMR of boys in Colombia by 5 percent, teenage girls in China by 9 percent, and black girls in the United States by 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Further studies are needed to determine whether specific equations are necessary for different populations. Such an equation has been proposed for obese children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resting metabolic rate (RMR) is closely related to BMR, and the terms are often used interchangeably. However, BMR is measured under carefully controlled conditions to ensure that the sympathetic nervous system is not activated, whereas RMR reflects measurements performed at rest but under less carefully controlled conditions. BMR is measured after a 12 to 14 hour overnight fast, with the subject resting comfortably, supine, awake, and motionless in a thermoneutral environment. RMR is measured two hours after eating with the subject resting comfortably, supine, awake, and motionless in a thermoneutral environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ENERGY COST OF GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The energy cost of growth is the energy deposited in newly accrued tissues, and the energy expended for tissue synthesis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Energy deposition depends upon the composition of the newly accrued tissues. The energy equivalents for fat and protein deposition are 0.039",
"      <span class=\"nowrap\">",
"       MJ/g",
"      </span>",
"      (9.25",
"      <span class=\"nowrap\">",
"       kcal/g)",
"      </span>",
"      and 0.024",
"      <span class=\"nowrap\">",
"       MJ/g",
"      </span>",
"      (5.65",
"      <span class=\"nowrap\">",
"       kcal/g),",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      Energetic efficiencies of synthesizing fat and protein are approximately 85 and 42 percent, respectively.",
"     </li>",
"     <li>",
"      Energy content of newly synthesized tissues varies in childhood, particularly around the adolescent growth spurt, from 0.01 to 0.03",
"      <span class=\"nowrap\">",
"       MJ/g",
"      </span>",
"      (3 to 7",
"      <span class=\"nowrap\">",
"       kcal/g),",
"      </span>",
"      but these variations have minimal impact on total energy requirements.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The energy cost of growth has been estimated from body composition data of normally growing adolescents. Estimates have been published for male and female reference adolescents that are based upon total body water, total body potassium, and total body calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/9\">",
"     9",
"    </a>",
"    ]. These estimates reveal significant differences in the energy cost of growth in males as compared with females:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On average, fat free mass (FFM) increases dramatically in boys from approximately 28 kg at 10.5 years to 61 kg at 18.5 years, with peak deposition coinciding with peak height velocity. The",
"      <span class=\"nowrap\">",
"       FFM/height",
"      </span>",
"      ratio is higher in boys than in girls [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"       \"Normal puberty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      On average, fat mass (FM) deposition is greater in girls, increasing from approximately 8 kg at 10.5 years to 14 kg at 18.5 years. As a percentage of body weight, FM increases from 23.5 to 25 percent in girls and actually declines in boys from 16 to 13 percent by 18.5 years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Institute of Medicine (IOM) recommendations for daily energy intake of adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/10\">",
"       10",
"      </a>",
"      ], the energy cost of growth for boys and girls were computed from rates of weight gain of children enrolled in the Fels Longitudinal Study [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/11\">",
"       11",
"      </a>",
"      ] and rates of protein and fat deposition for adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/9\">",
"       9",
"      </a>",
"      ]. The energy cost of tissue deposition was approximately 20",
"      <span class=\"nowrap\">",
"       kcal/d,",
"      </span>",
"      increasing to 30",
"      <span class=\"nowrap\">",
"       kcal/d",
"      </span>",
"      at peak growth velocity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSICAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the energy required for basal metabolic processes and growth, energy is needed for physical activity and for the attainment of physical, intellectual, and social well-being. The energy expenditure of physical activity is expressed as a multiple of basal metabolic rate (BMR) and is determined by the time spent on an activity and the intensity of effort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patterns of activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Time allocation studies attempt to provide estimates of time spent by children in activities with different energy costs. The patterns of physical activities among adolescents vary across societies. As an example, a review of a number of time allocation studies indicated that, in comparison to children in industrialized areas, children in developing rural areas sleep less at night, participate longer in moderate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heavy physical activities, and, therefore, have greater energy expenditures in relation to their BMR [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Energy cost of physical activity",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Measurement techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Habitual physical activity and its impact on the energy needs of adolescents may be assessed by the doubly labeled water (DLW) method, heart rate monitoring, and accelerometry.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The DLW method is a noninvasive technique that uses the stable isotopes deuterium and oxygen-18 to estimate total energy expenditure (TEE) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. It encompasses BMR, thermoregulation, the synthetic cost of growth, and physical activity. It is accurate but requires sophisticated instrumentation and is expensive.",
"     </li>",
"     <li>",
"      Monitoring heart rate, calibrated against indirect calorimetry, can be used to estimate energy expenditure because a linear relationship exists between heart rate and oxygen consumption during exercise. Monitoring heart rate provides a noninvasive and inexpensive alternative to calorimetry [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accelerometers are small, lightweight, portable, noninvasive, nonintrusive devices that record motion in one or more planes and provide an indication of the frequency, duration, and intensity of physical activity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Validity studies have yielded moderate to strong correlations between accelerometer counts and oxygen consumption, activity energy expenditure, or metabolic equivalents (METs) in adults and children [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/17\">",
"       17",
"      </a>",
"      ]. Accelerometers and heart monitors have been combined to improve the accuracy and precision with which energy expenditure can be predicted [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/18\">",
"       18",
"      </a>",
"      ]. In general, the combined accelerometer and heart rate monitor method has better accuracy and precision than either method alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Energy equivalents of physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The energy costs of some recreational activities as measured in adolescents are shown in the table as multiples of the resting metabolic rate (RMR) (",
"    <a class=\"graphic graphic_table graphicRef52989 \" href=\"UTD.htm?12/22/12652\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/19\">",
"     19",
"    </a>",
"    ]. Energy costs range from 1.1 times RMR for homework or reading to 8.2 times RMR while running. The energy cost estimates of activities often are derived from adult measurements that may not be valid for children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, energy cost is affected by age, size, level of training, ethnic background, and the presence or absence of obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/7,21\">",
"     7,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In kinesiology, METs are widely used to express the energy costs of physical activity as multiples of RMR. By convention, 1 MET is defined as an oxygen uptake of 3.5",
"    <span class=\"nowrap\">",
"     mL/kg/min,",
"    </span>",
"    or 1",
"    <span class=\"nowrap\">",
"     kcal/kg/h",
"    </span>",
"    in adults, a value derived for a 70 kg man aged 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/22\">",
"     22",
"    </a>",
"    ]. The conventional MET value is not applicable to children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]. Instead, measured or predicted RMR values should be used to appropriately adjust for individual differences in body size by expressing TEE as a multiple of RMR.",
"   </p>",
"   <p>",
"    The Compendium of Physical Activities is a coding scheme developed in adults that classifies specific physical activities by MET equivalents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/24\">",
"     24",
"    </a>",
"    ]. In children 8 to 18 years of age, age- and puberty-adjusted metabolic equivalents were estimated and found to be generally lower than the compendium MET values for sedentary and moderate activities, but were more varied for high intensity activities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/25\">",
"     25",
"    </a>",
"    ]. Since the ratio of activity energy expenditure to adjusted RMR in children appears to be similar or slightly less, the adjusted compendium MET values may be used to approximate energy cost of activities in children and adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The energy cost of physical activity is affected by age, size, level of training, ethnic background, and the presence or absence of obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/7,21\">",
"     7,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obese individuals have higher energy expenditure than do their lean counterparts in absolute terms. However, obese individuals typically have similar rates when corrected for body size and body composition [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/13,26\">",
"       13,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Energy requirements per kilogram body weight vary indirectly with age and size at any given walking or running speed [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Training can decrease the energy cost of running.",
"     </li>",
"     <li>",
"      One study measured the BMR and energy expenditure of 40 Caucasian and 41 matched African-American pubertal girls [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/7\">",
"       7",
"      </a>",
"      ]. After adjusting for fat free mass (FFM), the basal energy expenditure and energy expended for physical activity were significantly lower in the African-American girls than in the Caucasian girls (1333 versus 1412",
"      <span class=\"nowrap\">",
"       kcal/day",
"      </span>",
"      for basal energy expenditure and 809 versus 1271 for physical activity).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Estimated daily energy expenditure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily energy expenditure is determined by the energy cost for various activities and the amount of time allocated to those activities. The daily physical activity level (PAL) represents the summation of these activities, is defined as the ratio of TEE over BMR, and is expressed as multiples of BMR. Pooled data from studies that estimated PALs by activity-time allocation in urban and rural areas of industrialized and developing areas have shown the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean PALs ranged from 1.45 to 2.06 for children 6 to 18 years engaged in light to heavy levels of physical activity.",
"     </li>",
"     <li>",
"      Mean daily energy expenditure ranged from 0.18",
"      <span class=\"nowrap\">",
"       MJ/kg",
"      </span>",
"      to 0.28",
"      <span class=\"nowrap\">",
"       MJ/kg",
"      </span>",
"      (42 to 66",
"      <span class=\"nowrap\">",
"       kcal/kg)",
"      </span>",
"      depending upon sex, age, and geographical area.",
"     </li>",
"     <li>",
"      Daily energy expenditures were higher for boys than for girls and, in both groups, were highest in rural areas of developing countries and lowest in industrialized countries. They also tended to be higher in children 10 to 14 years of age than in children 15 to 19 years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TOTAL ENERGY REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marked variability exists in the energy requirements of adolescents because of variable growth rates and physical activity levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/27\">",
"     27",
"    </a>",
"    ]. The Institute of Medicine (IOM) has published recommendations for daily energy intake of adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/10,28\">",
"     10,28",
"    </a>",
"    ]. Dietary estimated energy requirements (EER) of adolescents have been based on their total energy expenditure (TEE) and requirements for growth, taking into account habitual physical activity level (PAL) and lifestyle consistent with the maintenance of health, optimal growth and maturation, and social and economic demands. Although the recommendations allow for four categories of PAL (sedentary, low active, active, and very active), the active or very active levels are encouraged for all healthy children (ie, at least 60 minutes of physical activity on most, preferably all, days of the week) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/28\">",
"     28",
"    </a>",
"    ]. PAL levels were defined based on the ratio of total energy expenditure:basal metabolic rate (TEE:BMR).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prediction equations",
"    </span>",
"    &nbsp;&mdash;&nbsp;TEE was predicted from age, height, and weight based on the stable isotope method, doubly labeled water (DLW), and an average of 25",
"    <span class=\"nowrap\">",
"     kcal/d",
"    </span>",
"    for the energy cost of growth based on rates of weight gains from the Fels Longitudinal Study and rates of protein and fat deposition for adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/10\">",
"     10",
"    </a>",
"    ]. Prediction equations for the EER of children, ages 9 through 18 years, are provided below, where PA represents the physical activity coefficient to be used in the prediction equation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Boys 9 through 18 years: EER",
"      <span class=\"nowrap\">",
"       (kcal/d)",
"      </span>",
"      = 88.5 - 61.9 x Age [y] + PA x (26.7 x Weight [kg] + 903 x Height [m]) + 25 (Growth Factor), where:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp;PA = 1.00 if sedentary (PAL &ge;1.0 and &lt;1.4)",
"   </p>",
"   <p>",
"    &nbsp;PA = 1.13 if low active (PAL &ge;1.4 and &lt;1.6)",
"   </p>",
"   <p>",
"    &nbsp;PA = 1.26 if active (PAL &ge; 1.6 and &lt;1.9)",
"   </p>",
"   <p>",
"    &nbsp;PA = 1.42 if very active (PAL &ge;1.9 and &lt;2.5)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Girls 9 through 18 years: EER",
"      <span class=\"nowrap\">",
"       (kcal/d)",
"      </span>",
"      = 135.3 - 30.8 x Age [y] + PA x (10.0 x Weight [kg] + 934 x Height [m]) + 25 (Growth Factor), where:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp;PA = 1.00 if sedentary (PAL &ge;1.0 and &lt;1.4)",
"   </p>",
"   <p>",
"    &nbsp;PA = 1.16 if low active (PAL &ge;1.4 and &lt;1.6)",
"   </p>",
"   <p>",
"    &nbsp;PA = 1.31 if active (PAL &ge;1.6 and &lt;1.9)",
"   </p>",
"   <p>",
"    &nbsp;PA = 1.56 if very active (PAL &ge;1.9 and &lt;2.5)",
"   </p>",
"   <p>",
"    The IOM report on dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids provides detailed tables on the EER for adolescents and can be accessed at",
"    <a class=\"external\" href=\"file://www.iom.edu/CMS/3788/4576/4340.aspx\">",
"     www.iom.edu/CMS/3788/4576/4340.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recommended composition of dietary energy intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Surgeon General's Report on Nutrition and Health [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/29\">",
"     29",
"    </a>",
"    ], the US Department of Agriculture (USDA), and US Department of Health and Human Services Dietary Guidelines for Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/30\">",
"     30",
"    </a>",
"    ], the American Academy of Pediatrics, and the American Heart Association [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] all recommend reduced consumption of cholesterol, total fat, and (especially) saturated fat, and achievement and maintenance of an appropriate weight for the American population older than two years of age.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"external\" href=\"file://www.cnpp.usda.gov/DGAs2010-PolicyDocument.htm\">",
"     Dietary Guidelines for Americans 2010",
"    </a>",
"    stress the need for adequate nutrients within energy needs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/30\">",
"     30",
"    </a>",
"    ]. &ldquo;",
"    <a class=\"external\" href=\"file://www.choosemyplate.gov/\">",
"     Choose my plate",
"    </a>",
"    &rdquo; is a teaching tool that shows how nutritional guidelines and requirements fit into an individual's daily food choices; it replaces the Food Guide Pyramid. This and other educational resources are available on the United States Department of Agriculture website (www.choosemyplate.gov). These teaching tools are applicable to special populations or individuals who practice vegetarianism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23735/abstract/33\">",
"     33",
"    </a>",
"    ]. Vegetarians can consume adequate protein by selecting protein sources from the Protein Food Group which includes eggs (for ovo-vegetarians), beans and peas, nuts, nut berries, and soy products (tofu, tempeh, veggie burgers). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8266?source=see_link\">",
"     \"Vegetarian diets for children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following recommendations are made for all Americans, with a few special considerations for adolescents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consume a variety of nutrient-dense foods and beverages within and among the basic food groups, while choosing foods that limit the intake of saturated and trans fats, cholesterol, added sugars, salt, and alcohol.",
"     </li>",
"     <li>",
"      Consume a sufficient amount of fruits and vegetables while staying within energy needs. Two cups of fruit and 2.5 cups of vegetables per day are recommended for a reference 2000-calorie intake, with higher or lower amounts depending on the calorie level.",
"     </li>",
"     <li>",
"      Choose a variety of fruits and vegetables each day. In particular, select from all five vegetable subgroups (dark green, orange, legumes, starchy vegetables, and other vegetables) several times a week.",
"     </li>",
"     <li>",
"      For children and adolescents, consume whole-grain products often; at least half the grains should be whole grains.",
"     </li>",
"     <li>",
"      Children nine years of age and older should consume three cups per day of fat-free or low-fat milk or equivalent milk products.",
"     </li>",
"     <li>",
"      Consume less than 10 percent of calories from saturated fatty acids and less than 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of cholesterol, and keep trans fatty acid consumption as low as possible.",
"     </li>",
"     <li>",
"      When selecting and preparing meat, poultry, dry beans, and milk or milk products, make choices that are lean, low-fat, or fat-free.",
"     </li>",
"     <li>",
"      Limit intake of fats and oils high in saturated",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      trans fatty acids, and choose products low in such fats and oils.",
"     </li>",
"     <li>",
"      For children and adolescents 4 to 18 years of age, keep total fat intake between 25 to 35 percent of calories, with most fats coming from sources of polyunsaturated and monounsaturated fatty acids, such as fish, nuts, and vegetable oils.",
"     </li>",
"     <li>",
"      Choose fiber-rich fruits, vegetables, and whole grains often.",
"     </li>",
"     <li>",
"      Choose and prepare foods and beverages with little added sugars or caloric sweeteners.",
"     </li>",
"     <li>",
"      Consume less than 2300 mg (approximately 1 tsp of salt) of sodium per day.",
"     </li>",
"     <li>",
"      Choose and prepare foods with little salt. At the same time, consume potassium-rich foods, such as fruits and vegetables.",
"     </li>",
"     <li>",
"      Consume sugar- and starch-containing foods and beverages less frequently, and practice good oral hygiene to reduce the incidence of dental caries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The current dietary intake of American children does not match these recommendations. Many adolescents receive a higher proportion of energy from fat",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    added sugar, and have a lower intake of a vitamin A,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    , fiber, iron, calcium, and zinc than is recommended (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16778?source=see_link\">",
"     \"Adolescent eating habits\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Energy requirements depend on basal metabolism, the energy cost of growth, and physical activity. The basal metabolic rate (BMR) relative to weight increases from birth to two years, and then gradually declines through adolescence (",
"      <a class=\"graphic graphic_figure graphicRef76918 \" href=\"UTD.htm?21/60/22479\">",
"       figure 1",
"      </a>",
"      ). The energy cost of growth peaks at the time of maximum growth velocity in early adolescence. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Basal metabolism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Energy cost of growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The energy expenditure of physical activity can be expressed as a multiple of BMR, and is determined by the time spent on an activity and the intensity of effort. Energy expenditure also varies with age, size, level of training, ethnic background, and the presence or absence of obesity; typical energy expenditure during some recreational activities is shown in the table (",
"      <a class=\"graphic graphic_table graphicRef52989 \" href=\"UTD.htm?12/22/12652\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estimated energy requirements (EER) of adolescents are based on their total energy expenditure and requirements for growth, taking into account habitual physical activity levels. Although the recommendations allow for various levels of physical activity, the active or very active levels are encouraged for all healthy children. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Total energy requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many adolescents receive a higher proportion of energy from fat",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      added sugar, and have a lower intake of several micronutrients than is recommended. Key dietary recommendations for children and adolescents are to keep total fat intake between 25 to 35 percent of calories (with most fats as polyunsaturated and monounsaturated fatty acids); emphasize fiber-rich fruits, vegetables, and whole grains; and to limit foods and beverages with added sugars. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Recommended composition of dietary energy intake'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     CDC Growth Charts: United States. Centers for Disease Control and Prevention; US Department of Health and Human Services.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics Committee on Nutrition. Adolescent nutrition. In: Pediatric Nutrition Handbook, 6th ed, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/3\">",
"      Holliday MA. Metabolic rate and organ size during growth from infancy to maturity and during late gastation and early infancy. Pediatrics 1971; 47:Suppl 2:169+.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/4\">",
"      Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr 1985; 39 Suppl 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/5\">",
"      Schofield C. An annotated bibliography of source material for basal metabolic rate data. Hum Nutr Clin Nutr 1985; 39 Suppl 1:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/6\">",
"      Torun B, Davies PS, Livingstone MB, et al. Energy requirements and dietary energy recommendations for children and adolescents 1 to 18 years old. Eur J Clin Nutr 1996; 50 Suppl 1:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/7\">",
"      Wong WW, Butte NF, Ellis KJ, et al. Pubertal African-American girls expend less energy at rest and during physical activity than Caucasian girls. J Clin Endocrinol Metab 1999; 84:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/8\">",
"      Tverskaya R, Rising R, Brown D, Lifshitz F. Comparison of several equations and derivation of a new equation for calculating basal metabolic rate in obese children. J Am Coll Nutr 1998; 17:333.",
"     </a>",
"    </li>",
"    <li>",
"     Haschke F. Body composition measurements in infants and children, Ross Laboratories, Columbus, OH  p.76.",
"    </li>",
"    <li>",
"     Institute of Medicine (IOM). Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids, National Academies Press, Washington, DC 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/11\">",
"      Baumgartner RN, Roche AF, Himes JH. Incremental growth tables: supplementary to previously published charts. Am J Clin Nutr 1986; 43:711.",
"     </a>",
"    </li>",
"    <li>",
"     International Dietary Energy Consulting Group. The Doubly-Labeled Water Method for Measuring Energy Expenditure: Technical Recommendations for Use in Humans. In: NAHRES-4, Prentice AM (Ed), International Atomic Energy Agency, Vienna, Austria 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/13\">",
"      Schoeller DA. Recent advances from application of doubly labeled water to measurement of human energy expenditure. J Nutr 1999; 129:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/14\">",
"      Treuth MS, Adolph AL, Butte NF. Energy expenditure in children predicted from heart rate and activity calibrated against respiration calorimetry. Am J Physiol 1998; 275:E12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/15\">",
"      Chen KY, Bassett DR Jr. The technology of accelerometry-based activity monitors: current and future. Med Sci Sports Exerc 2005; 37:S490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/16\">",
"      Corder K, Ekelund U, Steele RM, et al. Assessment of physical activity in youth. J Appl Physiol 2008; 105:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/17\">",
"      Trost SG, McIver KL, Pate RR. Conducting accelerometer-based activity assessments in field-based research. Med Sci Sports Exerc 2005; 37:S531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/18\">",
"      Zakeri I, Adolph AL, Puyau MR, et al. Application of cross-sectional time series modeling for the prediction of energy expenditure from heart rate and accelerometry. J Appl Physiol 2008; 104:1665.",
"     </a>",
"    </li>",
"    <li>",
"     Torun B. Energy cost of various physical activities in healthy children. In: Activity, Energy Expenditure and Energy Requirements of Infants and Children, Sch&uuml;rch B, Scrimshaw NS (Eds), International Dietary Energy Consultancy Group, Lausanne 1990. p.139.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/20\">",
"      Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993; 25:71.",
"     </a>",
"    </li>",
"    <li>",
"     Bar-Or O. Childhood and adolescent physical activity and fitness and adult risk profile. In: Physical Activity, Fitness, and Health. International Proceedings and Consensus Statement, Bouchard C, Shephard RJ, Stephens T (Eds), Human Kinetics Publishers, Champaign 1994. p.931.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/22\">",
"      Byrne NM, Hills AP, Hunter GR, et al. Metabolic equivalent: one size does not fit all. J Appl Physiol 2005; 99:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/23\">",
"      Puyau MR, Adolph AL, Vohra FA, Butte NF. Validation and calibration of physical activity monitors in children. Obes Res 2002; 10:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/24\">",
"      Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32:S498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/25\">",
"      Harrell JS, McMurray RG, Baggett CD, et al. Energy costs of physical activities in children and adolescents. Med Sci Sports Exerc 2005; 37:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/26\">",
"      Butte NF, Puyau MR, Vohra FA, et al. Body size, body composition, and metabolic profile explain higher energy expenditure in overweight children. J Nutr 2007; 137:2660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/27\">",
"      Zlotkin SH. A review of the Canadian \"Nutrition recommendations update: dietary fat and children.\". J Nutr 1996; 126:1022S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/28\">",
"      Brooks GA, Butte NF, Rand WM, et al. Chronicle of the Institute of Medicine physical activity recommendation: how a physical activity recommendation came to be among dietary recommendations. Am J Clin Nutr 2004; 79:921S.",
"     </a>",
"    </li>",
"    <li>",
"     The Surgeon General's Report on Nutrition and Health. US Government Printing Office; Department of Health &amp; Human Services, Washington, DC 1988.",
"    </li>",
"    <li>",
"     United States Department of Agriculture, Center for Nutrition Policy and Promotion: Dietary guidelines for Americans, 2010. Available at: file://www.cnpp.usda.gov/dietaryguidelines.htm (Accessed on June 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/31\">",
"      Gidding SS, Dennison BA, Birch LL, et al. Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association. Circulation 2005; 112:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/32\">",
"      Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation 2009; 119:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23735/abstract/33\">",
"      Haddad EH, Sabat&eacute; J, Whitten CG. Vegetarian food guide pyramid: a conceptual framework. Am J Clin Nutr 1999; 70:615S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5351 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23735=[""].join("\n");
var outline_f23_11_23735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASAL METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ENERGY COST OF GROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSICAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patterns of activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Energy cost of physical activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Measurement techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Energy equivalents of physical activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Estimated daily energy expenditure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TOTAL ENERGY REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prediction equations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recommended composition of dietary energy intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5351\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5351|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/60/22479\" title=\"figure 1\">",
"      Weight specific BMR children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5351|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/22/12652\" title=\"table 1\">",
"      Activity energy child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16778?source=related_link\">",
"      Adolescent eating habits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=related_link\">",
"      Calcium requirements in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28631?source=related_link\">",
"      Dietary history and recommended dietary intake in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8266?source=related_link\">",
"      Vegetarian diets for children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_11_23736="Lithium: Drug information";
var content_f23_11_23736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lithium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/29/28117?source=see_link\">",
"    see \"Lithium: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"    see \"Lithium: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lithobid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lithium&reg; Carbonate;",
"     </li>",
"     <li>",
"      Apo-Lithium&reg; Carbonate SR;",
"     </li>",
"     <li>",
"      Carbolith&trade;;",
"     </li>",
"     <li>",
"      Duralith&reg;;",
"     </li>",
"     <li>",
"      Euro-Lithium;",
"     </li>",
"     <li>",
"      Lithane&trade;;",
"     </li>",
"     <li>",
"      Lithmax;",
"     </li>",
"     <li>",
"      PHL-Lithium Carbonate;",
"     </li>",
"     <li>",
"      PMS-Lithium Carbonate;",
"     </li>",
"     <li>",
"      PMS-Lithium Citrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F189386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimanic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F189348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor serum concentrations and clinical response (efficacy and toxicity) to determine proper dose. Each 5 mL of lithium citrate oral solution contains 8 mEq of lithium ion, equivalent to the amount of lithium in 300 mg of lithium carbonate immediate release capsules/tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Bipolar disorders:",
"     </b>",
"     Oral: 900-2400 mg/day in 3-4 divided doses or 900-1800 mg/day in two divided doses of extended release",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F189366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"      see \"Lithium: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor serum concentrations and clinical response (efficacy and toxicity) to determine proper dose. Each 5 mL of lithium citrate oral solution contains 8 mEq of lithium ion, equivalent to the amount of lithium in 300 mg of lithium carbonate immediate release capsules/tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Bipolar disorders (unlabeled use):",
"     </b>",
"     Oral: Children 6-12 years: 15-60 mg/kg/day in 3-4 divided doses; dose not to exceed usual adult dosage.",
"     <b>",
"      Note:",
"     </b>",
"     Monitor serum concentrations and clinical response (efficacy and toxicity) to determine proper dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conduct disorder (unlabeled use):",
"     </b>",
"     Oral: Children 6-12 years: 15-30 mg/kg/day in 3-4 divided doses; dose not to exceed usual adult dosage",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F189349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bipolar disorders: Oral: Initial: 300 mg twice daily; increase weekly in increments of 300 mg/day, monitoring levels; rarely need &gt;900-1200 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F189350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% to 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 25% to 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialyzable (50% to 100%); 4-7 times more efficient than peritoneal dialysis",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16265652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as carbonate: 150 mg, 300 mg, 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as citrate: 8 mEq/5 mL (5 mL [DSC], 500 mL) [equivalent to amount of lithium in lithium carbonate 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as carbonate: 300 mg, 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as carbonate: 300 mg, 450 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lithobid&reg;: 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F189321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals to decrease GI upset. Extended release tablets must be swallowed whole; do not crush or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F189320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of bipolar disorders; treatment of mania in individuals with bipolar disorder (maintenance treatment prevents or diminishes intensity of subsequent episodes)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F189383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potential augmenting agent for antidepressants; aggression, post-traumatic stress disorder, conduct disorder in children",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F189394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Eskalith may be confused with Estratest",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Lithium may be confused with lanthanum",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Lithobid&reg; may be confused with Levbid&reg;, Lithostat&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Do not confuse",
"       <b>",
"        mEq",
"       </b>",
"       (milliequivalent) with",
"       <b>",
"        mg",
"       </b>",
"       (milligram).",
"       <b>",
"        Note:",
"       </b>",
"       300 mg lithium carbonate or citrate contain 8 mEq lithium. Dosage should be written in",
"       <b>",
"        mg",
"       </b>",
"       (milligrams) to avoid confusion.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Check prescriptions for unusually high volumes of the syrup for dosing errors.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F189384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrhythmia, hypotension, sinus node dysfunction, flattened or inverted T waves (reversible), edema, bradycardia, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Blackout spells, coma, confusion, dizziness, dystonia, fatigue, headache, lethargy, pseudotumor cerebri, psychomotor retardation, restlessness, sedation, seizure, slowed intellectual functioning, slurred speech, stupor, tics, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dry or thinning of hair, folliculitis, alopecia, exacerbation of psoriasis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Euthyroid goiter and/or hypothyroidism, hyperthyroidism, hyperglycemia, diabetes insipidus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Polydipsia, anorexia, nausea, vomiting, diarrhea, xerostomia, metallic taste, weight gain, salivary gland swelling, excessive salivation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Incontinence, polyuria, glycosuria, oliguria, albuminuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, muscle hyperirritability, ataxia, choreoathetoid movements, hyperactive deep tendon reflexes, myasthenia gravis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Nystagmus, blurred vision, transient scotoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Coldness and painful discoloration of fingers and toes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Drug-induced Brugada syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F189324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lithium or any component of the formulation; avoid use in patients with severe cardiovascular or renal disease, or with severe debilitation, dehydration, or sodium depletion",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F189306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal effects: Chronic therapy results in diminished renal concentrating ability (nephrogenic DI); this is usually reversible when lithium is discontinued. Changes in renal function should be monitored, and re-evaluation of treatment may be necessary. Morphologic changes with glomerular and interstitial fibrosis and nephron atrophy have been reported in patients on chronic lithium therapy; morphologic changes have also been reported in manic-depressive patients never exposed to lithium. The relationship between morphologic changes and renal function, and the association with lithium therapy, have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with mild-moderate cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dehydration: Use with caution in patients with significant fluid loss (protracted sweating, diarrhea, or prolonged fever); temporary reduction or cessation of therapy may be warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression/suicidal ideation: Use with caution in patients at risk of suicide (suicidal thoughts or behavior).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with mild-moderate renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease:  Use with caution in patients with thyroid disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Medications altering sodium excretion: Use caution in patients receiving medications which alter sodium excretion (eg, diuretics, ACE inhibitors, NSAIDs).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic medications: Use with caution in patients receiving neuroleptic medications - a syndrome resembling NMS has been associated with concurrent therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular-blocking agents: Administered neuromuscular-blocking agents with caution; the response may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be extremely sensitive to the effects of lithium, see Dosage and Reference Range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute manic phase: Higher serum concentrations may be required and tolerated during an acute manic phase; however, the tolerance decreases when symptoms subside.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring:",
"     <b>",
"      [U.S. Boxed Warning]: Lithium toxicity is closely related to serum concentrations and can occur at therapeutic doses; serum lithium determinations are required to monitor therapy.",
"     </b>",
"     Normal fluid and salt intake must be maintained during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May increase the serum concentration of Lithium. Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Lithium may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May increase the serum concentration of Lithium. Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: Lithium formulations may enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitonin: May decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered lithium concentrations have also been reported with this combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the serum concentration of Lithium.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Lithium may diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Lithium.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moclobemide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: May enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum lithium concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Lithium may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Lithium.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sulindac.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Iodide: May enhance the hypothyroid effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Lithium may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Bicarbonate: May increase the excretion of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Chloride: May increase the excretion of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Lithium may enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F189338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Limit caffeine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Lithium crosses the placenta in concentrations similar to those in the maternal plasma (Newport, 2005). Cardiac malformations in the infant, including Ebstein's anomaly, are associated with use of lithium during the first trimester of pregnancy. Other adverse events including polyhydramnios, fetal/neonatal cardiac arrhythmias, hypoglycemia, diabetes insipidus, changes in thyroid function, premature delivery, floppy infant syndrome, or neonatal lithium toxicity are associated with lithium exposure when used later in pregnancy (ACOG, 2008). The incidence of adverse events may be associated with higher maternal doses (Newport, 2005).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, women who are pregnant may require dose adjustments of lithium to achieve euthymia and avoid toxicity (ACOG, 2008; Grandjean, 2009; Yonkers, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For planned pregnancies, use of lithium during the first trimester should be avoided if possible (Grandjean, 2009). If lithium is needed during pregnancy, the minimum effective dose should be used, maternal serum concentrations should be monitored, and consideration should be given to start therapy after the period of organogenesis; lithium should be suspended 24-48 hours prior to delivery or at the onset of labor when delivery is spontaneous, then restarted when the patient is medically stable after delivery (ACOG, 2008; Grandjean, 2009; Newport, 2005). Fetal echocardiography should be considered if first trimester exposure occurs (ACOG, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F189354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16343841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lithium is excreted into breast milk and serum concentrations of nursing infants may be 10% to 50% of the maternal serum concentration (Grandjean, 2009). Hypotonia, hypothermia, cyanosis, electrocardiogram changes, and lethargy have been reported in nursing infants (ACOG, 2008).  It is generally recommended that breast-feeding be avoided during maternal use of lithium; however, treatment may be continued in appropriately selected patients (Grandjean, 2009; Sharma, 2009; Viguera, 2007). The hydration status of the nursing infant and maternal serum concentrations of lithium should be monitored (ACOG, 2008). In addition, monitor the infant for lethargy, growth, and feeding problems; obtain infant serum concentrations only if clinical concerns arise (Bogen, 2012; Yonkers, 2011). Long-term effects on development and behavior have not been studied (ACOG, 2008; Grandjean, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F189328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals to avoid GI upset; maintain adequate fluid intake.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F189326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Lithium Carbonate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $13.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $17.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $39.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Lithium Heparin Prefilled Syr)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (100): $209.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lithium Citrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mEq/5 mL (5 mL): $0.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Lithium Carbonate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $46.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     450 mg (100): $50.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Lithobid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $320.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lithium Carbonate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $21.52",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F189314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum lithium every 4-5 days during initial therapy; draw lithium serum concentrations 8-12 hours postdose; renal, thyroid, and cardiovascular function; fluid status; serum electrolytes; CBC with differential, urinalysis; monitor for signs of toxicity; beta-hCG pregnancy test for all females not known to be sterile",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F189317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Levels should be obtained twice weekly until both patient's clinical status and levels are stable then levels may be obtained every 1-3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Timing of serum samples: Draw trough just before next dose (8-12 hours after previous dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute mania: 0.6-1.2 mEq/L (SI: 0.6-1.2 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protection against future episodes in most patients with bipolar disorder: 0.8-1 mEq/L (SI: 0.8-1.0 mmol/L); a higher rate of relapse is described in subjects who are maintained at &lt;0.4 mEq/L (SI: 0.4 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly patients can usually be maintained at lower end of therapeutic range (0.6-0.8 mEq/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic concentration: &gt;1.5 mEq/L (SI: &gt;1.5 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adverse effect levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GI complaints/tremor: 1.5-2 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Confusion/somnolence: 2-2.5 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Seizures/death: &gt;2.5 mEq/L",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F189329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Calith (TW);",
"     </li>",
"     <li>",
"      Camcolit (AE, BE, BH, CY, EG, IE, IQ, IR, JO, KW, LB, LU, LY, OM, PK, QA, SA, SG, SY, TW, YE);",
"     </li>",
"     <li>",
"      Carbolim (BR);",
"     </li>",
"     <li>",
"      Carbolit (CN, CO, MX);",
"     </li>",
"     <li>",
"      Carbolithium (IT);",
"     </li>",
"     <li>",
"      Carlit (PY);",
"     </li>",
"     <li>",
"      Ceglution (AR);",
"     </li>",
"     <li>",
"      Ceglution 300 (EC);",
"     </li>",
"     <li>",
"      Contemnol (CZ);",
"     </li>",
"     <li>",
"      Eskalith (BB, BM, BS, BZ, GY, JM, SR, TT);",
"     </li>",
"     <li>",
"      Frimania (ID);",
"     </li>",
"     <li>",
"      Hynorex Retard (DE);",
"     </li>",
"     <li>",
"      Karlit (AR);",
"     </li>",
"     <li>",
"      Kilonum (TR);",
"     </li>",
"     <li>",
"      L:ithan (KP);",
"     </li>",
"     <li>",
"      Licab (IN);",
"     </li>",
"     <li>",
"      Licarb (HK, TH);",
"     </li>",
"     <li>",
"      Licarbium (IL);",
"     </li>",
"     <li>",
"      Limas (JP);",
"     </li>",
"     <li>",
"      Liskonum (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Litarex (DK, NO);",
"     </li>",
"     <li>",
"      Litheum 300 (MX);",
"     </li>",
"     <li>",
"      Lithicarb (AU, MY);",
"     </li>",
"     <li>",
"      Lithicarb FC (NZ);",
"     </li>",
"     <li>",
"      Lithionate (TW);",
"     </li>",
"     <li>",
"      Lithionit (NO, SE);",
"     </li>",
"     <li>",
"      Lithium Carbonicum (PL);",
"     </li>",
"     <li>",
"      Lithiumkarbonat &rdquo;Oba&rdquo; (DK);",
"     </li>",
"     <li>",
"      Lithocap (IN);",
"     </li>",
"     <li>",
"      Liticarb (HN, HU);",
"     </li>",
"     <li>",
"      Litij-karbonat (HR);",
"     </li>",
"     <li>",
"      Litil (DO);",
"     </li>",
"     <li>",
"      Litiumkarbonat &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Lito (FI);",
"     </li>",
"     <li>",
"      Litocarb (PE);",
"     </li>",
"     <li>",
"      Maniprex (BE, LU);",
"     </li>",
"     <li>",
"      Milithin (GR);",
"     </li>",
"     <li>",
"      Neurolepsin (AT);",
"     </li>",
"     <li>",
"      Plenur (ES);",
"     </li>",
"     <li>",
"      Priadel (BE, GB, LU, NL, NO, NZ, PT);",
"     </li>",
"     <li>",
"      Priadel Retard (CH);",
"     </li>",
"     <li>",
"      Quilonium-R (PH);",
"     </li>",
"     <li>",
"      Quilonorm (AT);",
"     </li>",
"     <li>",
"      Quilonorm Retardtabletten (CH);",
"     </li>",
"     <li>",
"      Quilonum Retard (DE);",
"     </li>",
"     <li>",
"      Quilonum retard (LU);",
"     </li>",
"     <li>",
"      Quilonum SR (AU);",
"     </li>",
"     <li>",
"      Sicolitio (UY);",
"     </li>",
"     <li>",
"      Teralithe (FR);",
"     </li>",
"     <li>",
"      Theralite (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F189305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alters cation transport across cell membrane in nerve and muscle cells and influences reuptake of serotonin and/or norepinephrine; second messenger systems involving the phosphatidylinositol cycle are inhibited; postsynaptic D2 receptor supersensitivity is inhibited",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F189323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Initial: 0.3-0.4 L/kg; V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.7-1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF, liver concentrations:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of serum concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erythrocyte concentration: ~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of serum concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Heart, lung, kidney, muscle concentrations: Equivalent to serum concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saliva concentration: 2-3 times serum concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyroid, bone, brain tissue concentrations: Increase 50% over serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Not protein bound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Not affected by food; Capsule, immediate release tablet: 95% to 100%; Extended release tablet: 60% to 90%; Syrup: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 18-24 hours; can increase to more than 36 hours in elderly or with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Immediate release: ~0.5-2 hours; extended release: 4-12 hours; syrup: 15-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90% to 98% as unchanged drug); sweat (4% to 5%); feces (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: 80% of filtered lithium is reabsorbed in the proximal convoluted tubules; therefore, clearance approximates 20% of GFR or 20-40 mL/minute",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins-Obstetrics, \"ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      ,  2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Belanger DR, Tierney MG, and Dickinson G, &ldquo;Effect of Sodium Polystyrene Sulfonate on Lithium Bioavailability,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1992, 21(11):1312-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/1416324/pubmed\" id=\"1416324\" target=\"_blank\">",
"        1416324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bogen DL, Sit D, Genovese A, et al, \"Three Cases of Lithium Exposure and Exclusive Breastfeeding,\"",
"      <i>",
"       Arch Womens Ment Health",
"      </i>",
"      , 2012, 15(1):69-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/22277970/pubmed\" id=\"22277970\" target=\"_blank\">",
"        22277970",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farag S, Watson RD, and Honeybourne D, &ldquo;Symptomatic Junctional Bradycardia Due to Lithium Intoxication in Patient With Previously Normal Electrocardiogram,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1994, 343(8909):1371.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/7910365/pubmed\" id=\"7910365\" target=\"_blank\">",
"        7910365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Finley PR, Warner MD, Peabody CA, &ldquo;Clinical Relevance of Drug Interactions With Lithium,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 29(3):172-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/8521679/pubmed\" id=\"8521679\" target=\"_blank\">",
"        8521679",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flaherty B and Krenzelok EP, \"Neonatal Lithium Toxicity as a Result of Maternal Toxicity,\"",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1997, 39(2):92-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/9080635/pubmed\" id=\"9080635\" target=\"_blank\">",
"        9080635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foster JF, Gershell WJ, and Goldfarb AI, &ldquo;Lithium Treatment in the Elderly. I. Clinical Usage,&rdquo;",
"      <i>",
"       J Gerontol",
"      </i>",
"      , 1977, 32(3):299-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/850057/pubmed\" id=\"850057\" target=\"_blank\">",
"        850057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller B, Cooper TB, Sun K, et al, &ldquo;Double-Blind and Placebo-Controlled Study of Lithium for Adolescent Bipolar Disorders With Secondary Substance Dependency,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1998, 37(2):171-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/9473913/pubmed\" id=\"9473913\" target=\"_blank\">",
"        9473913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goodwin GM and Young AH, &ldquo;The British Association for Psychopharmacology Guidelines for Treatment of Bipolar Disorder: A Summary,&rdquo;",
"      <i>",
"       J Psychopharmacol (Oxf)",
"      </i>",
"      , 2003, 17(4 Suppl):3-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/14964624/pubmed\" id=\"14964624\" target=\"_blank\">",
"        14964624",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grandjean EM and Aubry JM, \"Lithium: Updated Human Knowledge Using an Evidence-Based Approach: Part III: Clinical Safety,\"",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2009, 23(5):397-418.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/19453201/pubmed\" id=\"19453201\" target=\"_blank\">",
"        19453201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Groleau G, &ldquo;Lithium Toxicity,&rdquo;",
"      <i>",
"       Emerg Med Clin North Am",
"      </i>",
"      , 1994, 12(2):511-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/8187694/pubmed\" id=\"8187694\" target=\"_blank\">",
"        8187694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Groleau G, Barish R, Tso E, et al, &ldquo;Lithium Intoxication: Manifestations and Management,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1987, 5(6):527-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/3663296/pubmed\" id=\"3663296\" target=\"_blank\">",
"        3663296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hambrecht M, &ldquo;Lithium and Pseudohallucinations: A Rare Side Effect,&rdquo;",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 1995, 37(2):120-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/7718675/pubmed\" id=\"7718675\" target=\"_blank\">",
"        7718675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hicks R, Dysken MW, Davis JM, et al, &ldquo;The Pharmacokinetics of Psychotropic Medication in the Elderly: A Review,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1981, 42(10):374-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/7026541/pubmed\" id=\"7026541\" target=\"_blank\">",
"        7026541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Hyperosmolar Coma Due to Lithium-Induced Diabetes Insipidus,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 346(8972):413-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/7623573/pubmed\" id=\"7623573\" target=\"_blank\">",
"        7623573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Gundlapalli SP, Ryan WG, et al, &ldquo;Effects of Antimanic Mood-Stabilizing Drugs on Fetuses, Neonates, and Nursing Infants,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 2001, 94(3):304-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/11284518/pubmed\" id=\"11284518\" target=\"_blank\">",
"        11284518",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joseph M and Vieweg V, &ldquo;Electrocardiographic Changes of Sinus Bradycardia and Sinus Node Dysfunction Among Patients With Therapeutic Levels of Lithium,&rdquo;",
"      <i>",
"       Depression",
"      </i>",
"      , 1994-95, 2(4):226-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Langlois R and Paquette D, &ldquo;Increased Serum Lithium Levels Due to Ketorolac Therapy,&rdquo;",
"      <i>",
"       Can Med Assoc J",
"      </i>",
"      , 1994, 150(9):1455-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lehmann K and Ritz E, &ldquo;Angiotensin-Converting Enzyme Inhibitors May Cause Renal Dysfunction in Patients on Long-Term Lithium Treatment,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 1995, 25(1):82-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/7810540/pubmed\" id=\"7810540\" target=\"_blank\">",
"        7810540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy HB, Harper CR, and Weinberg WA, &ldquo;A Practical Approach to Children Failing in School,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1992, 39(4):895-928.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/1635811/pubmed\" id=\"1635811\" target=\"_blank\">",
"        1635811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linakis JG, Hull KM, Lee CM, et al, &ldquo;Effect of Delayed Treatment With Sodium Polystyrene Sulfonate on Serum Lithium Concentrations in Mice,&rdquo;",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 1995, 2(8):681-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/7584745/pubmed\" id=\"7584745\" target=\"_blank\">",
"        7584745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linakis JG, Savitt DL, Wu TY, et al, &ldquo;Use of Sodium Polystyrene Sulfonate (SPS&reg;) for Reduction of Chronically Elevated Serum Lithium Concentrations in Mice,&rdquo;",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 1995, 2:395.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone RP, Delaney MA, Luebbert JF, et al, &ldquo;A Double-Blind Placebo-Controlled Study of Lithium in Hospitalized Aggressive Children and Adolescents With Conduct Disorder,&rdquo;",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 2000, 57(7):649-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/10891035/pubmed\" id=\"10891035\" target=\"_blank\">",
"        10891035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moster R, Toren P, Mizrachi I, et al, &ldquo;Caffeine Withdrawal Increases Lithium Blood Levels,&rdquo;",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 1995, 37(5):348-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/7748990/pubmed\" id=\"7748990\" target=\"_blank\">",
"        7748990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newport DJ, Viguera AC, Beach AJ, et al, \"Lithium Placental Passage and Obstetrical Outcome: Implications for Clinical Management During Late Pregnancy,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2005, 162(11):2162-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/16263858/pubmed\" id=\"16263858\" target=\"_blank\">",
"        16263858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oshika T, &ldquo;Ocular Adverse Effects of Neuropsychiatric Agents. Incidence and Management,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(3):256-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/7646824/pubmed\" id=\"7646824\" target=\"_blank\">",
"        7646824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palatnick W, Rowe B, Bell D, et al, &ldquo;Diabetic Ketoacidosis Associated With Lithium Intoxication,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1993, 35:339.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perrier A, Martin PY, Favre H, et al, &ldquo;Very Severe Self-Poisoning Lithium Carbonate Intoxication Causing a Myocardial Infarction,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1991, 100(3):863-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/1909621/pubmed\" id=\"1909621\" target=\"_blank\">",
"        1909621",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Price LH and Heninger GR, &ldquo;Lithium in the Treatment of Mood Disorders,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 331(9):591-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/8047085/pubmed\" id=\"8047085\" target=\"_blank\">",
"        8047085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rampes H and Bhandari S, &ldquo;Hypersalivation and Lithium Toxicity,&rdquo;",
"      <i>",
"       J Psychopharmacol (Oxf)",
"      </i>",
"      , 1994, 8(4):261.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharma V, Burt VK, and Ritchie HL, \"Bipolar II Postpartum Depression: Detection, Diagnosis, and Treatment,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2009, 166(11):1217-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/19884236/pubmed\" id=\"19884236\" target=\"_blank\">",
"        19884236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SW, Ling LJ, and Halstenson CE, &ldquo;Whole Bowel Irrigation as a Treatment for Acute Lithium Overdose,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1991, 20(5):536-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/2024795/pubmed\" id=\"2024795\" target=\"_blank\">",
"        2024795",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2005, 66(7):870-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/16013903/pubmed\" id=\"16013903\" target=\"_blank\">",
"        16013903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swanson CL Jr, Price WA, and McEvoy JP, &ldquo;Effects of Concomitant Risperidone and Lithium Treatment,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(7):1096.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Szerlip HM, Heeger P, and Feldman GM, &ldquo;Comparison Between Acetate and Bicarbonate Dialysis for the Treatment of Lithium Intoxication,&rdquo;",
"      <i>",
"       Am J Nephrol",
"      </i>",
"      , 1992, 12(1-2):116-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/1415356/pubmed\" id=\"1415356\" target=\"_blank\">",
"        1415356",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tomaszewski C, Musso C, and Pearson JR, &ldquo;Lithium Absorption Prevented by Sodium Polystyrene Sulfonate in Volunteers,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1992, 21(11):1308-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/1416323/pubmed\" id=\"1416323\" target=\"_blank\">",
"        1416323",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viguera AC, Newport DJ, Ritchie J, et al, \"Lithium in Breast Milk and Nursing Infants: Clinical Implications,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(2):342-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/17267800/pubmed\" id=\"17267800\" target=\"_blank\">",
"        17267800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ward ME, Musa MN, Bailey L, &ldquo;Clinical Pharmacokinetics of Lithium,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1994, 34(4):280-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/8006194/pubmed\" id=\"8006194\" target=\"_blank\">",
"        8006194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watling SM, Gehrke JC, Gehrke CW, et al, &ldquo;",
"      <i>",
"       In vitro",
"      </i>",
"      Binding of Lithium Using the Cation Exchange Resin Sodium Polystyrene Sulfonate,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(3):294-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/7755820/pubmed\" id=\"7755820\" target=\"_blank\">",
"        7755820",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weller EB, Weller RA, and Fristad MA, &ldquo;Lithium Dosage Guide for Prepubertal Children: A Preliminary Report,&rdquo;",
"      <i>",
"       J Am Acad Child Psychiatry",
"      </i>",
"      , 1986, 25(1):92-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/3081617/pubmed\" id=\"3081617\" target=\"_blank\">",
"        3081617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Worthley LT, &ldquo;Lithium Toxicity and Refractory Cardiac Arrhythmia Treated With Intravenous Magnesium,&rdquo;",
"      <i>",
"       Anaesth Intensive Care",
"      </i>",
"      , 1974, 4:357-60.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Vigod S, and Ross LE, \"Diagnosis, Pathophysiology, and Management of Mood Disorders in Pregnant and Postpartum Women,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(4):961-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/11/23736/abstract-text/21422871/pubmed\" id=\"21422871\" target=\"_blank\">",
"        21422871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9566 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23736=[""].join("\n");
var outline_f23_11_23736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709018\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189343\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189344\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189386\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189348\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189366\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189349\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189350\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265652\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189316\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189302\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189321\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189320\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189383\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189394\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189384\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189324\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189306\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299613\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189311\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189338\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189312\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189327\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189354\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16343841\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189328\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189326\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189314\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189317\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189329\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189305\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189323\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9566\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9566|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/29/28117?source=related_link\">",
"      Lithium: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=related_link\">",
"      Lithium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_11_23737="Treatment of Wilson disease";
var content_f23_11_23737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Wilson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/11/23737/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/11/23737/contributors\">",
"     Michael L Schilsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/11/23737/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/11/23737/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/11/23737/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/11/23737/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/11/23737/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wilson disease (hepatolenticular degeneration) is an autosomal recessive defect of cellular copper export. Reduced biliary excretion leads to accumulation of copper, initially in the liver and then in other tissues, particularly the brain. Tissue copper deposition causes a multitude of signs and symptoms that reflect hepatic, neurologic, hematologic, and renal impairment. The incorporation of copper into ceruloplasmin is also impaired.",
"   </p>",
"   <p>",
"    Patients most often present with liver disease (which can range from asymptomatic elevations in the serum aminotransferase or bilirubin concentrations to fulminant hepatic failure to chronic hepatitis) or with neuropsychiatric disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H69500435#H69500435\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the treatment of Wilson disease. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of Wilson disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines for the treatment of Wilson disease include a 2008 consensus guideline from the",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     American Association for the Study of Liver Diseases",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef57105 \" href=\"UTD.htm?43/9/44187\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] and a 2012 guideline from the",
"    <a class=\"external\" href=\"file://www.easl.eu/_clinical-practice-guideline\">",
"     European Association for the Study of the Liver",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/4\">",
"     4",
"    </a>",
"    ]. Our approach is generally consistent with these guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lifetime therapy is required in patients with Wilson disease and treatment should be given in two phases: removing the tissue copper that has accumulated and then preventing reaccumulation. Copper removal is achieved by the administration of potent chelators. The primary chelator that has been used is D-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    . However, approximately 30 percent of patients do not tolerate long-term therapy because of side-effects and it may not be the treatment of choice in patients with neurologic symptoms.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     Trientine",
"    </a>",
"    has traditionally been used as a second-line agent but is also a reasonable option for primary therapy, and may be the preferred treatment because of its lower incidence of side effects. There are few controlled trials that have compared these agents to one another and thus recommendations for their use are based mainly on observational data and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who stop taking chelating treatment may develop new neurologic abnormalities. Rapidly progressive hepatic decompensation refractory to treatment may also occur. Prevention of reaccumulation during the maintenance phase can be achieved with either lower doses of chelators or zinc. Oral zinc acts by preventing copper absorption. A newer agent, tetrathiomolybdate (another metal antagonist) is still being evaluated.",
"   </p>",
"   <p>",
"    Patients with Wilson disease should also be maintained on a low copper diet and avoid copper-rich foods such as liver, kidney, shellfish, nuts, dried fruits or beans, peas, unprocessed wheat, chocolate, cocoa, and mushrooms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Penicillamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;D-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     Penicillamine",
"    </a>",
"    contains a free sulfhydryl group that functions as a copper chelating moiety. Its major effect is to promote urinary excretion of copper, although it may also function by other mechanisms. Penicillamine reduces the affinity of proteins for copper, thereby allowing previously protein-bound copper to bind to penicillamine. It has also been used in the treatment of rheumatoid arthritis and cystinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     Penicillamine",
"    </a>",
"    is absorbed rapidly from the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/2\">",
"     2",
"    </a>",
"    ]. Its absorption is decreased by as much as 50 percent when taken with food. More than 80 percent is excreted by the kidneys. Its half-life is in the range of 1.7 to 7 hours, although there may be considerable individual variation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drug should be introduced at a dose of 250 to 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and then increased by 250 mg increments every four to seven days to a maximum of 1000 to 1500 mg daily in two to four divided doses. For children and adults who weigh less than 100 lb (45 kg), we start with 250 mg daily with a maximum total daily dose of 1000 mg. This regimen may reduce the incidence of early adverse side effects such as fever and rash, but does not appear to reduce the incidence of late-onset toxicity, such as the nephrotic syndrome. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Adverse effects and their management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A lower dose (750 to 1000 mg daily in two divided doses) is sufficient during the maintenance phase (usually after four to six months). The therapeutic response to changes in the maintenance dose usually will not become evident for six to eight weeks. The dose in children is 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (rounded to the nearest 250 mg) given in two or three divided doses.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     Penicillamine",
"    </a>",
"    should ideally be given one hour before or two hours after meals since food interferes with its absorption. However, some patients may require dosing closer to food intake, which is an acceptable compromise if it increases compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have demonstrated the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    in patients with Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]. Clinical improvement in patients with advanced liver disease is usually observed during the first two to six months of therapy, but can continue thereafter. Even advanced fibrosis or cirrhosis may show reversibility following prolonged treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/14\">",
"     14",
"    </a>",
"    ]. A repeat liver biopsy is not necessary as long as there is a progressive improvement in symptoms and liver biochemical tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Adverse effects and their management",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     Penicillamine",
"    </a>",
"    is associated with multiple side-effects leading up to about 5 percent of patients to discontinue therapy. Other treatments should probably be used in patients who are at increased risk for toxicity including those with a history of renal disease, severe thrombocytopenia, or an autoimmune tendency. Crossreactivity to penicillin may occur. Thus the drug should be used cautiously in patients with known penicillin allergy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early sensitivity reactions (occurring within one to three weeks of beginning therapy) are characterized by fever, cutaneous eruptions, lymphadenopathy, neutropenia, thrombocytopenia, and proteinuria. The drug should be discontinued immediately in such patients and alternative treatment (principally",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"       trientine",
"      </a>",
"      ) begun. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Trientine'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Prior to the availability of alternative treatments, patients could be desensitized to these reactions by stopping the medicine for one week, then restarting it at a dose of 25",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      after which it was doubled at weekly intervals as long as it was tolerated. Some patients were also treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      . Desensitization is now rarely required.",
"     </li>",
"     <li>",
"      Several side effects occurring months to years after initiating therapy have also been described. The appearance of proteinuria may herald the onset of nephrotic syndrome, which may occur years after treatment begins. The onset of nephrotic syndrome necessitates cessation of the drug. However, protein excretion of up to 2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      produces no symptoms and may not progress. Although cessation of therapy always leads to resolution of the proteinuria, the mean time required for this to occur is approximately one year and some patients take more than two years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/15\">",
"       15",
"      </a>",
"      ]. A much less common but more serious renal complication is the development of a crescentic glomerulonephritis.",
"      <br/>",
"      <br/>",
"      Other later reactions include Goodpasture syndrome, bone marrow toxicity including severe thrombocytopenia or total aplasia, myasthenia gravis, polymyositis, hepatotoxicity, loss of taste, and a lupus-like syndrome characterized by hematuria, proteinuria, and a positive antinuclear antibody.",
"     </li>",
"     <li>",
"      Skin changes have been described including elastosis perforans serpiginosa pemphigus, lichen planus, and aphthous stomatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nausea, vomiting, and anorexia are dose-related signs of gastric irritation and improve if the dose is reduced.",
"     </li>",
"     <li>",
"      Aplastic anemia is rare but may not reverse with the cessation of therapy.",
"     </li>",
"     <li>",
"      The neurologic status of patients with predominantly neurologic symptoms may worsen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      . Limited data suggest that approximately 10 percent of such patients will have neurologic deterioration after beginning treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/1,18\">",
"       1,18",
"      </a>",
"      ]. Furthermore, new neurologic symptoms may appear in some patients. These events may be caused by two potential mechanisms: mobilization of hepatic copper stores leading to increased brain copper exposure, or the development of intracellular copper complexes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/19\">",
"       19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although some patients recover with continued use, the manufacturer recommends that the drug should be stopped (and an alternative used) in patients who develop worsening neurologic symptoms (other than loss of taste). Although there are limited data, we generally switch to trientine in these patients. We also usually add zinc acetate to the regimen of patients with preexisting or new neurologic symptoms. It should be spaced several hours apart from the chelating agent. The combination of these two drugs may increase the risk for development of sideroblastic anemia (an uncommon complication); thus, we monitor hemoglobin levels closely. Zinc is discontinued in those whose hemoglobin levels decline. Worsening of neurologic symptoms has been described with other copper chelators, although possibly less frequently than with penicillamine.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       Penicillamine",
"      </a>",
"      inactivates pyridoxine. Thus, small doses of pyridoxine, 25 mg per day, should be given to patients treated with penicillamine to prevent pyridoxal phosphate deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Monitoring penicillamine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compliance is often a problem, particularly in children. It can be ascertained by measuring 24-hour urinary copper excretion or determining the presence of D-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    in urine by amino acid analysis. The binding of copper to D-penicillamine is stoichiometric. Thus, the amount of copper excreted in the urine will increase with increasing excretion of D-penicillamine. The presence of elevated serum aminotransferases does not necessarily indicate non-compliance since up to one-third of children continue to have elevated aminotransferases despite adequate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial goal is urinary copper excretion of 2000",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (32",
"    <span class=\"nowrap\">",
"     micromol/day).",
"    </span>",
"    The rate of copper excretion falls as copper stores become depleted. Values usually fall to below 500",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (8",
"    <span class=\"nowrap\">",
"     micromol/day)",
"    </span>",
"    at four to six months. Once the excess copper is removed, patients can be switched to maintenance therapy. Prior to switching to maintenance therapy, patients should be clinically well, have stable, normal, or near normal serum aminotransferases and hepatic synthetic function, have a normal nonceruloplasmin-bound copper concentration (&lt;15",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    or 150",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    and have 24-hour urinary copper repeatedly in the range of 200 to 500 mcg (3 to 8 micromol) per day on treatment. Most patients require one to five years of therapy to achieve these goals.",
"   </p>",
"   <p>",
"    We obtain a complete blood count, urinalysis, and serum creatinine every month during the first three months, at three month intervals for the next nine months, and twice per year thereafter. The manufacturer recommends that treatment should be withdrawn if the total white blood cell count falls below 3000 cells per mm",
"    <sup>",
"     3",
"    </sup>",
"    , neutrophils fall below 2000 cells per mm",
"    <sup>",
"     3",
"    </sup>",
"    , platelets fall below 120,000 per mm",
"    <sup>",
"     3",
"    </sup>",
"    , or if a steady decline over three successive tests is observed, even though the counts remain above the values set for discontinuation. In patients with portal hypertension and hypersplenism, the platelet count may be low prior to the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    . However, many patients may tolerate therapy, so each patient must be managed individually. Patients should be periodically monitored for iron deficiency.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     Penicillamine",
"    </a>",
"    should also be withheld (and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     trientine",
"    </a>",
"    begun) if proteinuria exceeds 2+ on a dipstick, if red cell or white casts are observed at microscopic examination of the urine, or if more than 10 red cells are seen per high-power field. Our approach is to switch to trientine if there are any signs of renal toxicity given that there is significant experience with the drugs and it appears to have fewer side effects than penicillamine, though some authors would continue penicillamine if quantitative proteinuria does not exceed 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and is stable. However, penicillamine should be permanently discontinued if proteinuria exceeds 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or the glomerular filtration rate falls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dose adjustments prior to surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should",
"    <strong>",
"     never",
"    </strong>",
"    be discontinued altogether; patients who stop therapy for Wilson disease are at risk for the development of hepatic decompensation and acute liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, it may be reasonable to reduce the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    prior to surgery since laboratory and some human data suggest that it may impair wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/23\">",
"     23",
"    </a>",
"    ]. Dose reductions during this time may be in the range of 25 to 50 percent of the presurgery dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Penicillamine and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    is safe during pregnancy. Successful pregnancies without teratogenicity have also been described in the published literature [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/24-28\">",
"     24-28",
"    </a>",
"    ], though there are reports of women taking penicillamine giving birth to neonates with cutaneous abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Stopping therapy is associated with a high risk of hemolytic episodes with hepatic insufficiency including maternal fatality.",
"   </p>",
"   <p>",
"    We agree with a guideline published by the American Association for the Study of Liver Diseases that suggests treatment be maintained during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/2\">",
"     2",
"    </a>",
"    ]. The dose should be reduced by 25 to 50 percent of the prepregnancy dose (particularly in the third trimester) to promote better wound healing should a cesarean section be required.",
"   </p>",
"   <p>",
"    In addition, one authority made the following comments in an editorial regarding a study of zinc in pregnant patients with Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mothers and infants tolerate pregnancy safely if they comply with prescribed regimens (750 mg to 1 g of either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"       trientine",
"      </a>",
"      in patients with well controlled Wilson disease during the first two trimesters and 0.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      during the last trimester).",
"     </li>",
"     <li>",
"      Nursing mothers taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      report no ill effects on babies, although breast milk concentrations of zinc and copper may be reduced.",
"     </li>",
"     <li>",
"      The relatively low doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"       trientine",
"      </a>",
"      used to treat patients with Wilson disease have not been associated with teratogenicity. This is in contrast to patients with cystinuria who require larger doses.",
"     </li>",
"     <li>",
"      Interruption of therapy is associated with a high risk of hemolytic episodes with hepatic insufficiency including maternal fatality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Trientine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     Trientine",
"    </a>",
"    , another copper chelator, has been used successfully in patients unable to tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    as well as for primary therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/21\">",
"     21",
"    </a>",
"    ]. It differs from penicillamine by a lack of sulfhydryl groups and chelates copper by forming a stable complex with its four constituent nitrogens. Like penicillamine, it also functions principally by increasing renal copper excretion.",
"   </p>",
"   <p>",
"    Whether it is a less potent chelator of copper compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    is controversial since the amount of copper chelated can be adjusted by the dose used. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     trientine",
"    </a>",
"    seems to have fewer side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     trientine",
"    </a>",
"    have not been well studied. It is poorly absorbed; only 1 percent of the ingested amount (and 8 percent of its principal metabolite, acetyltrien) is excreted in the urine. The amount of iron, zinc, and copper chelated correlates with the amount of trientine in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual dose in children is 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, rounded to the nearest 250 mg, given in two or three divided doses. Similar dosing is used for adults (20 mg per kg), but the total dose should not exceed 1500 mg per day. The drug should be taken ideally one hour before or two hours after meals. The drug is not stable at high ambient temperatures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     Trientine",
"    </a>",
"    has been available since 1969; thus, clinical experience has probably outpaced the published experience. The available data and clinical experience suggest that trientine is as effective for Wilson disease as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/21,34-36\">",
"     21,34-36",
"    </a>",
"    ]. Trientine is suitable for initial treatment of disease as well as for treatment of patients who developed side-effects from penicillamine.",
"   </p>",
"   <p>",
"    Data summarized in the manufacturer's drug information focused on 41 patients between the ages of 6 and 54 who were intolerant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    . The average dose required to achieve an optimal clinical response ranged from 1000 to 2000 mg daily. After a mean of 49 months of follow-up, 34 of the 41 patients improved clinically, while four had no change in global response, one showed deterioration, and two were lost to follow-up. One patient who improved experienced a recurrence of lupus-like symptoms, which had prompted her to discontinue penicillamine and led to discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     trientine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     Trientine",
"    </a>",
"    is associated with fewer adverse effects than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypersensitivity reactions and pancytopenia are rare.",
"     </li>",
"     <li>",
"      Neurologic worsening is seen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"       trientine",
"      </a>",
"      , but appears to be less common than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hemorrhagic gastritis, loss of taste, and a rash have been reported in a patient treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"       trientine",
"      </a>",
"      for primary biliary cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/37\">",
"       37",
"      </a>",
"      ]. Another case report described the development of colitis and duodenitis that improved after drug withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A reversible sideroblastic anemia has been described in case reports possibly because of the drug's effects on mitochondrial iron metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"       Trientine",
"      </a>",
"      chelates iron; coadministration of iron should be avoided since the trientine iron complex is toxic.",
"     </li>",
"     <li>",
"      Copper deficiency induced by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"       trientine",
"      </a>",
"      can lead to iron overload in the liver, although the clinical significance is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/41\">",
"       41",
"      </a>",
"      ]. Many patients with Wilson disease have iron overload in the liver unrelated to therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Monitoring trientine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same clinical and laboratory monitoring described for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    also apply to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     trientine",
"    </a>",
"    . The adequacy of treatment should be determined by measuring 24-hour copper excretion, which should be in the range of 200 to 500 mcg (3 to 8 micromoles) daily. Normalization of nonceruloplasmin-bound copper to &lt;15",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (150",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    can also help document effective treatment. Patients should be monitored for iron deficiency. As noted above, if iron supplementation is needed, it should be given in short courses and at least two hours should elapse between administration of trientine and iron. Elevation of aminotransferases during treatment may signal noncompliance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Monitoring penicillamine therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70847542\">",
"    <span class=\"h3\">",
"     Trientine and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     trientine",
"    </a>",
"    during pregnancy is unclear. Trientine has been administered during pregnancy with the delivery of normal infants, although chromosomal defects have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The number of exposed infants is too small to demonstrate a clear causal relationship. Animal data suggest the potential for teratogenicity, possibly due to the induction of copper deficiency or zinc toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/46\">",
"     46",
"    </a>",
"    ]. Whether the drug is excreted in breast milk is unknown. We agree with the guideline from the American Association for the Study of Liver Diseases, which suggests that trientine can be used during pregnancy but that the dose should be reduced (particularly in the third trimester) because of the issues related to wound healing described above for penicillamine. We reduce the dose by 25 to 50 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Oral zinc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral zinc interferes with the absorption of copper, providing a rationale for its use in Wilson disease. Zinc induces metallothionein (an endogenous chelator of metals) in enterocytes, which has a greater affinity for copper than for zinc, causing it to bind luminal copper and thereby preventing its entry into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The bound copper is excreted fecally during normal turnover of enterocytes. Copper secreted from saliva and gastric and intestinal secretions is also bound, thereby further enhancing a negative copper balance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/49\">",
"     49",
"    </a>",
"    ]. Zinc may also induce hepatic metallothionein [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several forms of oral zinc salts, which probably have similar abilities to interfere with copper absorption, but differ in their tolerability.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/12/11460?source=see_link\">",
"     Zinc acetate",
"    </a>",
"    has the fewest gastrointestinal side effects, followed by zinc gluconate, which is more tolerable than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/57/17300?source=see_link\">",
"     zinc sulfate",
"    </a>",
"    . Dosing is in milligrams of elemental zinc. The dose of zinc acetate in adults and older children is a total of 150 mg daily given in three divided doses. Twice daily dosing is also effective in patients who cannot comply with three times daily dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/52\">",
"     52",
"    </a>",
"    ]. Smaller children (less than 50 kg body weight) should be given a total of 75 mg daily in three divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/53\">",
"     53",
"    </a>",
"    ]. The optimal dose for children younger than five is unknown. Dosing of zinc should be separated from food and beverages by at least one hour.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most experience with zinc in the treatment of Wilson disease has been in the care of patients during maintenance phases following treatment with a chelator [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/54\">",
"     54",
"    </a>",
"    ]. However, it has also been used as primary therapy, in patients who developed worsening neurologic symptoms with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , during pregnancy, and in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/13,49,52,54-62\">",
"     13,49,52,54-62",
"    </a>",
"    ]. One report of 17 symptomatic patients (mean age 18 years) treated exclusively with zinc and followed for a median of 14 years concluded that treatment was effective for neurologic disease, but less satisfactory for hepatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study described in the manufacturer's prescribing information focused on 60 patients who had been treated successfully with chelation therapy who were then treated with varying doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/12/11460?source=see_link\">",
"     zinc acetate",
"    </a>",
"    . Treatment was considered to be adequate if copper balance was maintained at less than +0.25 mg copper per day. Adequate copper balance was observed in 64 of 70 patients taking the 50 mg dose three times daily. A dose of 25 mg three times daily also seemed to produce adequate copper balance, but only 11 patients were studied.",
"   </p>",
"   <p>",
"    A second study described in the manufacturer's information focused on 30 presymptomatic patients whose diagnosis was established based upon hepatic copper concentration. No patient developed symptoms of Wilson disease during ten years of follow-up. The manufacturer notes that the results have not been replicated.",
"   </p>",
"   <p>",
"    A later retrospective series compared outcomes in a total of 288 patients who had been treated with zinc monotherapy or chelating agents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/64\">",
"     64",
"    </a>",
"    ]. Both approaches were effective, but chelating agents were more effective at preventing hepatic deterioration. The authors advised that liver biochemical tests be monitored in patients receiving zinc monotherapy and that consideration be given to adding a chelating agent in patients who have an increase in liver enzymes.",
"   </p>",
"   <p>",
"    Most clinicians still rely on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     trientine",
"    </a>",
"    as primary therapy. We consider using zinc in patients who cannot tolerate these treatments, who have neuropsychiatric disease that is not responding, and for maintenance in those who have had all of their excess copper removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse effect of zinc is gastrointestinal upset, which as noted above, appears to be least with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/12/11460?source=see_link\">",
"     zinc acetate",
"    </a>",
"    . Hepatic deterioration (including a fatality) has been described in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Neurologic deterioration is uncommon. Elevation in serum amylase and lipase without clinical evidence of pancreatitis has been observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Zinc and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in pregnant women have not demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/12/11460?source=see_link\">",
"     zinc acetate",
"    </a>",
"    or sulfate increases the risk of fetal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/67\">",
"     67",
"    </a>",
"    ]. Furthermore, teratogenicity has not been observed in animal studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ammonium tetrathiomolybdate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ammonium tetrathiomolybdate given orally both interferes with copper absorption and binds to plasma copper [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. It has been proposed as a more effective treatment for patients with neurologic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/70\">",
"     70",
"    </a>",
"    ]. A controlled trial comparing it to trientine suggested that it may reduce the risk of neurologic deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/70\">",
"     70",
"    </a>",
"    ]. It is not yet commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drugs, such as potassium sulfide and carbacrylamine resins, which bind copper in the gastrointestinal tract, are not recommended.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/42/9893?source=see_link\">",
"     Dimercaprol",
"    </a>",
"    (BAL), the first drug that successfully treated Wilson disease, is rarely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DIETARY RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should consume only in moderation foods that contain high concentrations of copper (principally, shellfish, nuts, chocolate, mushrooms, and organ meats), particularly during the first year of therapy. However, dietary restriction is insufficient as sole therapy. It may be prudent to test drinking water obtained from wells for copper content. Municipal water supplies usually do not require analysis. Patients who have copper pipes in the household should be advised to flush the system before using water for cooking or consumption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ACUTE LIVER FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic approach is different in patients who present with acute liver failure. Emergency liver transplantation must be considered. A prognostic scoring system for children with Wilson disease presenting with acute liver failure was proposed and then later revised [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. The revised system (based upon an index of serum bilirubin, the prothrombin time INR [international normalized ratio], aspartate aminotransferase level, and white blood cell count) had a sensitivity, specificity, and positive predictive value for determining the need for liver transplantation of 93, 98, and 88 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/72\">",
"     72",
"    </a>",
"    ]. However, further validation is required before its clinical role can be established.",
"   </p>",
"   <p>",
"    Initial treatment must be aimed at the rapid removal of copper. Although hemodialysis, peritoneal dialysis, and hemofiltration have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/73\">",
"     73",
"    </a>",
"    ], plasma exchange with fresh frozen plasma replacement may be preferred since it can remove relatively large amounts of copper in a short period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/74\">",
"     74",
"    </a>",
"    ]. Net copper removal is proportional to plasma concentration and can reach 12 mg per session. Most of these patients also have hemolytic anemia. Copper ions leak from necrotic hepatocytes into the circulation and cause lysis of red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/74\">",
"     74",
"    </a>",
"    ]. Hemofiltration and albumin dialysis have also been described as temporizing measures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation may be the only option for patients who present with acute liver failure and in those with decompensated liver disease who are unresponsive to drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/78-82\">",
"     78-82",
"    </a>",
"    ]. Liver transplantation is curative for Wilson disease, and patients do not require treatment for Wilson disease following transplantation.",
"   </p>",
"   <p>",
"    Whether or not liver transplant is indicated in patients with predominantly neurologic manifestations is controversial. This may be due in part to differences in the resolution of neurologic manifestations when the recipient also has extensive hepatic disease compared with those with neurologic manifestations as the principal indication for transplantation. Survival appears to be worse in patients with neurological involvement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series included 13 patients with Wilson disease who received a liver transplant, four of whom had intractable neurologic impairment as the only indication [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/81\">",
"       81",
"      </a>",
"      ]. All required continuous nursing care prior to transplant and all showed improvement beginning four to six weeks after transplant. One was asymptomatic after five years, two had noticeable improvement, and one showed only slight improvement.",
"     </li>",
"     <li>",
"      In another report of 55 transplants, seven with hepatic insufficiency had neurologic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      psychiatric manifestations at the time of transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/80\">",
"       80",
"      </a>",
"      ]. Four showed improvement. One patient given a transplant for intractable neurologic disease improved but died of a vascular complication.",
"     </li>",
"     <li>",
"      A third report included 37 patients of whom 32 percent had mixed hepatic and neuropsychiatric symptoms, while eight presented with acute failure [",
"      <a class=\"abstract\" href=\"UTD.htm?23/11/23737/abstract/83\">",
"       83",
"      </a>",
"      ]. Neurological symptoms improved significantly after transplantation but overall survival was significantly worse among patients with mixed neurological and hepatic involvement compared with those with liver disease alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in patients with Wilson disease is excellent in all but those with advanced disease and those who present with rapidly progressive liver failure and hemolysis. The neurologic, psychiatric, and hepatic abnormalities gradually improve with treatment, and liver biochemical tests results usually return to normal. Whether patients are at increased risk of hepatocellular carcinoma is not clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H69500463#H69500463\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Cancer risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is most effective when it is applied early in the course of the disease. As a result, it is mandatory to screen all siblings of patients with Wilson disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59392926#H59392926\">",
"     \"Tests used in the diagnosis of Wilson disease\", section on 'Genetic testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234586#H65234586\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Screening family members'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Wilson disease require lifelong therapy. Discontinuation of therapy can lead to the development of acute failure. Treatment should be given in two phases: removing the tissue copper that has accumulated and then preventing reaccumulation. The following will summarize our approach, which is consistent with recommendations proposed by the American Association for the Study of Liver Diseases (",
"    <a class=\"graphic graphic_table graphicRef57105 \" href=\"UTD.htm?43/9/44187\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In asymptomatic patients identified through screening, we recommend treatment with a chelating agent (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     trientine",
"    </a>",
"    ) (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). Zinc may be used in patients who are reluctant to use a chelating agent or who are intolerant of them, but liver biochemical test should be monitored at least every four months and a chelating agent added if these tests worsen (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). Evolving consensus has been to use trientine because of its relatively favorable side-effect profile. Copper balance should be monitored regularly in such patients by obtaining a 24-hour urine collection and by estimating nonceruloplasmin bound copper.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic patients should be treated with a chelating agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     trientine",
"    </a>",
"    ) until stable. As noted above, trientine may be preferred, especially in patients with neurologic symptoms, since it appears to be less likely to exacerbate them.",
"   </p>",
"   <p>",
"    Patients typically require one to five years of higher-dose treatment, after which they can be transitioned to maintenance therapy. Prior to the transition, patients should be clinically well, have normal serum aminotransferases, and hepatic synthetic function, nonceruloplasmin-bound copper in the normal range (&lt;15",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    or 150",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    and 24-hour urinary copper repeatedly in the range of 200 to 500 mcg (3 to 8 micromoles) per day. Maintenance therapy can be achieved with zinc or with lower doses of a chelator, and patients should be monitored regularly as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy appears to be safe in patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    . Data are relatively limited with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/46/14052?source=see_link\">",
"     trientine",
"    </a>",
"    . Although both drugs have been used during pregnancy, potential teratogenicity has been suggested in case reports and in animal studies. We suggest the dose be reduced to approximately 25 to 50 percent of the prepregnancy dose during the third trimester since both drugs may impair wound healing should a cesarean section be required (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). Case reports have suggested that zinc may be a safer and effective alternative, but experience is limited. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Penicillamine and pregnancy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H70847542\">",
"     'Trientine and pregnancy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23\">",
"     'Zinc and pregnancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Acute liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with acute liver failure due to Wilson disease require liver transplantation. Plasmapheresis, exchange transfusion, hemofiltration, or dialysis may be performed while transplant is being awaited. Albumin dialysis may also be beneficial but experience is limited. As noted above, recovery with supportive therapy has been described. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Acute liver failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27228114\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/1\">",
"      Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine (Baltimore) 1992; 71:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/2\">",
"      Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology 2003; 37:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/3\">",
"      Roberts EA, Schilsky ML, American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/4\">",
"      European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012; 56:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/5\">",
"      Wiggelinkhuizen M, Tilanus ME, Bollen CW, Houwen RH. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther 2009; 29:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/6\">",
"      Gibbs K, Walshe JM. Studies with 35S-labelled DL-penicillamine in patients with Wilson's disease. Q J Med 1971; 40:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/7\">",
"      Lau JY, Lai CL, Wu PC, et al. Wilson's disease: 35 years' experience. Q J Med 1990; 75:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/8\">",
"      Falkmer S, Samuelson G, Sj&ouml;lin S. Penicillamine-induced normalization of clinical signs, and liver morphology and histochemistry in a case of Wilson's disease. Pediatrics 1970; 45:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/9\">",
"      Walshe JM. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride. Q J Med 1973; 42:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/10\">",
"      Sass-Kortsak A. Wilson's disease. A treatable liver disease in children. Pediatr Clin North Am 1975; 22:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/11\">",
"      Grand RJ, Vawter GF. Juvenile Wilson disease: histologic and functional studies during penicillamine therapy. J Pediatr 1975; 87:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/12\">",
"      Sternlieb I. Copper and the liver. Gastroenterology 1980; 78:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/13\">",
"      Czlonkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate. J Neurol 1996; 243:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/14\">",
"      Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001; 344:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/15\">",
"      Hall CL, Jawad S, Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988; 296:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/16\">",
"      Coatesworth AP, Darnton SJ, Green RM, et al. A case of systemic pseudo-pseudoxanthoma elasticum with diverse symptomatology caused by long-term penicillamine use. J Clin Pathol 1998; 51:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/17\">",
"      Narron GH, Zec N, Neves RI, et al. Penicillamine-induced pseudoxanthoma elasticum-like skin changes requiring rhytidectomy. Ann Plast Surg 1992; 29:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/18\">",
"      Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987; 44:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/19\">",
"      Pall HS, Williams AC, Blake DR. Deterioration of Wilson's disease following the start of penicillamine therapy. Arch Neurol 1989; 46:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/20\">",
"      Iorio R, D'Ambrosi M, Marcellini M, et al. Serum transaminases in children with Wilson's disease. J Pediatr Gastroenterol Nutr 2004; 39:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/21\">",
"      Scheinberg IH, Jaffe ME, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N Engl J Med 1987; 317:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/22\">",
"      Walshe JM, Dixon AK. Dangers of non-compliance in Wilson's disease. Lancet 1986; 1:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/23\">",
"      Ansell BM, Moran H, Arden GP. Penicillamine and wound healing in rheumatoid arthritis. Proc R Soc Med 1977; 70 Suppl 3:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/24\">",
"      Shimono N, Ishibashi H, Ikematsu H, et al. Fulminant hepatic failure during perinatal period in a pregnant woman with Wilson's disease. Gastroenterol Jpn 1991; 26:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/25\">",
"      Morimoto I, Ninomiya H, Komatsu K, Satho M. Pregnancy and penicillamine treatment in a patient with Wilson's disease. Jpn J Med 1986; 25:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/26\">",
"      Dupont P, Irion O, B&eacute;guin F. Pregnancy in a patient with treated Wilson's disease: a case report. Am J Obstet Gynecol 1990; 163:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/27\">",
"      Soong YK, Huang HY, Huang CC, Chu NS. Successful pregnancy after D-penicillamine therapy in a patient with Wilson's disease. J Formos Med Assoc 1991; 90:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/28\">",
"      Scheinberg IH, Sternlieb I. Pregnancy in penicillamine-treated patients with Wilson's disease. N Engl J Med 1975; 293:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/29\">",
"      Crawhall JC, Watts RW. Cystinuria. Am J Med 1968; 45:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/30\">",
"      NUNEZ RAMOS C, TORRES P, RAMALLO M, VIDAL J. Phlebothrombosis: clinical study and treatment. Can Med Assoc J 1960; 83:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/31\">",
"      Mjolnerod OK, Dommerud SA, Rasmussen K, Gjeruldsen ST. Congenital connective-tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet 1971; 1:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/32\">",
"      Sternlieb I. Wilson's disease and pregnancy. Hepatology 2000; 31:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/33\">",
"      Kodama H, Murata Y, Iitsuka T, Abe T. Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci 1997; 61:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/34\">",
"      Walshe JM. The management of Wilson's disease with trienthylene tetramine 2HC1 (Trien 2HC1). Prog Clin Biol Res 1979; 34:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/35\">",
"      Saito H, Watanabe K, Sahara M, et al. Triethylene-tetramine (trien) therapy for Wilson's disease. Tohoku J Exp Med 1991; 164:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/36\">",
"      Dubois RS, Rodgerson DO, Hambidge KM. Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine). J Pediatr Gastroenterol Nutr 1990; 10:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/37\">",
"      Epstein O, Sherlock S. Triethylene tetramine dihydrochloride toxicity in primary biliary cirrhosis. Gastroenterology 1980; 78:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/38\">",
"      Dahlman T, Hartvig P, L&ouml;fholm M, et al. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine). QJM 1995; 88:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/39\">",
"      Perry AR, Pagliuca A, Fitzsimons EJ, et al. Acquired sideroblastic anaemia induced by a copper-chelating agent. Int J Hematol 1996; 64:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/40\">",
"      Condamine L, Hermine O, Alvin P, et al. Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride. Br J Haematol 1993; 83:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/41\">",
"      Shiono Y, Hayashi H, Wakusawa S, Yano M. Ultrastructural identification of iron and copper accumulation in the liver of a male patient with Wilson disease. Med Electron Microsc 2001; 34:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/42\">",
"      Walshe JM, Cox DW. Effect of treatment of Wilson's disease on natural history of haemochromatosis. Lancet 1998; 352:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/43\">",
"      Arnon R, Calderon JF, Schilsky M, et al. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment. J Pediatr Gastroenterol Nutr 2007; 44:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/44\">",
"      Walshe JM. The management of pregnancy in Wilson's disease treated with trientine. Q J Med 1986; 58:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/45\">",
"      Devesa R, Alvarez A, de las Heras G, Ram&oacute;n de Miguel J. Wilson's disease treated with trientine during pregnancy. J Pediatr Gastroenterol Nutr 1995; 20:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/46\">",
"      Keen CL, Cohen NL, L&ouml;nnerdal B, Hurley LS. Teratogenesis and low copper status resulting from triethylenetetramine in rats. Proc Soc Exp Biol Med 1983; 173:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/47\">",
"      Yuzbasiyan-Gurkan V, Grider A, Nostrant T, et al. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992; 120:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/48\">",
"      Sturniolo GC, Mestriner C, Irato P, et al. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients. Am J Gastroenterol 1999; 94:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/49\">",
"      Brewer GJ, Hill GM, Prasad AS, et al. Oral zinc therapy for Wilson's disease. Ann Intern Med 1983; 99:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/50\">",
"      Schilsky ML, Blank RR, Czaja MJ, et al. Hepatocellular copper toxicity and its attenuation by zinc. J Clin Invest 1989; 84:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/51\">",
"      Cousins RJ. Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 1985; 65:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/52\">",
"      Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998; 132:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/53\">",
"      Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years. J Lab Clin Med 2001; 137:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/54\">",
"      Anderson LA, Hakojarvi SL, Boudreaux SK. Zinc acetate treatment in Wilson's disease. Ann Pharmacother 1998; 32:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/55\">",
"      Najda J, Stella-Ho��owiecka B, Machalski M. Low-dose zinc administration as an effective Wilson's disease treatment. Biol Trace Elem Res 2001; 80:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/56\">",
"      Huang CC, Chu NS. Wilson's disease: resolution of MRI lesions following long-term oral zinc therapy. Acta Neurol Scand 1996; 93:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/57\">",
"      Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, et al. Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 1994; 123:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/58\">",
"      Milanino R, Deganello A, Marrella M, et al. Oral zinc as initial therapy in Wilson's disease: two years of continuous treatment in a 10-year-old child. Acta Paediatr 1992; 81:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/59\">",
"      Veen C, van den Hamer CJ, de Leeuw PW. Zinc sulphate therapy for Wilson's disease after acute deterioration during treatment with low-dose D-penicillamine. J Intern Med 1991; 229:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/60\">",
"      Rossaro L, Sturniolo GC, Giacon G, et al. Zinc therapy in Wilson's disease: observations in five patients. Am J Gastroenterol 1990; 85:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/61\">",
"      Hoogenraad TU, Van Hattum J, Van den Hamer CJ. Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients. J Neurol Sci 1987; 77:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/62\">",
"      Marcellini M, Di Ciommo V, Callea F, et al. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J Lab Clin Med 2005; 145:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/63\">",
"      Linn FH, Houwen RH, van Hattum J, et al. Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients. Hepatology 2009; 50:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/64\">",
"      Weiss KH, Gotthardt DN, Klemm D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 2011; 140:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/65\">",
"      Walshe JM, Munro NA. Zinc-induced deterioration in Wilson's disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet. Arch Neurol 1995; 52:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/66\">",
"      Lang CJ, Rabas-Kolominsky P, Engelhardt A, et al. Fatal deterioration of Wilson's disease after institution of oral zinc therapy. Arch Neurol 1993; 50:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/67\">",
"      Brewer GJ, Johnson VD, Dick RD, et al. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. Hepatology 2000; 31:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/68\">",
"      Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994; 51:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/69\">",
"      Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003; 60:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/70\">",
"      Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006; 63:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/71\">",
"      Nazer H, Ede RJ, Mowat AP, Williams R. Wilson's disease: clinical presentation and use of prognostic index. Gut 1986; 27:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/72\">",
"      Dhawan A, Taylor RM, Cheeseman P, et al. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl 2005; 11:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/73\">",
"      Hamlyn AN, Gollan JL, Douglas AP, Sherlock S. Fulminant Wilson's disease with haemolysis and renal failure: copper studies and assessment of dialysis regimens. Br Med J 1977; 2:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/74\">",
"      Kiss JE, Berman D, Van Thiel D. Effective removal of copper by plasma exchange in fulminant Wilson's disease. Transfusion 1998; 38:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/75\">",
"      Rakela J, Kurtz SB, McCarthy JT, et al. Fulminant Wilson's disease treated with postdilution hemofiltration and orthotopic liver transplantation. Gastroenterology 1986; 90:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/76\">",
"      Kreymann B, Seige M, Schweigart U, et al. Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins. J Hepatol 1999; 31:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/77\">",
"      Stange J, Mitzner SR, Risler T, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999; 23:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/78\">",
"      Guarino M, Stracciari A, D'Alessandro R, Pazzaglia P. No neurological improvement after liver transplantation for Wilson's disease. Acta Neurol Scand 1995; 92:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/79\">",
"      Bellary S, Hassanein T, Van Thiel DH. Liver transplantation for Wilson's disease. J Hepatol 1995; 23:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/80\">",
"      Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson's disease: indications and outcome. Hepatology 1994; 19:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/81\">",
"      Schumacher G, Platz KP, Mueller AR, et al. Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson's disease. Clin Transplant 1997; 11:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/82\">",
"      Emre S, Atillasoy EO, Ozdemir S, et al. Orthotopic liver transplantation for Wilson's disease: a single-center experience. Transplantation 2001; 72:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/11/23737/abstract/83\">",
"      Medici V, Mirante VG, Fassati LR, et al. Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders. Liver Transpl 2005; 11:1056.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3591 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23737=[""].join("\n");
var outline_f23_11_23737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Penicillamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Adverse effects and their management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Monitoring penicillamine therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dose adjustments prior to surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Penicillamine and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Trientine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Monitoring trientine therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70847542\">",
"      - Trientine and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Oral zinc",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Zinc and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ammonium tetrathiomolybdate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DIETARY RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ACUTE LIVER FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Acute liver failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27228114\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3591\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3591|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/9/44187\" title=\"table 1\">",
"      AASLD guideline Rx Wilson",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_11_23738="Sequestration CXR I";
var content_f23_11_23738=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55015%7EPULM%2F66166%7EPULM%2F63685%7EPULM%2F73428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55015%7EPULM%2F66166%7EPULM%2F63685%7EPULM%2F73428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration left lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph demonstrates a left lower lobe mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration left lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 290px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEiAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5uooooAKKKbQBFKvzZAppGTyKlYfNRgUAR7Fp6r0pwXNSIlADAgNOEY9KmVOK07HSJ7iISkeXD/fPf6UAZSQs5wgJY9hWna6P8vmXT7B/dHJNdDomnPKyRWcHzs20sBkmvXPB3wX1LVs3Wpx/ZoOytyz0AeJRWoRljtLfJP8AEOSa6fQfh7rmuEFbV0Q8b5FIFfTvhjwJovh6IAWaNMOTIygn866cmIKqxRoFHcAUAfPOj/A282Kb24Te3GFXpXb6L8FtKiiUXW95B1OcZr1i3ZthKrwO9Vr/AMQaTpaBtQ1Gztj/ANNZgv8AM0AUNF8FaXpIU2NjBEwH3lUZP41sXcASE4A4rkbz4v8AguyyH120Yg4IjJfn8K6DQ/Fug+KdHlutE1CC6SL/AFiofmX6g8igDPvJzEw3EYNZ73SeYyMQAB3715D8R/ietvqb2WmuGWNuWU96n8EeK5/EVw0E3ZeCT1oA7LVdFs9WleKaMOpwwPWtjRfDelWVsRFZRCUgBjtHzVV0XULeORbeUr5inGfau0sYI5VJixg8igDD/sezO5TbIqsRkAVn6x4I0PVrcpPaRq2CN6jBHHWuxnjEe5RgkVVit5fM3yYEfpQB8meN/h3qGh6y0dosk9rIfkkVT+VO8IfC/VdfvSk+bW2UbmkkB/Ie9fSXj3X9M0PT1e42t2C4yazvButWfiCxaTTlZPmwykYxQBzdn8IfD9vAqPG8xA5cnBP4U2f4O6JdO3kb4zjA5r1iGFQFRutaElukcI2gbsZoA+ctQ+C8dvcLsusxZ+b5eRT7b4KySfNDICD0Jr3eSBJJd7nOegrVskEKKE4PtQB8yal8E9YRysE0DD05FYF/8Itet95WASbeBtPWvsC4XJ6An3rJmR/OYFRjtigD4p1bwjq+kkm4tZlGM52nFYU8ckafvY1Ye619zXenQ3h2ywq4AwQwzXGeI/h9oN8HVrFYzjOYuOaAPkF7eBxyhRj6VEdP3n9y4b68V77qnwYy7tZXOMjKq46Vx1/8LPENoXZbQzRr0aMg5oA8sltZIjh0I9+1MCYrq77Tr2wYRXMLoc/ddazHtomyGXY/t0oAxiOaQrweK0ZLORRuUbl9RVdkoAqbAOoxUUkIY9OlXWSo2XFAFMRnvz+FI0Oen51bIx1ph60ATx/6tfpTqrqxXpTvNPpzQBNUG4tcA4+UDANNOW6kmnD7woAnooooAQe9LSUlABRRRQAbc05VweKUA9+1Sxr7UANRKnjjLMFUEt0AHenwxNI2xBljXaaBp0FtEPJXzb8/8tCMrGPb3oAoaVokUIMmohjcYykI7H1avUfAHw51LxFfRSXcRjscAj0x7Cun+G3wzfVrqK/vFYWi4JMgyZD+NfQ9jZW9jAsVtGqIoxwKAOb8NeBdG0RUaGzh81R129/WusAAAAGB6Vm+Idd0vw7pkuoa3fQWVnGMtJK2M+wHUn2HNfM/xI/aXuJjLZeBLUQx8qdQuly590ToPqfyoA9j+J/jDRvBZSbWr0RrMpaOFPmkfHoP69K8M8R/tITKHi8MaMiL2nvTk/go6fnXg+t6xqOvajJf6zfT314/3pZnLH6D0H0rPoA7LxD8UPGWvOxvtdukQ8GKBvKTH0XFchLLLMxaeWSVjzl2JpmM04CgAVR6Vd0+7u7CUy2NzNbSEbS0TlSR6HFV40yRXS+BvCl/4w8RW+kaXHumlyWfHEajqxoAzNP8+8vUjO6R3YD1Jr6N+H/gm/0m1MzxKZZUG0A8rmuq8C/BjTfD21ni+1Xg6yyr0PsO1em6bo4tgAM7fQ0AcTZ+HpoljLwqJCeeK6WwsL+OLarBQO1dXHBGSp28irIC4PAoA4t9Ov2kaXJ/OpBp+pSxOHbaM4FdgAoPAFRzMo4PWgDy2/8Ah7bare+dqm+YE52FuK2NI8PWOiLs0+IRJnJUetdgwyc1B9kWQlsc5xQBzt3Bcy3CNGxEQ6gVdeRorP8AibtW6lpGFAOaiuLWMgqOM+tAHL2sxFyqyEMQM59K3LWeJmKhgcVlazpJtwZ7dyeMkV82/FjxB4r0LUW/s69ube1k5LRnofrQB9Vs6nfjOR7Vhatrdjpwee8uIoYolyzu4UCvh+fx14qkJD+INSIIwR57DNc9d3t1clmubmaUtyS7k5oA+3tG+Inh+fzZZdVs0VDklpQP50yf4i+ESshXXLEuckAPk18M72A25OPrTOeoNAH3VH4r0e6SB4r63KS/d+cc10FjLb3NuHgcMhPB618BW+oXUBVo53G08c9K+svgx4w0a68F2w1DU4ob+LKvFI4B9iM0Aei6v4S0rWozHe2kchPO7HIrgtZ+CmkXMjNbl4c5PHNep6beC6iWaH5oWwVYdDWoiebwM59KAPkTxH8Kdc0maRrGJrqBf4kBJ/KvO7vTjG7JMhgmBwQwxX6IW9pHHDtZFbPXIzXm/wASvhXpXiJTdwQeVcqCSYxjP19aAPiO5t3iOHH0PrVVkPOeK9A8XeHLjQL97S+iPlD7rY7eorjr61MTbl+aI9CKAMop1FMZeKsutQsKAIsUbeKkYdqTbQBHSjqKcw560UATUU1DkU6gBtFGPmAHc1IqjA45oAZg09Vx160oAzk1IgzigAVeelW7S2aaQRoM021geZ1RRljXSWdgzBLazUu5++wGcmgCKxskciG3GZT1f1PtXuvwP+G13dXP2/W7Yx2EZBRZBzIf8Kt/Bn4V+Y8ep6zHtiTDImOSfevomNFijVI1CoowAO1ACQxRwRLHEgRFGAAK8z+L3xg0b4f27W0ZTUNeYfu7JG+5/tSH+Ee3U/rXLfHb44QeF/tOgeFpEn17Gya44aO0/wDin9u3f0r5AvLma8uprm7mknuZmLySyNuZ2PJJJ60AbnjjxnrnjXVTf+Ib1p3GfLhXiKIeir2+vWubY80HrSdqAE70Y9KO+RTgKAEUZqVEpEU1Zjj3MMUALbwtK6oilmY4AHevtX9nb4eJ4Q8Mf2jfRD+2NRUNIWHMUf8ACg/ma8w/Z2+FZ1K5h8Q6ym20iIaCMj77DufavqwAKAFAAHQCgBDgc1Ey9dw61K/3TUUudgIOaAI04bGTin7gpIJJqEtt5qu7t97P1+lAFwtlcnrmoGfJOeg4qHzgxYA9RxUW4gkFck/pQBdQg/jVqNdo6D8KzoCy/e5HY1eEnAyaAJTgckVVuOXJA4pxdj34prcg9zQBjX4dty5615L4x0p5b5muYVms24dXHFezzxgk5GWA6VzOtWwuIWWVfl9KAPn2++Emna4tzJpsj2lxuxEMZRj6V5H4s8E614UuzFrtsbaNiRHKTlZP9019Xi6gs2aGBtjIcgntXzr8c/FV54h1+K2uCBb2WVjA7k9SaAPMpU29CCPUVH3pxHPtSY5oAcmQfX2r1z4O/DG/8YW9zevMbS0T5Ucrne3t/jWF8HvBM/i/xRbh4S2nQOHuG6Ar6fjX2npOn2unQJbWlslvCgwqIuAKAJ/DunxaNoVlYI24W0ax7j1OBjNaMU3kyBl5A6iqQ2RsdzjOfWnJKju21hkcUAdBb3Ec65Rue4qauXYyI4MeQRWnY6nu+S6wrD+LtQBy/wAT/ANn4s0wgIEuUBKsB3r498UaBd+HtWnsb6P7hIwRww9RX38CGUEcg15z8WPANp4nsDMqKlzGCVcDH50AfDt5bBCXj5Q/pWewPWvQvFfhe88PXckVxETG2eSOCK4m8t9h3Jyh/SgDPbJoIOKlZeOlMxjtQA0etIR0xTsAjpTRQA4cUuaSigB38Y+tSHFMP3vxqTHNACgdM4qWNckAc5pqLnrWlYxBB5jDpyKALtpAYYwq8yuMH2r3z4E/D8Xc66nfrhQPkGM/ia4L4V+E5Ne1aOWQZiByQe9fYWg6ZFpWmw28SBSqgGgC9BFHBEscShUUYAFeCftEfGQ+HFm8M+F5h/bUi4ubpTkWqnsP9sj8vrXRfH74qx+A9IFhpLxyeIrxD5SnkW6f89GH8h3/AAr4luZ5rm4luLmR5Z5XMkkjnLOx5JJ9aAGSSNI7PIxeRmLMzHJJPUk+tM60UlADTSdqU9aVRz70AHanKvNAAJqaNcigB0cZPSvVvgv8Nrjxfq8c9whGmQsDIx43n+6K5T4e+FrrxV4itdPtkJV2y744Ve5r7m8FeHLXw1pkdjZRCOKMYyByx7k0AbOl2EGm2ENpaRrHDEu1VUYGKtUUUANY5BHf0qvJ0NTn/WZxxjmmykJyByaAKUxIH/1qqSsdhJ4FW7hiB0qoPmODxkUAIpBUAA+xxUiJlhnikjY7lGPk7kdqssMKTjmgATJwADgHtUv8JPeo4ZNgPvT1YGgAb5VzUe7cpYdR2p8gJXk8VCxPCr6UAR7snc3XpisXVAQXLdCMdK2WALYbINUL8gI2QCRQB5J4xhVZhFHuV2UnI6mvJvjZ4YsLDQ9N1i2lzdzt5cqdjxnNen/E5blrpWhfywozx3rmfEPha78VfD/bbxO99AwZUz1oA+cWBzVnTNPuNSvIrW0ieWaRgqqo5Jrt774UeK7aG0lGmSOlxwNuDsP+16V7f8H/AIaP4Ot31LVPLmv5kGAvIj9vrQB0nwe8NweB/CkcN0AL+UmSYj17D8K6e/18DhAR9K5/UrpjI5Y4j649awbd7k3DyyviHHA/GgDo73VZ3jd48/LyM8c1Da6tMswZpCWXBYA/pWTNOVAAjMpPQA8CmCQQ2u5vvFjuC/w0Ad1pPiNbyV1kG3advNbrBJR1GO5FeXxyqsStCGMhPzEdq3NK1ifY3nsVA4wetAHoOn3rwMI2O+L19K2kkjnT5SCD1FcXY6gjMihg26tXLRuHjJANAHE/E3wlDrMbxhAHH3Wx0r5o8Z+ErnQJgZI90LZBI7V9n3LpcDawy3rXL+J/CdtrNjJC8QkLAjp3oA+Hb21MTbl5Q9DVUpxmvQfGHhW70HVZrO9hZIGY7HI7eua4u8tXtpjG3I/hPqKAM5xx0Ofamnk5qdlx0qJhwcUARilzSkUhHSgB/VjU+CTyKiA+YGrKKaAJLaEvIFHTqa6nwzpb6tqkNrErbSQOlY1nblQFXmR+1e2/DfSk0OzGo3kPzsOM9qAPZfhb4btdNgRoYgEiUDPq1bPxS8c2PgHwrPqt4BJOf3drb5wZpSOB9O5PpUuiarY6T4Tl1O+lW3s4YzLJI3YAV8U/GHx/d/EHxXNfMXj06HMVlbk8In94j+83U/lQBzHiXW7/AMR63eavq83m3t1IXduw9FA7ADgVl0rdOaSgBMY5pBTvTNJ+FACetAGTS09BQA5VrR0qzkvLqOGJSzuQoA71Whj3MBXsfwL8IHVdciv5F/c2jBzkdT2oA94+CfgC28J6OLhxv1CZQXY9vYV6mox161iabeLFgOpwPl4HvW0jBgCCDQA6g8CignFACN901FcNtTce1PZtpJ7VWuZlKkLzxigCvKxbDAdagKg5J+lIknJz0zilllBO3ke9ACoNvbipgOMgioA3lqP4qsFlKcYGKAFUqRluuMU0tjAPIFBITG1gSf0phYAmgCR3bAYYIFMVd5LEYJNMXIJPc9qRXO/GKAHyc9elZ2olNn7vqetXWJZT2IrF1WVUGTxj070Aeb+NLZ3uoI3QyFnwAvJrs9FsIdO02EvxI4HGKp6bZ/a9Ta6mX5VPepdS1EzXOyHiGM4JxQB0zQJJbDAwDWLqcjW8axA5Ocge1aFve/u1UnjbxXPeJZLhQWiYKxGNxoA5/XpYvOKZIbHQd6y7CR3Ew2sqqMfOelZkt1/xMo2mlaWUMRkc8VNO7l22uSufuZ60AaMkixoi7iCeaZJJ5seJAAd2BzgGktxhUVlG9+cjnbT2kjUR4UFg2FDc/jQA9IBbvIDI2AMkA1ct4QhcvKOVzg9qqm5MjSbwCB39arSuzTB1G0gYOaAOp0u7WLZGpBDdWPaux0y9SZBGTnHvXlguhF5IhbIXlsVqWWqTRiNlO0Fstn09KAPTJgu0lRzjrWpoyD7KGOCSa5nRtRS/i2r98ds10mktsZ4WPzfeoA5P4peCYfE2iSrGqidQWUgc5xXx1q+lz211Ppt5GUuYWIXPX6V+gZGeD0r53/aK8EiLZr2nRbWU/vSP50AfLUyFWYMMEcYqswrf1eHeq3Sj7/D47GsWVaAK1IVzzTyDmkoAmUEkYrRsYt0gZvuLyaqwrk4rcsLVnaOFQSzmgDu/hP4TPiPW1llX/R4iC3qfavpZPCcL2wR4xsXgDHQVjfBDwkNK0VLmVfnkAJyK7X4ha5F4Z8E6zq0hVRbWzMme7kYUfmRQB8r/ALRHjqa6vz4T0uRk06zI+0BTxJIOx9h6eteI1NdXMt5dTXNy5eaZy7sxySScmoGOOlACE8c0tIBSmgBKb2pT1oPXAoAAKmjUngVEO1W7QZlH1oA7r4Z+ELnxHrcECwubfOZHA4UV9geFfCFl4c0tYLFdoOCePvGuW/Z4060XwjHPEg3ufmPvXruwY6UAc66rDKFYcntir1vMy8oSVHbNXbmzjmBJGG9ayJoZ7eQADK+1AGxFchxyMH61IZVA96w7a6EjY6EHkGrRZtrFT90ZxQBdfcyEgnHWqKqc7mPy1A92BHkkgelM+071UAfWgCcRjBAGcnNEqfut3B9qhWQ5xu4HWrAmjMWMHHrQBFkgKSOD0qUruQFain+eIbCdo6UJJ8gRT2oAjZ3EuSOMUM2eQT+NQu0jufLB+tTONkJ4y5HSgA8zAU54HegzbcYIOTkn0qvu+UKw696bJsCFMnJPWgCS7ufKU5yUPcVgX0xnnSKByCe2M1p3EoNm8RJz296qafCsAeV/4ehNAFfVbuDSrBlLASEVgWAa+tQVYhHbdvx1rK1S4fVfEEkTMDCowoB5auisf9DtYYJBg4wB0oAnuryO3tdynIU4LZ6VzniHVjdWxjVwqngHPWqPjNni8uGKXYHPzDPUd65q/uInmVImYqg5570ARXV2I7jyojhgMMe2abBfG7k+zqNuOC54rMk3DmXo5+U0sMxsV3SYZWbcfULQBvq6afdLKZ3l3cKueKtxyRO/nHcZWPCqeAKwLhvOt0uLc7l5+XPA96jtr0wmF4ZG38hhigDohLIpcsyqSflXsB70XEkixFQQ3OWf0FZaXwLyMkZdOjluop91cpJMmxyqFeVHb60Aacbq+PKYE455qlc6gRIsUW6TY2XI6GqhBWSZbZtm84JPp7U+1kEKmO3AG5sGQ0Abuka3NY3MdwjMIs/OM163oOrLdRQXcbZRuGHtXgM0hkRrdB8yty3qa7/4fX04gktpGVUAAAzzQB7iCCAR0NZfibS49Y0W6s5VDCRCACO+KdoNx59iFbO6P5SfWtKgD4P8VaG2j6/eaTcgqCTsz+hrhbmIo7owwynBr6M/aZ0T7JrdvqkSYWRdpYeteCawgdkuFHEo5+ooAwmFMzUsg5qI9elAGzp0PmTAfwjk16t8JPDT63r8DyRboA3Ujv6V51odsXUADLykAewr66+CPh5dM0pHkUhyN/PuOKAPTdPtUsrOK3iACooFeCftg+IxaeFtM8PxORNfz+fKB/zzT1+rEflX0HXwx+0prp1r4t6oiyB7fT1Szjx0BUZf/wAeJoA8tPpikbpxTjQBQAwU7vSjg0bcmgBuPzpp69Kd0NKetADR2q1bna4NVhyfpU0TEHFAH2b+y/d/aPBUqMV3RzEYHUDg17PXyd+y34hFv4kn0yeURpcR5TJ6sP8A62a+rVkUk89KAJKguBkc/nUjOMcHmq8sq/dJ5zQBnXlmhUmMBWznNVUEmOeMfrWpIQxxVS6BhBIH40AY93I6yAKhI706WVI4R821++KV5xyQAx64rNM0T3TLIcE8AGgC/ZyhyzbiRViWRpF2xnB6YzVK3jRCY0fDYz9asJGVZXPJBoAsRiQqBu4AyaeWZIcqCS3HSlELZyGO49qWScohQKeOvFAAz7SvljJ70z7U3938aYzLvB7kdKjLBXAJBAoAV5CcEjOO1RLIszttbCjr71WvLhUSR13ZHOB6UyyfzoDNg7D270ARPKZrvYF4BxUXii58jTHjgOGIwcVNbKxn3AZFQ6rapMhWRgM9OaAOV8M6esFybp8AqvzZNW767a5vkfbtVDx71rmwjg05RER8oyc965HW7+4hfZamNnX7y56CgDF8VD7QxcyL5xYFeaw4/s8axNcNtk+6+R1rea2+1apBNz5meVJ4NY+u2czagVKPszk+goAhvIwyxvEG8hBwT3rMx5L7xGJY5Dg59K0raWcu8H/LHvkdKrOm0kGQ4ydgFAEVpMSXPCxDKgelT2pSIebGMyDjBqtNEXibG5CB1xUjSKsMa28gkdxzz0+tAEcc00LysJsqT0xx9KvKYWhWJARcHDMxHQVmLa3MaOCVEhIIq4xaFlc4bIAJ+lAE9xI006RRD7g+ZqdPLMQpcARDkBBzUKXQMbuQVLDacDmizilhywO5D0GeaAHSN5cZcNsPT3JroPAssa3qF2kaUkAknArnvIy370kqeQKv+GJGTWEMbDlhlaAPorQZfLnQMQFkXAGe9dFXF6cSY4ZQ3zKQa7NWDKGHQjNAHmfx60NdW8Hytj95F84z6ivjmYb7SaAg7ozuH9a+/wDxPaJe6LcxSLuXGcV8SePNLTQfF9xCoPkscj/dagDzyUc1Ax5q7doEmdR0BqoRzQB6j8MrAXfiK1ULmNCM5HFfZnhJV/ssOowCcfkK+WvhNaxwWLXkmA5bA45FfVfhiPy9CtARgsm786ALWrXsem6XeX05AhtoXmcn0VST/Kvzb1W+k1PVLy/nOZbqZ5mPuzE/1r7p/aE1VtI+EPiGVDh5ohbL/wBtGCn9Ca+Cx0AoAcKKSloAOlFKKU8YoAYRkk00U+mCgABwSaeDTD0pwOKAOh8I61LoWuWeowHDW8itjPUZ5H5V996JqEOpaTaX1q++C5jWRGHcEV+dKNg17t8B/ix/YKJoOuNu08n9xKTzET2+lAH1dM4XBzVOaQF+vTvXLz+MrG5ZRZzLNk/wHNSR3d3cylYkIz3NAHSrIAACwJ+tNmljKEsen61QstPnyrXUuST0FX7mJI48E5xQBxmrXEtvcebF9zB+XvWe/nXABI+fOeTiupNkJZGIUbe5asXWLUW0DmLIbP5UAPt5JVcEnB/i5yM1cS+VXAeTI/nXKxX14zsDH8nAyB1rTsbdm/eSHcpGQD1oA6gXWFDD73Y0LcPJkAD3NZ8UvyKG+X3pLyaOGMM0q7iCQBQBb81MZAye9RecjbiT0rM+0tP5hi+9jgDtTckHyyeQAWP1oAuvcZAVVyDxn1qaNY7aHbI20v6+tZ1w8iqGgHzLzx3pRcG9UeYhyoyDigDTtleNCIwMP3NZ9zE0jK2RuB6E1cgeVIOh4rmdV1JPtBEkpjIPQd6ANLUkYWQSJtzZ6Z7Vw3imxkQtLCSrt+tdtakPbGdTkBTisLUXjvTDHOwEzZ4FAHPaRqcMF7Gs2HkGASF7niq/jRWa/V4m2jGcLWhLp8dncHYqIerZPI96nfSFvLUz+dvm56H17UAcejQxPyWdnUgcY59aoyNPbSySMisCMYNS36yw3qpKuwxcDHNV/tRuLd0eMmQH7xPWgA8xpY/N83BI+ZRUDrDHbk2wLTsM5psrx29l5CruY8lhTLGdl2ME+VcAUAT5l2I0kgBXhgaSGdyCu7cBx83AFNbE12gBBBb5hmn3ti91P5UTeXGvzEDpxQBJcXLErFFtC7c8DrTUuJZkRMsjZxz6VClwwbagBCdD3qdrmGTDREtMDkj0oAnkZ0KrIx8vpx1Na3htEg1QOxCL1B71krtWVZJZQNw+71q2ceZ5nmAjbkE8H6UAe4aLdbkRd4feOorttHm8y0CMfnj+U14J8P8AxBK1wIJmCxk/KTxXtGjTpBebCwxKM5z3oA3LtQ9rMp6FCP0r5L+Oujss0V/Ep2j5Cfxr6yv5PKs5W9FNeH/EK1j1Hw3frKhZwpK8dxQB8o6guXDjuKzzwa2dQj2owx9xjWO6/NQB7jpLvZaZDHBxtUFwPevrjR126TZD0hT/ANBFfNsOmOY4U2ruZ0Xge9fTNquy2hXptQD9KAPAv2xtWFv4N0fSgxD3l55rKO6xr3/FhXyQcdq90/a91gX3xCsNNRwY9PsxuAPR3OT+gWvC19qAFFFKMHqcUYI4NAAKXjvQKMetADTzTTxT6Z9etACYpQcmkIoz1IoAeDzxU0MhR1YHBzmoB0BNOU4NAH0R8DdTtr0mKYAzAAgGvf7F+QBgYGK+QPglqcVj4mCzOFDrgE19UafdvJAjwkEnmgDq45UVfnI3deKp3U+7IHIJ71Sildv9YR83HHannC+pNAF2Eo8Rjbnjn3rJ8QhUsmYLyowADV+LdvBOAD29KxfEl8lnbEt8+W24oAo28SmyibBUk5Pqae86wyoSCF28AU+1kEtvGR3puplI4kZ+i9qAIJbxWIZclT+lV55jJNEVAdyMBfQVlQXyLLcRuMDqDWfq149lLBcQsQx5DE8YPWgDtbNhtOxQOeakcAEEYJNY+k324BlwzPy1W4pJJJiNhVc4zQBfjQsG8odetSWsRCkKo+WoZ7tLWEyOQpUdK5hvEl07l442fqAoPU0Adk1w5AjcYJ615t4mYJey+YQuXwpJzmuvj1EOALiVY5AORjk+1UdV0ax1lEYTESKcgZ60AT+FrjztMkXgoOhHSuT1o7dV8uMnzS2d30rutHigs4RZ5VSPvAVynii2jtb8yBWLHO0/WgDmNTuJJQpMwMu4ggdx710fhJi1k0krfu0PQd65DUbb7PLG0jZdh2rqfC0oh0C4aQY2sTtPegDkNfvVfVbzyVwGJHzVkMx88KmTheT2Jq3dyxTXtxvAycn6VUE6R7WI+UcCgCGcyNCsaBEcnLbjyRUs8iweXE5JUDcxX09KgupYJ8vghj09jUcQfkSjeW6kUATu6RJ5sKjc54z296dG83nhnkyR129xUd0I02+UuWPBzziq+AmEMmefXpQBoblLs8eFJ61TtpB9qkUBmLA5wKI28nLSkEDotTW0rs5AyiN3A7UAWLVjcruZAGQEA+taJiM1uSCExwT6VTiCQF2gXc23HJqK3WZPM8xzt6lc0Aay3MFqkRgLGRCBk9Ca9n066abSLO7Vh5iheleAGaHbhi2M/WvU/AmqST6U0LsNq4C4NAHttr/plhG0o5deciuP8SaRGI54nOQwOBjtXa2C7bKAHsg/lWZ4giVijHqRigD4a8Y2H2DXNRtW6hiR+dcbIPm4r2f446bHYeLQ8a4Fwmfxrx6UbZGB6g0AfcuiaBHPqa5A8uN9x4r0asbw9AqGeUdWwPwrZoA/O/4qX8mp/EnxJdTOXZr2RAfZTtA/IVy1bvj+JofHfiKKT7yahOD/AN9msIUAOBpc5xTRSigBadkgHHQ0lB5GKAELAnApCBQBjpRQA3tQacQCMUCgBpHy4pVNL1ooAs2N1LZXUdxCxEiHcCK+ovhH4tt9aso41kP2pQA6E8+lfKma0NI1a+0m7S5064kgmQ5DIcUAfeMcUgYsVq6kTGLcByOoNfOfgr9oCW1SOHxPY/aVXj7Rb8OfqDwa9s0r4neDL/Svt0etWscePmjlbY6/8BNAGpcuYhvJwg9a5jUybybACso55P8AKq1r458PeK9Ql07TNTRscgYK7vpmtj7PbWnBmRgOeWoAiiLIYgnEeMn61V1a6beiAYz365p2o3lvFbySNKiKoyMnFeTeMfG0qwmPT90ztwjqKAOhuNQjTWXS8dVRTjOQOtQ67pd7rEZktJNka/KgJ6153Yab4n1pC728hWTne4xXa6F4f8TRQotxebYVO7B5P0oA3fDiX1qmLph5q8A5yK62C6ZoTtbkEc1l+H7B43c3rBhngds1sFWE5ChVjJIPHWgBNStxeWJDtgsOtYkUSWVqYxxsOQ57murCKUCEDpWXqQthayeeoVenNAFSMWNyQC6vdkZAzjNRz2tyLpFijKlQSCTgZrgn1O7h1SWW3UfuiSpI7V3ei64NXtEaZcTAYagDA2TafqAMlxJNPI2Wwcgc107XtlflIJMNLjjPrWddTW0OpOzockYAIrCvLV49YF1A7JG2G+tAHQ61o1vexqoVUkXkVj3Mf2fRmW2DKVOHP0rUgjuLp5ZMtvIwuTUenRPf6bdx322IRkgDP3hmgDya9Pn3bpGdjE8FjjHPeqc7PHPGrzF4k6j1q3rUEUF5N+8yA3y47iqEDfvWkYKOMAGgC1dXNsSqxoQQckDpTG8xlBiGXJxj0FVmlWaJ1OxH6+hqSGOa3QMH47D3oAtSIbZl3gKWGSTTVaHIYgNjoVqCbzHdTdNvdl6E8CoVUmUZfy4wOg70AWw8bSpkMCeuama5MIIz+7Pf3qnMXV1JTIIwCfSoo2E8LAgoB696ALUbtOCZJiqjt3NXIJUk+aZmCDjBPWsyAx+USXGOgxUkYi8pQ7Mdx5welAE13cRlpFi2gDooFdp8MtQD3S2pUgswJ49687upNhPkrtz6812HwrJfxNajzOXZcr680AfXEIxDGPRR/KqOtoGtgx/hNaIGAB6Vna++zTXb3oA+c/2i7NRbafdx4LIxUn6187XyFblx0719H/HFvP8AD5G4ko4bBr51vQXmDAZyooA/Qrw65aCQMeQRWvXG+CNTWe9uLfcN2wMBmuyoA+Bvj/px034w+JI9u1ZphcLx13qGz+ZNefivdf2wbPyPiPpt0EwtzpwBb+8Vdh/LFeFHtQAo6GlpB0NL0oAdS9qbmgHmgB1JnnpQOnrSHrQAGkPWlooASlNJ3x3pD0oAUdaM80080mTmgCUNxS7zjGahJq1psazX0Mb8qzDPvQBe0FL4XiyWBkSQdGXg16Kl74hit4ku7qcs+MBmNL4KtYRfSoYf3qg7FI716FeiyNrF9pjHmR4IPrQBxjXWp3kRjvLh0VB8wPeuk8KjT55lgihDshDbgM1zt/Hfa7qtvbWcJjSR9gbHB5617z4K8FWmhWIC/PPgFmbqTigDntXS8s4vtemQPK23HlgVyWneNbz+1mt9YtDbIw2BMEYNe8rbqAECiuY8VeGbW6HnTxr5inIbHIoA5HTdRe5BaQYjBwvvXQ2sqGFWc7mGeMVl2llbJF5cJUBT1J61fiObZYo+G6hqAG3GoSPGDAPmzjHoKzdV81kCO3DdavS2hWQMrHP6VLa6d55YyBjnv6UAcNdW8lvK8SpuD/xVveH7TyEUlgzYzhat3ekTRTbypdFPT1FaOm2DQuJIo/ncZJPagCrqdr5VsJWiDT44BFZUTmK3XzgrM3Usfu+1dHqtz5EOJQDIRwaw/IjuGKMcuwyo96AJ9HYSR7DKSSaxvGzy2drIls/DHlhxgVpG2kskQMCSp6p3qDUZk1USwyIUVQcGgDyOZxuR2G4t1zVVUlRWdIw8m7IyMgVcvLX7PdSQliQHIyarQM0EkiltwIyuOlAAIFcea0eJMZY9qbGA1wnlyM4zk+1KWnuEZOVRjQIfKjzGcspHIoAUqxZvMUuAeFFQu8fnlGGOMkGp5pcSBkbGOW9qtfZoryASjhz1oAzyZpB+6X5V4GaryEqSknJA4xV6a0m3jycsgODiq0sSLIGdimOSMc0ARxEYVGQA56VYDiO2fKkAHAYimJGJTuAaNf7571NNE4gCMQVxQBWlO6LKlcd+a774EQC48awfJkL8xavOmiXlkJJ9K9m/Z0td+vzTFcbY6APo2sHxndra6VkkAswHNb1eb/FzUfK+xWYcDIMhHc9qAPHvijI1zpd64dWjUDA9Oa8LkO4IePu/1Nez+IyLjw5qjyFhheMdM5rxUnhfp/WgD6y8DXF1a+KrJ7kjY+YyR717dXh62ssGowz7tkUbBtv0r2u0lE9rFKCDvQNx9KAPnT9s7S9+ieHtWUcwXD27n2dQR+qmvlX0Nfcn7T9gL74Oau23LWzxTr7YcA/oTXw124oAdmlBpufWl7UAOozikPTigc84NADtxx6Ud6bxQKAFzQDzzRSUAKfbrSDOaO9IW4oAQ8fSkHQ04nmg0ANNOhdo5FkQ/OhyPrTaAcHIoA96+FOu6L4juVs9SaOy1UgbZGOBMR2z6mvSNU0MWrImVfcMAHnivj9WKtlSQw5BB6V1Np4512O3jg/tG4dUGFLNkgelAH0LYQm08RWMCoPmbhh0Fez23+rUnk8A18QaV4y1m2v4bw3MjtE4cb+RkV9JeB/ifpmu2sCXMogvm4eM9PqDQB6qAFYYrF8YXX2bSp5nZVREJJPFLJrNnbrve4QqehFeafES7ufGlu+laTcbFXlmPAb2oAxvD2oRa0JxaTn5Xy3r+Fd5YsptoxkEqMV8++DL6Xwz4vWyvGC/P5UnPGK+irGODgpyDyCBQBE7MI3JyADuA9a1dAnEigOACecCmOMbU2Bgf0qAH7I7bcAtyPagDop7dXTc2NxNU1j/ANI2KNox1qCK9Y7RM/UdqtpOpIZRkigDmfE9izSFcfLj72e9VNA01V+d3LY6muuvIjcRnKBs8HNUbK1jtreZW2qc96APPvHPiaO1Z7C3Gwp1f0NcVpXiGea5VLmQuh64GM1e8c2bS69NunTa5yfb0FcjHEkEjqJvmP3QBQB2Xiyzhns0ltQnlyHJPeuMe1dN0ZPmHHyj3rstFNteacYJfMLLkDFc7rFgYGKJuypznOKAMhUdWYTn5McAetTWiNG+YUJU5GD3qCWcqEjkG0ng98+9DTSiRAsxRQMD3oA0Y4omu0hUBnf5SewrSubR7S4eNwuxFABHSuaTzHuvMG7I5zXV2yrdWGJyWmZhgZ5NAFDzRFGQigc/ez3qGU2nl7pPndh8xX1qLUDLFuiZAEB44qlAxh6qsintjmgBZXkxtjTMZ6A9aineRo1CY4pzs6vvjIDHjB7VCV8kkZJY9xQBBEwaVQTtwcdK+kvgNZQwxTyxr8/ljJxivnTT7cSaiuAWfPWvpL4LsbaGdbiQ+Y54UdhQB6zXgfxTu/tvjiRQSVt0EYAPfvXut5cLa2ks7kbUUtzXzzfSC81O5u2OXkkLAmgDH8SWgHhTUCvQR5JrwB3PHP8AnNe/eMWaHwXqDkk7sACvn+RlG3I5x/WgD7cntQybJFBJ9K7HwpNv0lIiTuhOw59O1YCbMAnmtvw2Qsk6DocNQBmfGGKOb4XeJ0mGUNjIce4GR+uK/PRR8ozxxX6O+PtObVvBOuWCAl57OVFA7nacfrX5xMpQlD1U4P4UAKR1oDcc00cZo7getAEn8Oe9L2BHQ03qAKVTxigB3FIRnpQwXjHXvSH0oAKWkyOaQnNAC00ZxzjGeMUinJp30oASkY5605gVAJHHamk/rQAYxR0ppzQDzQA41v8AgXRxr3iOCwLqgYFst3wM1zwrd8IyTwass9sxWaMZBFAHsOr/AA+th4fmktgPMjBOO/SuK8E6Ff6lrkdtZxOWzjIHSuoTX9d1SWDTEX5rgiMYGCxNfSHwz8C23hjS42njRr6QbpGx3oAwvC/w7uorBVvpmY5yQWrQm8AzRFzasqhuoBxXpNFAHyV8RfhbrEOoSalaoWC/M3PJ969C8D38k/h+3aYFJ40COG9RxXt1xbxXMZSZA6n1Fee+IPDjWV95tvhbd+SF4oAqxzMYCxI4HX1qOYLOyhD+8A6k1n3V1HAEi5bOe/Smx3wjRjIoUn7uOaANKaILABLJsVDnNN0vWAbt7cRNtJBWQnjFZGpajHOixSthvU8ZHtXKX3iU2kmFYBUOMd6APY1d5MbcbfWob2yiljZpH/PpXF+HPGENwyxyvtPTB711lxdpPbnJ/d9SRQB5T8RNOitbj7RGpIPcHvXnouRtZyBnORgcivbvE1tDqGnui4KuCo46GvJLrS/7OuWEyl2HC8cUAW/C+oTW8wzFiJ8ZZh29a6TxF4fkv7ZLqycOf7o/nWRZaTiBXnmZAwztr0rw4ls2mpEHCjGAe9AHh+oaabaffM2H6c9qilRFiV2QkhcjHevVfEPhbTppg8kjcnHBrNm8LaeLSUTzH5OUUNzQB51YsBcBnc+X1IA6GtSW+cSK1qNoPBJFdZpek6VAipIUIP0JzWZqfhOe6uSbKQeW5yFPagDnb+dZkw5LE8nFZjylCFHCjvXpmn+Af9CZJnLTkZzjgVxuuaFc6dK0dxExTswHBoAxZbVsrOJMq3bNEoZYgSmP609XeJRGyjnPOOlaOm6Zd6jPFFbNv5xnHSgC74M0m51PU7dIgAgOWOOgr2ewVtL1aJIFwDjJFZ2gaZa+G7FXuGAnYcn1NX/CGnNrevyXRlcxKeVB4FAHXeLJ5LnRfKVj5ZX5wO9ebTW4QxYTAHYV7HrFlEmlyhR0HevMdT2LOipgbeuaAPMPivdrF4ZaFcpvYcV4PenEqj0UV7H8bdQR57ayAAZPmbFeMXkgadsYx0oA+8LebzYFkU8EZBre8PzAXABIBYY+teOfDLxSNS0eK2dx9oiUIRnr6V6Ba6iba4iYjHIOfSgD0br1r4E+O3hJvB3xH1G1RCLK6Y3dqccFHOSB9DkfhX3vbzJcQJLGco4yDXkP7Tngj/hKfAb6jZx7tT0fdcIAOXix86/kM/hQB8SnlqPSkXBHfNLQA7OKN2KZnFOoAUEmnIcHPWoyfek5xQA7dRuGKb9KXjrmgCa1jWZypbZ71MlpJuJGCoPaqanbn3rY0VZJ18mP5nY8CgD174QW3hDxDZyaR4isYVvR80UxbaSAORmvL/Hmh22meKtRtdDm+1WET5R15wPTPtVXVVutGvHt3DQzj7w6EA16Z8Arnw/JD4iTxI0QnNvuiaXHK87sZ79KAPG0iHls0nA9KgFWr91e6m8s/ut7bB7Z4qtQAA4JzXoXws0l7tri8Ee5EYL0z1rz0GvdvhBNDa+C3LlUdpixJ4yOAKAPXfhr4estR1W3vngJltsNnGADXtdcn8OLH7LoKysBmXkMO4rrKACiiigAqlrVr9r06eIfe2kqfertFAHzz4iZvtbWUJbzYjufHGRXPX2uXMUCCzT94nBLGuw+IUL6Z45d4oSyzKDwMda4XWNlvdSjyj853bfWgChqurSXQRrmfMqrjYo4U1hPHM85Mrkoq7gD1q1KJnkLIqBepBqG5kMgAYhD0yDmgBEvLoSB7dgmw5ye9ekeC9bmvoBHc3G5uhU15nDMzzx2+xTuP3zXb+GLZIFiSJt8jNksP4RQB3h8sTKkbblHXJqCaytrxnVog7I27kcVO7IY0QHD9OPWqOoX0WlWxmkfcx7dz7UAT/2NHexhXXaT1ArI1S3u9JG213E9Mk8AVjt8QZEK/ZoCfmxkmrFx4m/tG3xeRCJWOA1AFpL1Z7bYsgLryST0rlte1UWrlJJDKW4LLSalqCW9i5gfKMdvB5Nch5rPPyrn1LHigC4up3Lzh7YthRnBNW7PxLqEF0P3vOOTWBK+4sEYqD1Ipi5UcDPP3qAO5tfH94LlQSWK8EetdXD4ns9X2xXUaDA+bNePRMBkE4YHOasWMk0V55kcm48ZoA9lTw7oV2zPEFbIzgVs6TpFnpjA2sCqSOvvXC+Frmd50ZpMKfw/CvRRdxRWbSykKqDJJoA5rx3qhRYLcYM0zbEUdSa9h8B6L/Yvh+COQD7RIoeQ47+leS/Dfw+fF3jSTXbwF9NsW/c56O//ANavfaAMjxROINLfJAJ9a8llnjnaa5lBCJkk44GK67xxrC3GojT4WDbB83oK8n+J/iKPRtBeytyBNOCuB6HvQB418QNWXU9evLmLPlg7Uz6VwczfP1rS1KXc23v1PuayZ3Afn0oA9H8FeJH0jXYp1J8rGSvavovTtXTW9IjuICMMOV7g18i6VKFn2ucBhjPpXo/gPxdPoN2IpWL27HBU9PrQB9K/DLxek+oz+HtQfy7xAZIA3G9e4H0r0tlDKVYAqRggjIIr5tv7Oe/urLxJoLqL+3YTRlT1H90/rXv/AIZ1iLXdFtr6L5S6/vE7ow6g/jQB8S/H/wCHsngTxlK9rERoeoFprRhyEOfmjPuO3tivMBz9K/Rb4jeDrDxz4Uu9G1FQPMG6GbGTDIPuuP6+ozX5+eJ9Cv8Awzr97o+rRGK8tXKOMcMOzD1BHIoAyqUE0n1ooAXvTyw8vGOajzxSA0AOzQaQnrRmgB68nGKsWNy9ndJJGSGU5GKrw48xcnA7midv3pIORmgC3q19PqF89xdMXdurN1NVfOdfuMVPTg9aYz7jk03NACkknPeg0lL1oAcoyQMZr0zwMZHuLLTZ32WruoY+metcj4H8O3vijxFb6dp0RlmfJ9gB3Ne9+FfhddWPiGzt9WBX5snB64oA+kNJa3s9OtbeIgRpGFWtSsaPQ4lSNC74QdQa1oY/LQLuLY9aAH0VHPPFAMzSKg9zTYrqCY4jlRj6A0ATUUVFND5pHzMMehoA86+LLWdrcWd7csgZFxg9TzXn2p2ketwwXFmyoM5yRzXUfH7RJrnTLW4gZ3cPtx7GuCsVv9IaG2uUYbow0WQcfTNAGHqmiT2sLIGYkscnHQVhvYyKVUgnJ5wM16vGBd26i+YRTvzg9zWNcoyX6xxxARZ+Y7f1oA57SPDU75lusRKCPmIzlTXc+HdMjiDGPBjAwAOtV5JHmhKbhhBj0p+mavDZl7fcNwHDA9DQBYhkD6o6BwoXnk9K5DxxqqlpIkXCDPPqa6S4js4ZPOfh3GdwPFcd4lsvtMqyqCIQefTNAHJ23mFYx5pVSc4Ira1gTLBEqn5GIGf61WVTBdgBVIDYHtXVa3awmzt5I3Vhsy2e1AHF3hjR1jJ4HI54qtnfLhj8n1p100ZuXj3Bjnj2qqrNHkuBjtQAkYRiV6Kn60pj3k4OFxx71AQqgOM5qw5yqkNlj/CO1ADCpLKMgKODmp4ttvIDCxYn2qRFQxqGjy4HWn2hdrhQIsjJH0oA7/w0ZriOFgh8seoq1qw1HxJrNvoOmHDzEb2B4Ve5NX9Gs5xpMUdtGfPmwFUDua9b+Hfg2Lw1ZGa4xLqU/Msh5x7D2oA3PC2h23h3Q7XTbNQI4VAJ/vHuTTPFutx6Dos95Jy4G2NfVj0rZrxv4k+IbXUtWS1Eo+zWhJbngsO9AGHqF7a2WnT3t3cgXMoMjE9c18+eLNck1XUZrqV2ZRxGD6Vr/EDxM2rai9vbNi1jyMjjNefXtxvbaCdi9KAK07bjuJ5NZ10wEn4VbkPFZ92f3vXtQBqRNgnHWuh0q4+1qImYCdOVz/EK5mI8kVZhkZHDIcMvINAHs/w68Xrpdz5N87eQflYddtfQXgq/gsbo3FvKH0+9wW29Fbs1fImmN/bCZt8DUIxkx/8APQeo9/avRPhx45k0iXyLks8JIV42/h9xQB9hAggEHIPNeU/Hz4XQeP8Aw81zp8UaeIrNS1tL081e8TH0Pb0P412Hg3xBbarp0TRSAow+U5/SumoA/MS7gmtLuW1u4XhuYWMcsbjDIwOCCKibpX2b8ffgpD4wEuu+HVjt9eVf3sfRboD19H9+/evje9tLixvJbS9hkhuYWKSRuMFSOoNAFeloPWkPSgBc0ZqOloAk3UZ4pgGDRQAueMUq03BPQZpwFADwcdqciF3CoPmPGKaor2j9n/4U3ni7V4dW1WB4tBt23FmGPPI/hX29TQB7d+zZ8OIfC3hyPWr1N2rahGGyR/qozyB9T3r0/wAQRIjQXQRfMRx82K1FKQCOGNMIFwoHQAdqq6n5FxJBayMPMdg20HnAoA0ByKzte1WHR7Fricj0A9a0a8O/aV8R3GkppFjbAD7UHZmPYDHH60Acj448f6jqd/MNNnJRCR8vQCueg8Ya9prpdC5YlcEj/wCtWHocoWGQMQoc9e+akupoHJXe2PfvQB9PfDLx5Z+K9PijL7b9E+dD3967qvkX4SaudM+JmjWlt8y3U3lvjsCDX11QBzuu20WqarbWUmGSP946mofGfhy31PRmWKMLPCNyMoweKlC+T43Z3bCy2w2g9yDXR0AfPE6wTmIE75Yjyc4xjg5q3q5hgsY3kdFjxWt478NSaDrsmqW6l9NvD+9H/PJv8DXEeP5M6ZbrCPlJySBnigDB1HVIxO6JcYjkzyp6VT0mQQMRMxKMeGJrDgXdOSyttByTWqkolt08razBuAegFAHX6vcxW+jxty7sfkz6VkWd2l7cC3c5UnLKeBirGu37R2kcLpGSqfKQOh71x0Nw6Ts2Tuz2oA6bU9MgN2zeYFUDhAMmrFrZJf6dsluNgTJ5q/a24ufD321FV7lRhc9hXPfafmkEhVJD1A4oA5y9sv8ATZAuMqcDFRG3IOzG6tG8hUSErLk5piAQrtcj5+Q3tQBWFpHEmXYDsVFPEUYGYgcjqSKfIdhDAgjtmqxuVQMsm47vQcUASM7jiBSSOSTXVeB9FutQ1JXnjKxYyqgcMay/Dei3WrXaRwxt5Z5yRxX0z4C8Jw6VaxyypmTHGe1AFvwh4bXT41uLtQ1yVG0Y4UV1dFYPizxFBoVi7lla5KnYnvQBznxX8ax+HrH7DatnULhTwP4F9a+VfGXiPzSYraRizZ3t3zWv8QfFktzqE0skglupcgk9F9hXmM8p5mlOSTwD3oAhu5SiFcneetZrn3p80hdmZuSarsTmgBGbOapXJBk+gq01U7k5lNAF1G5ODU6NWfC53sDz3q0rY9qANG1neGVZInZJEOQwOCDXd6Rqln4gMcN2Us9WAxHcD5UmPo3ofevOI3qzFJ05x9KAPdvBXi2+8L6ytrqXmxxg4aM9PYivp7wz4gttXs45I5AwYZDZ618Lad4k863Sz1gNNEoxHOOZIv8AEe1dv4V8Zaj4XuopYbj7TYnpg/Kw9MdjQB9oNyp78V5P8UPhHonjzNxNG1jqirhbuEcn0Dj+KtDwZ8R7HXrOPy5AkxHzI55/Cunt/Edst+tpOdruMqx6GgD4Z+I/wt8Q+BrpnvbZrnTyfkvIFJQj3/un2NcJkN61+n1xbwXVu8NxFHLDIMMjqCrA+oryHxr+z14N8Qu8+nxS6LdsSS1pzGT7oePyxQB8OkHPHSjBr6E8Qfsu+JLZi2h6vp99H2WYNC/9R+tcVffAf4i2ZI/sIzgd4biNv60AeZAEmjGelejR/BD4iPgjw3cDP96WMf8As1b2m/s4+P7zaZ4LCyB6+dcgkfguaAPHQAtT2Nnc6jdx21hbzXNzIdqRRIWZj7AV9T+E/wBlzT4Y0k8VazNczZBMNkNiD23MMn8hXt/hDwP4c8IQeX4f0m2tGxhpQu6Rvq55/WgDwX4Pfs7gJBq3j1CHyHj01W6enmH/ANlH419MWltDZ20VvaQxwwRKFSONQqqB2AFTVFczx20ReQ4A/WgDB8X+Irbwxpcl5dtulPEUQ+9I2OABWd8O7XUru3fXNfUx3938yQ/88U7D8qwm0tdW8XLrGvtmOAn7HbHlV/2j716RYyCSLI/AUAWa8Y/af8NXGq+EbXVrGJpZ9LlLyKgJPlMMMfwIBr2ekdQ6lXAZSMEEZBFAH5/W1+zbJEOEznAqze3nmR78EN39MV3n7RXwwm8J3jeIvDqN/Ytw/wC+hQf8ezn/ANlPb06elcB8LvBusfETxAlhaF0soyGu7kj5Yk/qx7CgD1X9mXw5Nq/iyXxDNEfsGnIY4nb+KZhjj1wCc/UV9T1m+G9EsPDmi2ul6TAsNpbrtVR1PqSe5Pc1pUAcn8QNHv76xjvdEn8nVbM+ZEez46qfaoPh942tvEkT2Vyywa1bDFxbNwcjqQO4rsJWCISfwrzjxZ4HivNXg8Q6DKtjrds2dw4Eo/utQB6JeW0N5bSW9zGskTjDKR1ryzxb4ENvA/2Ms1p16ZKV6Xo9495ZI86eXOBh09DV4gEYIyKAPlS98Ky+W6gSO2TzjFV9O8O3Ym2Lbnax6MK+ltV8OwXQLW+2KQ89ODXL3WiXVnGzSRcr0ZelAHjXiLSpow7lCRGMbQOBXJR2RklGGOepA/xr3DV9Ma+sZoA+GdeT3rzvV9EudPtsW8RLHO496AGaNcGxdYA4kEo2FR2zUGv6IIX3qpfOc1seD9EuSFmZMlu71u6roM95K20nfjHHQUAeXIot5BJLECDxjH86vXFtBPEBsUMefoK7S08ENeu32pz8vb3q9J8PlCkCYg4wM9qAPIZIJYrt0jj8yNeM4rqfDHhs6nGr3EYjQdSRXd6d4WtdLwsoEx4bIHNT+INQXS7Tz0tzHGgzgjrQB1PgnSLS3aOOKJdq9yO9ekoMKAOwryX4b+Jbe8tHuD8oDHr3q340+JMOl2UnkuiPjAJYBjQB1fjDxRFodqwhXz7sj5UXt9a+bviJ8Q5XeSLduu2HzNn7vsK57xb8Tb27aVLaYjfwX7156VkuN11fylIs5Jb7zfSgBskr3czzzsfLBySe/tWTeXHnOSBhf4R6CpdRvfPwkS+XAv3UH8z71nO35UADt+dRZprNzzTA4A+Y/SgCQnHWqc2TK3Wp5nwox61Wc5bJ60APRsMT7VYjclfnIzVSlBoAuxybhUyPz1rPSRkHAz+FSpNkc4zQBppJ71o6bqs1k37sq8Z+9G/KmsNHyARUiyHpxigDvdM1VVU3OlSvDMuN8Jbke6nv9K9D8J/FMi4gh1hTIoOBLj5lrwWC5eGZZI22upyCK6aHUdP1NFW6VbG9xgTIP3bn3Hb8KAPtHwp4xhvol+zSLcRkA8Hmuys9UtrnhX2t3VuK+GdC1/V/CV4lxFKTGfulTuRxXtvhD4s6Xqqql/8A6Pc4HJ+6T3oA+hwQehzRXntjrkdx89lfq3H3Q2avx6zdgAGfI9cUAdnRXJx61clf9aDz6VYOp3DLgPgmgDpO9MkmjjGXdVHua5OW+uFciSZ2HsarXFysh5JOKAN/VPEVjYQM7ShyBnArz3wt4hv/ABZ42vPOV47G1TEceMZNas8UUi5kVWU+tRaM0Onan58CKhP3lA6igDthpMTOJGQZ9DzirXkpABI8gUL68CqR8Q2Swh3YgkfdxXL63qjalKQjssQ/hBoA6k+JNHFyLd9Qt0mJwEZwCTWspDAFSCD0Irxi98O6df5kuIF8zPDA4I9/rWh4N1q/8O3bWGpyPPprH91I7Fmj9ifSgD1G+s7e/tJrW9hjntplKSRyDKsp6giqPhvw7pPhnT/sWhWENlali5SIdSe5PU1pxuskavGwZWGQR3p1ABTGlRTtLqG9Cea4P4l+MrnRUj0/RY/M1Kf5d+MiIep968vsdJ15btr7UNYu5LmY5b5yAPoOlAHvN+J52/d5Kio4I3RTuBLelcH4R17VdLdk1Kb7VbbsZI+YV6LaanZ3cfmrKmMdzQBzvizX08NaWdRZCfLIDBe+a2PC3iSw8RadFdWUqksMlCeQa5H4lWC+IrI2ENwYYjyXHevLNH8J6voU5uNO1Voih6r3H0oA+nKCARg8g15ho/jXVLWGNNRjjuSerA8/WuusPFunXIAdzE+MkEUAadxpVlccvAoPqvFZNx4P0+WXeN49ic1tQ6jaTDMVxGw+tWFkRxlWUj2NAHL/APCHwLkRTFFPYCrUfhqFAMStxXQZHrQSBQBjReHrRDn5iT15xVn+x7Q/eQk+5q3NcQwjMsiqPc1yvibx/ouhRP5twHlVSQooA3JtOsLaIyPGihe7V4j8V/GGlvG9nbhCikhm4riPiN8abzVHeHT2MMPIwD1rxa91C+1SYqDJKzH7o5oA9Hu/iRb6RYiDR0Pm9CSOBXnep61fa1es8rvJI56VXls4LJM6jLmf/nihyR9fSqk2qOAyWqLAhGPl6kfWgDRf7PpwDXWJrgjKxA8Kf9o/0rLvL2W6mMkzbj2A4Aqk0hJySST3PWk3d80APJzTGRiPlapAKWgCsIZW6lRSNbO2PmWrdKKAKotmbAkIAHpUn2SI9j+dT0UAYx6mlHQ0UUAJUkPWiigCQE735qWAnBoooAlB5qVelFFAHReGHZ5TG7M0f90nI6elOuwI5z5Y28/w8UUUAdH4bu7iOdWS4lVgByHIr6J8KSyS6MrSOzt6scnpRRQB0VmTtXmtaD7o+tFFADZuoqrdgDbgdqKKAKbHpVaXifI4OKKKAIZifO6mmKTvvOT92iigBISfLHJ7fypmpfNY3G7ngdfrRRQB6J4Idn0CDcxbHAyc1ut90/SiigDybVAH1e7ZwGbd1PJpl1/yz/3KKKAJLUAhyQDVRXZZMKzAZ7GiigC3cu20fMfzrDld/Kb5m6nvRRQBBCT5Y5NX14Zcf54oooAxtTlkjePZI68joSK2rW6uFf5Z5Rx2c0UUAWYb268w/wCkz9f+ehrRjurgnmeU/wDAzRRQBia9czi0mImkzg/xGvnLxrczvdyb5pWye7k0UUAcVIcsM8812OlqIfB93NEAk2QPMUYbHpmiigDzqdmZiWJJPUk1GpOTzRRQA81HL9z8aKKALS/dFKKKKAFpRRRQAtFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan displays the multicystic nature of the sequestration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration left lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph several months later reveals that the multicystic structure is now gas-filled due to decreased drainage of secretions with subsequent infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration left lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An aortogram demonstrates the systemic supply of the left basilar sequestration. The splanchnic artery originates from the lower thoracic aorta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23738=[""].join("\n");
var outline_f23_11_23738=null;
var title_f23_11_23739="Sx diabetic autonomic neurop";
var content_f23_11_23739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of diabetic autonomic neuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        System",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular",
"       </td>",
"       <td>",
"        <p>",
"         Postural hypotension",
"        </p>",
"        <p>",
"         Postprandial hypotension",
"        </p>",
"        <p>",
"         Fixed tachycardia",
"        </p>",
"        <p>",
"         Foot complications",
"        </p>",
"        <p>",
"         Sudden cardiac death",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        <p>",
"         Esophageal motility disorders",
"        </p>",
"        <p>",
"         Gastroparesis",
"        </p>",
"        <p>",
"         Constipation, diarrhea, incontinence",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitourinary",
"       </td>",
"       <td>",
"        <p>",
"         Bladder dysfunction",
"        </p>",
"        <p>",
"         Sexual dysfunction",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sudomotor",
"       </td>",
"       <td>",
"        <p>",
"         Distal anhidrosis",
"        </p>",
"        <p>",
"         Gustatory sweating",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal pupillary responses",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroendocrine responses to hypoglycemia",
"       </td>",
"       <td>",
"        <p>",
"         Reduced glucagon secretion",
"        </p>",
"        <p>",
"         Delayed epinephrine secretion",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23739=[""].join("\n");
var outline_f23_11_23739=null;
var title_f23_11_23740="Epidermolysis bullosa";
var content_f23_11_23740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        EB type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathogenesis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Key clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        EB simplex (most common)",
"       </td>",
"       <td>",
"        Autosomal dominant; most due to mutations in genes for keratins 5 and 14 expressed on epithelial cell cytoskeleton",
"       </td>",
"       <td rowspan=\"2\">",
"        Typically presents at birth or early infancy. Bullae with mild trauma, heal without scarring. Most forms with mild or no mucosal involvement. Chronic course but blistering tends to decrease with age, usually normal lifespan.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraepidermal separation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Junctional EB",
"       </td>",
"       <td>",
"        Autosomal recessive; mutation in genes encoding hemidesmosomal proteins such as laminin 5 resulting in defective cell adhesion",
"       </td>",
"       <td rowspan=\"2\">",
"        More severe variant characterized by widespread bullae and erosions with nonhealing granulation tissue; associated with absent nails, dysplastic teeth, oral lesions, and pyloric stenosis. Death usually occurs in early childhood due to malnutrition or infection. Normal life expectancy in patients with milder variant who develop bullae, primarily on the extremities, that may heal with atrophic scarring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intra-lamina lucida separation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Dystrophic EB",
"       </td>",
"       <td>",
"        Autosomal recessive and autosomal dominant; type VII collagen mutation leading to defective anchoring fibrils",
"       </td>",
"       <td rowspan=\"2\">",
"        Onset at birth; generalized bullae, heal with extensive scarring, milia. Repeated episodes of severe blistering and scarring lead to contraction flexures at knees and elbows and fusion of digits (\"mitten deformities\") of hands and feet. Oral, GI, and ocular mucous membrane involvement is also frequently seen and can be severe. Risk of developing squamous cell cancer within scars. Patients often die in early adulthood from complications such as infection or severe malnutrition. Milder phenotype seen with autosomal dominant forms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sub-basal lamina separation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Kindler syndrome",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td rowspan=\"2\">",
"        Blisters induced by mild trauma, progressive poikiloderma, and skin atrophy (particularly of the dorsal hands and feet). Photosensitivity may or may not be present. Additional features may include desquamative gingivitis and strictures of the esophagus, anus, vagina, and urethra. Blistering and photosensitivity may decrease with age.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Separation at the level of the basal keratinocytes, within the lamina lucida, or sub-basal lamina separation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23740=[""].join("\n");
var outline_f23_11_23740=null;
var title_f23_11_23741="Young child hip imaging overview";
var content_f23_11_23741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of the use of various imaging modalities in the evaluation and management of common hip problems in young children (toddlers to 10 years)*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plain radiograph",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ultrasonography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Computed tomography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Magnetic resonance imaging",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radionuclide bone scan",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arthrography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Acute transient synovitis",
"        </strong>",
"       </td>",
"       <td>",
"        May demonstrate effusion",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        May demonstrate effusion",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        May demonstrate joint effusion and synovial inflammation (with contrast enhancement)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Septic arthritis",
"        </strong>",
"       </td>",
"       <td>",
"        May demonstrate effusion",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         May demonstrate effusion",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         May guide aspiration",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         May demonstrate joint effusion and synovial inflammation (with contrast enhancement)",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Bone marrow edema is suggestive of septic arthritis but not always present",
"        </p>",
"        <p>",
"         May identify adjacent osteomyelitis",
"        </p>",
"       </td>",
"       <td>",
"        May suggest adjacent osteomyelitis",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Osteomyelitis",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Usually normal in the early stages",
"        </p>",
"        <p>",
"         Bone destruction and/or joint effusion in advanced cases",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        May demonstrate bone marrow edema and joint effusion",
"       </td>",
"       <td>",
"        May facilitate diagnosis in children with normal plain films and poorly localized symptoms",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Developmental coxa vara",
"        </strong>",
"       </td>",
"       <td>",
"        Demonstrates decreased femoral neck-shaft angle (&lt;120&deg;), vertical orientation, and widening of the physis",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Preoperative planning (demonstrates the relationship between the acetabulum and femoral head, neck and shaft)",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Legg-Calv&eacute;-Perthes disease",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Diagnosis, classification, and follow-up",
"        </p>",
"        <p>",
"         May be normal early in disease, but subsequently demonstrates sclerosis, fragmentation, and subchondral collapse of the ossification center of the femoral head",
"        </p>",
"       </td>",
"       <td>",
"        Adjunct to other imaging modalities",
"       </td>",
"       <td>",
"        Early diagnosis of bone collapse and definition of anatomy",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Facilitates early diagnosis (bone marrow edema)",
"        </p>",
"        <p>",
"         Evaluation of complications (femoral head subluxation; physeal abnormalities)",
"        </p>",
"        <p>",
"         Contrast enhanced MRI facilitates staging (avascular or revascularization and reparative)",
"        </p>",
"       </td>",
"       <td>",
"        May facilitate early diagnosis if plain films are normal; scintigraphic changes (decreased uptake in the femoral head) precede plain radiographic findings by about 3 months",
"       </td>",
"       <td>",
"        <p>",
"         Conventional arthrography: surgical planning in advanced disease",
"        </p>",
"        <p>",
"         MRA: assessment for complications",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Neuromuscular hip dysplasia",
"        </strong>",
"       </td>",
"       <td>",
"        Demonstrates valgus deformity, abnormal shape and location of the femoral head, and dysplastic changes in acetabulum",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Preoperative planning",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable; MRI: magnetic resonance imaging; MRA: magnetic resonance arthrography.",
"     <br>",
"      * This age range is approximate; these problems may occur in children outside this age group.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Cannot differentiate between acute transient synovitis and septic arthritis of the hip.",
"       <br>",
"        &Delta; Use of computed tomography is limited because of the risk of radiation exposure.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23741=[""].join("\n");
var outline_f23_11_23741=null;
var title_f23_11_23742="Drug and toxin induced ECG abnormalities";
var content_f23_11_23742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug- and toxin-induced electrocardiographic abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Bradycardia/AV blockade",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beta blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Calcium channel blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cardiac glycosides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Digoxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Digitoxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Red squill",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Digitalis lanata",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Digitalis purpurea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Bufotenin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Oleander",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Alpha-adrenergic agonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenylpropanolamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Clonidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Imidazolines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Organophosphates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbamates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Opioids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sedative-hypnotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Magnesium",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Supraventricular tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Methylphenidate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ephedrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pseudoephedrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Albuterol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Dobutamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Epinephrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Dopamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Anticholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            TCAs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenothiazines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Clozapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Atropine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Scopolamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyroid hormone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cellular asphyxiants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug withdrawal states",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Ventricular tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            TCAs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antipsychotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenothiazines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Chlorinated hydrocarbons",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Chloral hydrate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Solvents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluoride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiac glycosides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Potassium",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            QRS and QT interval prolongation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antipsychotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Diphenhydramine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Astemizole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Terfenadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antiarrhythmics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Quinidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Disopyramide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Procainamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Propafenone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Flecainide, encainide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amiodarone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Calcium channel blockers (rare)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Beta blockers (rare)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Propoxyphene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Organophosphate insecticides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antimicrobials",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amantadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Azithromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Chloroquine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Erythromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pentamidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Quinine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Quinolones (eg, ciprofloxacin)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arsenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thallium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluoride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Citrate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23742=[""].join("\n");
var outline_f23_11_23742=null;
var title_f23_11_23743="Prepatellar bursitis MRI";
var content_f23_11_23743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prepatellar bursitis with fluid and debris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This sagittal short tau inversion recovery (STIR) magnetic resonance image of the knee shows a inhomogenous high signal fluid in the prepatellar bursa (arrow) consistent with bursitis and intrabursal debris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD, and Celia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_11_23743=[""].join("\n");
var outline_f23_11_23743=null;
